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Thesis Abstract 
Cigarette smoke (CS) is the most common cause of chronic obstructive 
pulmonary diseases (COPD) including emphysema. Emphysema is a 
debilitating disease characterized by oxidative stress, apoptosis, and 
alveolar tissue loss. CS, which contains and enhances reactive oxygen 
species (ROS), impacts all cell types within the lung parenchyma and 
airways, causing alveolar tissue destruction through four mechanisms: 1) 
oxidative stress, 2) inflammation, 3) protease-induced degradation of the 
extracellular matrix, and 4) enhanced alveolar epithelial and endothelial 
cell (EndoC) apoptosis. Importantly, these mechanisms all cause apoptosis 
through intrinsic mitochondrial pathways or through extrinsic death 
receptor-mediated pathways. With emphysema progression, oxidative stress 
is continuously exacerbated in response to CS, contributing to enhanced 
apoptosis that by definition out paces repair processes. Recognizing that 
about a fifth of all smokers will develop emphysema, suggesting differential 
genetic susceptibilities, we focused on intrinsic modifiers of disease that 
may be altered by chronic CS exposure.   
Macrophage migration inhibitor factor (MIF), a pleiotropic cytokine 
with intrinsic oxidoreductase activity is one potential factor conferring 
cytoprotection from CS-induced damage. Studies in human pulmonary 
EndoC demonstrate that MIF antagonizes CS-induced apoptosis. Here we 
show for the first time that MIF is significantly reduced in patients with 
COPD. This is confirmed in our murine model of chronic CS exposure. The 
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absence of MIF leads to enhanced CS-induced DNA damage, lung EndoC 
apoptosis, and exacerbated alveolar airspace enlargement. These results 
highlight a crucial role for MIF in antagonizing CS-induced toxicity in the 
lung and resultant emphysematous tissue remodeling by maintaining 
EndoC homeostasis. 
To further investigate the capacity and molecular mechanism(s) by 
which MIF modifies oxidant injury we aimed to understand the potential 
effect of MIF on xanthine oxidoreductase (XOR), a superoxide-generating 
enzyme that is increased in human COPD and mediates CS-induced DNA 
damage and EndoC apoptosis. Here we showed that superoxide 
concentrations are elevated following CS exposure in the absence of MIF. In 
addition this report demonstrates that XOR hyperactivation and apoptosis 
in the absence of MIF occurred via a p38 mitogen activated protein (MAP) 
kinase-dependent mechanism. This is the first report to show that MIF was 
sufficient to directly suppress ASK1 enzymatic activity, upstream of p38 
activation, and providing one possible mechanism by which MIF 
suppresses CS-mediated cytotoxicity in the lung.   
We uncovered another potential and novel mechanism whereby MIF 
confers protection from oxidant injury, by positively regulating nuclear 
factor erythroid 2-related factor 2 (NRF2), a major regulator of the 
antioxidant (AO) response element (ARE). We demonstrated that the 
downstream targets of NRF2 are significantly decreased following CS 
exposure in MIF deficient animals. This report further links MIF to the 
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stabilization of NRF2 through a mechanism involving c-Jun activation 
domain binding protein-1 (JAB1), a recognized intracellular receptor for 
MIF.   
Taken together, the results of this study provide strong support for a 
novel role for MIF as a determinant of emphysema disease severity in 
mouse and man, impacting on pulmonary EndoC and alveolar homeostasis, 
and regulating both oxidant and antioxidant production, that in the 
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Chapter 1:  Introduction 
1.1 COPD 
“…The slow space...dominates the behavior of the lung in obstructive 
disease. [This space] applies to a large group of alveoli whose location is 
unknown but which are probably scattered throughout the whole of both 
lungs. They washout nitrogen very slowly when oxygen is breathed. The 
properties of the slow space, its ventilation, volume, and blood flow are 
most important in the understanding of the severity of the obstructed lung.“ 
Briscoe and Nash 1965  
 
1.1.1 A Brief History of COPD 
 
The term COPD, which stands for chronic obstructive pulmonary 
disease, was not coined until 1965 by Briscoe and Nash at the 9th Aspen 
Emphysema Conference (Briscoe and Nash 1965, Petty 2006); however 
the chronic nature and devastating emphysematous tissue destruction 
inherent to the disease were long appreciated. The earliest written 
descriptions of capacious and over-inflated lungs in patients with 
difficulty breathing dates back to the late 1600’s and 1700’s (Bonet 1679, 
Ruysch 1691, Morgagni, 1769). In the early 1800’s several disease 
manifestations were investigated; Badham described patients with 
chronic cough and persistent mucus hypersecretions (Badham 1814) 
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and Laennec, the originator of the stethoscope, described varying degrees 
and types of emphysema, pulmonary or interlobular, both resulting in 
lungs that did not empty well even after post-mortem dissection (Laennec 
and Forbes 1829). While improving procedures with the stethoscope 
Laennec noted that there is “no disease that illustrates the importance 
and necessity of percussion more than [emphysema],” because diagnosis 
was often inaccurate using the stethoscope alone. In 1846, Hutchinson, 
further advanced diagnostic proficiency to detect emphysematous lung 
damage with the advent of spirometry and although underutilized, it 
provided the ability to detect precise differences in total lung capacity in 
the context of health and disease (Hutchinson 1846). 
 Very few novel diagnostic procedures and devices were improved 
upon until almost 100 years after the invention of the spirometer. Before 
this time smoking was uncommon and susceptibility was often limited to 
genetic factors and increasing industrial pollution (Laennec and Forbes 
1829). However, with the rise of the cigarette in the early twentieth 
century, it was not long before COPD burden increased and interest in 
diagnostics and treatment were reestablished. By 1944, leading 
physicians began to appreciate that the separate and individualistic 
etiologies of COPD, including emphysema and bronchitis, were part of 
the same disease process (Christie 1944). The medical recommendation 
henceforth was to complete a thorough review of patient history as well 
as physical examination for proper diagnoses. Several leading experts 
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published on the various clinical presentations and case reports of each 
disease manifestation to aid in better analysis and treatment (Christie 
1944, Oswald, Harold et al. 1953, Noehren, Barach et al. 1964). In the 
1950’s, Donhurst, further described the classic phenotypic patients as 
“blue bloaters” and “pink puffers” (Dornhorst 1955). In these extreme 
depictions of COPD, blue bloaters were cyanotic from bronchial 
inflammation and related hypoxia, and were often obese or visibly 
swollen due to water retention and increased red blood cells or 
polycythemia; pink puffers were often older and thin with barrel-shaped 
chests, pursed lips, and clear dyspnea from emphysema. While these 
phenotypes were described as independent disease manifestations, 
signifying the prominence of one disease indicator over the other, upon 
autopsy many blue bloaters were described as having emphysematous 
damage, and many pink puffers as having airway hypersecretions. By the 
late 1970’s genetic susceptibility was hypothesized as driving the 
differential and pronounced disease manifestations (Mountain, Zwillich 
et al. 1978).  
Over this same time, Tiffeneau pioneered key spirometric 
advances, namely the inclusion of a timed vital capacity to analyze 
airflow (Tiffeneau and Pinelli 1947); and by 1951 Dayman had published 
on spirometric and air flow differences observed between healthy patients 
and those with emphysema, recognizing airway collapse as a possible 
contributing factor in altered lung function examinations in symptomatic 
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patients (Dayman 1951). These early studies into the presentation, 
pathophysiology, and treatment of emphysema or bronchitis during this 
era culminated in the commencement of two international symposia 
(Ciba Guest Symposium 1959, American Thoracic Society 1962), where 
the definitions of these chronic obstructive diseases were discussed and 
designated, providing the substance for which the current COPD 
definitions are based. The burgeoning issue of emphysema also led to the 
birth of the Aspen disease conferences, named for the meeting location in 
Aspen, Colorado in 1959. Over the next decade the discussions at these 
conferences formed the foundations for COPD therapy and related 
treatments (Aspen Emphysema Conference 1965). It was around this 
time that Briscoe elegantly described a new technique called the nitrogen 
washout to study patients with emphysema; nitrogen in healthy subjects 
was washed out in minutes, whereas it took substantially longer in those 
with emphysema (Briscoe, Cree et al. 1960). This technique was further 
improved upon the following year to yield quantitative data used to 
determine fractional alveolar ventilation and pulmonary capillary blood 
flow (Finley 1961).                    
 In the context of a genetic impact on disease, the discovery of 
alpha-1 antitrypsin deficiency in 1962 proved to be groundbreaking in 2 
aspects: 1) it signaled the beginning of new therapies for some patients 
with idiopathic lung disease, and 2) it provided a platform for 
understanding the cause of emphysematous tissue destruction (Laurell 
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and Eriksson 1963). From a public health perspective, over the first 60 
years of the twentieth century smoking consumption increased 
precipitously, escalating from 54 cigarettes per person in 1900 to 4345 
cigarettes in 1963 (Giovino 2002). An important event in the medical 
history of COPD occurred the following year; the Surgeon General 
officially reported that smoking was the main cause of COPD, correlating 
smoking history with chronic bronchitis and emphysema onset, marking 
the beginning of preventative measures and perhaps models of disease 
development and/or progression (Wellmann 1964). By 1967, Petty and 
Nett were publishing on clinical aspects of CS related lung alterations, 
and new effective treatments (Nett and Petty 1967, Petty, Ryan et al. 
1967). In the 1970’s Fletcher established methodologies to better utilize 
spirometric data and in fact was the first to associate smoking with 
enhanced deteriorations in the forced expiratory volume in 1 second 
(FEV1), further publishing data showing that smoking cessation would 
stem the rapid decline (Fletcher et al. 1976). In the late 1970’s CS was 
officially linked to disruption of anti-proteases, including alpha-1 
antitrypsin, greatly impacting the understanding of CS-induced lung 
disease (Gadek, Fells et al. 1979). It was not until the 1980’s that the 
ratio of FEV1 to forced vital capacity (FVC) was used to detect the early 
functional changes and airway obstruction, a key element for improving 
treatment (Burrows, Knudson et al. 1987). The advent of CT imaging to 
detect pathological alterations in COPD would not become practical and 
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commonplace until much closer to modern times with the invention of 
high-resolution computed tomograpgy (CT).  
       
1.1.2  A Current Understanding of COPD 
 
COPD is a term used for a group of pulmonary and respiratory ailments 
that by definition obstruct airflow, making it hard to breathe. COPD is 
treatable to a degree but is associated with an irreversible decline in 
airflow limitation, and tissue loss. CS causes approximately 90% of 
COPD cases domestically, but other occupational factors, such as dust 
and fumes, biomass fuel sources in less developed countries, and genetic 
variants also lead to disease (Blanc, Iribarren et al. 2009, Lamprecht, 
McBurnie et al. 2011, Po, FitzGerald et al. 2011). The onset of disease is 
variable, with a long asymptomatic period followed by characteristic 
clinical symptoms, including chronic cough, worsening dyspnea, mucus 
hypersecretion and sputum production, difficultly exercising, wheezing, 
chest tightness, and altered mental status, usually emerging once the 
disease has already progressed to mild and advanced stages. Exertional 
dyspnea is the most commonly reported early symptom (Rennard, 
Decramer et al. 2002). As in the early descriptions of COPD, the most 
common iterations of the disease are emphysema and chronic bronchitis, 
although the occurrence of either form is not mutually exclusive, but 
variably concomitant in most patients suffering from the disease. The 
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destruction of the pulmonary tissues with emphysema is debilitating, 
making it progressively harder to properly exhale or draw in fresh air, 
and this process can be further compounded by swelling of the bronchi.  
While this definition for COPD has remained relatively simple since 
1965, it is important to underscore that heterogeneity of COPD 
presentation and progression between individuals is still a key focus in 
continuing work. This could not be more evident than in patients who 
stop smoking but continue to suffer from enhanced deteriorations in 
lung function, while other patients may return to a more normal rate of 
lung function decline as observed with aging in non-smokers (Vestbo, 
Edwards et al. 2011). This also raises questions as to the underlying 
nature of disease progression in the absence of the main stimulus. 
Nonetheless, basic lung function examinations are used to analyze the 
FEV1/FVC and screen most patients with suspected COPD. This is in 
addition to a thorough evaluation of smoking and inhalational exposure 
histories as set forth after the first lung conferences in the 1960’s.  
 
1.1.3  The Natural History of COPD  
 
The natural history of COPD clearly differs on an individual basis, but in 
general terms onset of symptoms occurs decades after the disease 
initiation (Anto, Vermeire et al. 2001). Physical exams of patients in the 
early stages of disease typically reveal prolonged expiration during the 
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forced expiration maneuver. These patients often describe a sedentary 
lifestyle and fatigue, probably due to the avoidance of activity-induced 
dyspnea (Rennard, Decramer et al. 2002). With increasing disease 
severity, patients may present with hyperinflation as determined by 
increased resonance with percussion, decreased breath sounds, 
wheezing, chronic cough, and in the most sever cases, an increased 
chest diameter, a depressed and stiff diaphragm, Hoover’s sign (inward 
movement of the lower rib cage during inspiration), cyanosis, and an 
enlarged liver due to right heart failure (Badgett, Tanaka et al. 1993, 
Garcia-Pachon and Padilla-Navas 2006). Increasing dyspnea appears to 
coincide with a more persistent and purulent cough, which begins and is 
worst upon waking but progresses to an intermittent occurrence 
throughout the day (Kessler, Partridge et al. 2011). Also early disease 
and exertional dyspnea can occur in tandem with weight gain due to 
activity avoidance, but as dyspnea worsens, late stages of COPD can 
often be associated with weight loss, which carries a worse prognosis        
With disease progression it is currently understood that the decline 
in lung function is not a smooth curve from onset through severe COPD 
but more closely resembles a staircase. This step-wise decline in lung 
function is due to the progressively worse and more frequent 
exacerbations experienced by COPD patients, especially those still 
actively smoking (Vestbo, Prescott et al. 1996, Kanner, Anthonisen et al. 
2001). These exacerbations can be caused by numerous stimuli 
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interacting with host factors, including bacteria, viruses, and changes in 
air quality that generate amplified inflammatory responses in the lower 
airway and compound the effects of CS (White, Gompertz et al. 2003, Au, 
Bryson et al. 2009). In addition hypoxemia, which is progressively worse 
with disease, can be acutely severe with exacerbation, and accompanied 
by hypercapnia (Kent, Mitchell et al. 2011)   
 
1.1.4  Diagnosis of COPD  
 
Unfortunately there is currently no laboratory test whereby alterations in 
the serum or plasma can be used to diagnose COPD. Accurate diagnosis 
usually relies of the occurrence of indicative symptoms, exposure history, 
and family history, while confirmation of the disease is determined 
mainly using spirometry and chest CT scan. The incomplete reversibility 
of FEV1 with inhaled bronchodilators is also a confirmatory measure, 
especially in the absence of other, alternate explanations for airflow 
limitation (Qaseem, Wilt et al. 2011). To further aid in the clinical 
classification and treatment of COPD, the hallmark decline in lung 
function as determined by FEV1, the frequency of exacerbation, patient 
history, and the severity of symptoms are part of the new classification 
system for COPD, termed the Global Initiative for Chronic Obstructive 
Lung Disease, or GOLD stages (Global Initiative for Chronic Obstructive 
Lung Disease. 2011) (Table 1-1). As indicated in the table GOLD stages 
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1-4 are associated with an FEV1/FVC of less than 70%, indicating 
airflow obstruction, compared to above 80% for healthy individuals. The 
FEV1 shifts from around the normal 80% predicted in GOLD stage 1, to 
less than 30% in GOLD stage 4. 
 It is important to reiterate the importance of patient history and 
presentation for accurate diagnosis as several other disease processes, 
such as acute heart failure or carcinoma of the central bronchi, may 
share similar associated symptoms (Price, Yawn et al. 2010). Usually, in 
cases where the cause of disease is not understood, or a better 
understanding of the disease is needed, chest radiography and CT are 
employed. Radiography is often used to exclude certain alternate 
diagnoses or other diseases and is generally sensitive enough to detect 
COPD related characteristics including, vascular shadows, increased 
transparency of the lung, and a flat diaphragm, in 50% of patients with 
mild to moderate disease (Wallace, Winter et al. 2009). CT, especially 
high resolution CT, is considered more sensitive for detecting 
emphysema, particularly loss of capillary beds and distal vasculature in 
undiagnosed smokers, but it is not necessary for diagnosis, carries a 
high cost, and is associated with high radiation exposure (Miniati, Monti 
et al. 2008, Estepar, Kinney et al. 2013). CT is usually employed for 
better understanding of disease complications and exacerbations or for 
extreme treatment (Mair, Miller et al. 2009). However depending on the 
radiographic criteria others have shown that radiography is a simple test, 
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yielding 90% sensitivity for patients with emphysema (Miniati, Monti et 
al. 2008).  
 An additional and highly effective index for the diagnosis of 
moderate to severe emphysema is the diffusing capacity of the lung for 
carbon monoxide (DLCO) (diffusing factor or DFCO in animal models). 
The DLCO is taken into consideration with the measurement of blood 
gases, indicating hypoxia. While the blood gas measurements do not 
indicate alteration in alveolar ventilation, the DLCO can detect with 
reasonable certainty the loss of alveolar surface area indicative of 
structural losses due to emphysema (Macintyre, Crapo et al. 2005, 
Fallica, Das et al. 2011). However it is not considered to be overly specific 
for mild emphysema, especially in current smokers due to already 
persistent carboxyhemoglobin levels and possible thickening of the air-
liquid interface and/or the endothelial cell (EndoC) and pneumocyte 
(EpiC) barrier (Graham, Mink et al. 2002). Comorbidities may also 
further confound the accuracy of DLCO in the absence of other 
diagnostic tools (Morrison, Abboud et al. 1989, Gould, Redpath et al. 
1991, Saydain, Beck et al. 2004)              
 
1.1.5 Treatments for COPD 
 
The overwhelming majority of COPD cases can be linked to 
smoking, and therefore the first line of defense is to recommend smoking 
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cessation for those still actively using cigarettes. Secondly, the GOLD 
classification system, with recent modifications, provides a platform for 
treatment, which generally attempts to reduce declines in lung-function, 
exacerbations, hospitalization, and increase quality of life, largely by 
improving upper airway symptoms versus treating the underlying cause 
(Qaseem, Wilt et al. 2011). Early treatments include short-acting 
bronchodilators on an as-needed basis for all stages and respiratory 
rehabilitation, including exercise training, education, nutritional 
intervention, and psychosocial support, starting in stage 2 (Balkissoon, 
Lommatzsch et al. 2011). Also beginning as early as Stage 2, long-acting 
inhaled beta-agonists, bronchodilators, or anticholinergics like 
formoterol, salmeterol, and tiotropium, are prescribed alone or together 
in varying combinations depending on each patients specific symptoms 
and GOLD stage, and are generally associated with a significant 
improvement in annual FEV1 declines, occurrence of dyspnea, and 
exacerbation frequency (Qaseem, Wilt et al. 2011). Antibiotics are usually 
prescribed for the treatment of acute exacerbations following sputum 
cultures, and as the disease progresses to include repeated yearly 
exacerbation, long-term corticosteroids are considered the next step in 
treatment. In advanced stages of COPD, where hypoxemia is a significant 
factor, and possibly with acute and or severe exacerbations, oxygen 
therapy is recommended and several studies show improved survival in 
patients receiving long-term supplemental oxygen therapy (Stoller, Panos 
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et al. 2010). In patients with confirmed and extensive upper lobe 
emphysema, removal of 25-35% of the poorly functioning lung tissue via 
lung volume reduction surgery has been shown to improve breathing 
function and quality of life (Miller, Berger et al. 2005)   
    
1.1.6  Epidemiology of COPD 
 
COPD is currently the fourth leading cause of morbidity and mortality in 
the developed world and in 2012 was the third leading cause of death. 
On a global scale as much as 10% of the population was projected to be 
in GOLD stage 2 or higher, a prevalence that also increased significantly 
with age (Buist, McBurnie et al. 2007). This is a striking estimate given 
that GOLD stage 1 was excluded to avoid age–related biases. In the 
United States COPD prevalence has increased 183% since 1965, while 
other major causes of death steadily decline (Doherty 2003). From 1999-
2009 COPD was the third leading cause of death in the United States 
(American Lung Association 2013). In 2009 alone over 130,000 people, or 
about 41 individuals per 100,000, died of COPD, of which just over half 
were women (Murphy, Xu et al. 2013). In 2008, over 12 million people 
were estimated to have diagnosed COPD in the United States, while an 
additional 12 million people are projected to have some degree of 
undiagnosed COPD based on lung function examinations (American 
Lung Association 2013). Of those diagnosed with COPD, emphysema was 
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the main diagnosis in approximately 5 million patients, but accounted 
for 15 times more deaths than chronic bronchitis (Centers for Disease 
Control 2011). From 1979-2001 it was estimated that over 8.5% of all 
hospital discharges were for COPD patients, where COPD was the 
primary or secondary diagnosis (Holguin, Folch et al. 2005). In addition 
cigarette smoking diseases, including emphysema, contribute to an 
estimated 2.5 million deaths worldwide and a healthcare cost 
approaching 38.8 billion dollars annually in the United States alone 
















“Emphysema of the lungs is a much more frequent disease than is 
commonly imagined. I meet with it constantly in practice, in some 
intermediate degree between what may be called its first stage, the dry 
catarrh, and its complete development...”  (Laennec 1819) 
 
1.2.1 Defining Emphysema 
 
Emphysema, a word of Greek origin meaning inflation, is currently 
defined pathologically as the atypical and permanent enlargement of 
airspaces that are distal to the terminal bronchioles coincident with 
destruction of the alveolar tissue in the absence of apparent fibrosis. This 
pathologic definition has changed very little in the past 30 years 
(National Heart, Lung, and Blood Institute, Division of Lung Diseases 
1985). This debilitating disease is further characterized by oxidative 
stress, apoptosis, and alveolar destruction (Demedts, Demoor et al. 2006, 
Boutten, Goven et al. 2010, Mohamed Hoesein, Zanen et al. 2013). This 
destructive process is described as the heterogenous pattern of airspace 
enlargement which thereby alters the orderly appearrance of the acinus, 
or cluster of air sacs and alveolar ducts including the associated 
capilaries. This specific acinar distinction is key in the comprehension of 
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emphysema, as airspace enlargement alone can be observed in other 
disease states with no apparent tissue destruction (Yamada, Nakanishi 
et al. 2013).  
 
1.2.2  Histopathological Description of Emphysema 
 
There are three main histopathological classifications of emphysema that 
vary in their relation to the changing lobule structure containing the 
acini. The acinar structures are not readily distinguished in gross 
dissection, therefore the types of emphysema generally reference the 
damage of the acini within secondary lobules, circumscribed by septal 
tissue. Centrilobular emphysema is the most frequently described 
manifestation and it clearly correlates with smoking history, which has 
long been described (Thurlbeck 1963, Satoh, Kobayashi et al. 2001). In 
centrilobular emphysema, lesions occur in the proximal acini, and 
generally in the center of the acinus where the terminal bronchioles are 
situated. This type of emphysema predominates in the upper lobes of the 
lungs, may be an early manifestation of CS-induced disease, and is 
hypothesized to alter the microstructures of the aveoli and alveolar pores 
(Desplechain, Foliguet et al. 1983, Thurlbeck and Churg 1995, Fishman, 
Elias et al. 2008). In contrast panlobular emphysema is worse in the 
lower lobes and often discovered in histological examinations of patients 
with alpha-1 antitrypsin deficiency. However both manifestations are 
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observed in the later stages of emphysema in COPD (Fishman Elias et al. 
2008, Sverzellati et al. 2014). The third type of emphysematous 
destruction is paraseptal in nature, referring to lesions of the peripheral 
lobules along the septal lines, usually adjacent to the pleura and 
occurring concurrently with fibrosis (Anderson and Foraker 1973, 
Fishman, Elias et al. 2008, Takahashi, Fukuoka et al. 2008). In all three 
instances there is clear pruning and distortion of the microvasculature 
and an absence of alveolar walls around large emphysematous airspaces; 
all three types of tissue destruction are apparent and the distinction is 
blurred in later stages of COPD (Fishman, Elias et al. 2008, Jindal and 
Vijayan 2013). The loss of the microvascular structures would 
undoubtedly have adverse affects on the surrounding tissues, as the 
cognate circulation is necessary for bathing the acini with nutrients and 
removal of the products of metabolism. 
 
1.2.3  Emphysema, Cigarette Smoke, and Alveolar Maintenance 
 
As noted above, emphysema alone is a significant cause of COPD related 
mortality and, while the main cause of emphysema is understood to be 
CS, the underlying molecule pathogenesis of emphysema is not fully 
understood. The pathologic observation with CS-induced tissue 
destruction has lead to several emerging hyoptheses into disease 
development including increased oxidative stress, persistent 
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inflammation, and a protease/anti-protease imbalance, all of which 
promote and point towards an overarching phenotype of increased 
alveolar-capillary apoptosis and therefore alveolar maintenance as a 
therapeutic approach (Rahman and MacNee 1996, Kasahara, Tuder et al. 
2000, Tuder, Zhen et al. 2003, Petrache, Natarajan et al. 2006, Tuder, 
Yoshida et al. 2006). 
To understand the impact of CS, it is necessary to consider its 
impact on the breathing process. Airflow velocity and breath size are 
often increased, disturbing laminar flow but also recruiting alveoli to 
receive the increased volume. Air that reaches the alveolar space is 
polluted with a mix of extrinsic factors and oxidants capable of altering 
cell fate, including carbon monoxide, sulphur dioxide, nitric oxide, 
hydrocarbons, volatile organic compounds, and particulate matter 
(Fowles and Dybing 2003, Rodgman and Perfetti 2013). This polluted air 
is often held in the alveoli, increasing the incubation time of CS with 
alveolar EndoC and EpiC, the major structural components of the alveoli, 
both of which are susceptible targets of CS-induced oxidative stress and 
emphysematous remodeling (Thorley and Tetley 2007, Damico, Simms et 
al. 2011, Guarino, Cantarella et al. 2011). Hence, the concept of alveolar 
maintenance and homeostasis is becoming more appreciated as it 
pertains to the protection of these delicate microvascular structures from 
CS induced oxidative damage. More specifically, new hypotheses as to 
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the root of emphysematous destruction are linked with altered EndoC 
death and repair.  
 
1.2.4   Emphysematous Progression   
 
After smoking cessation, emphysema continues to progress in a 
persistent cascade of tissue destruction (Mohamed Hoesein, Zanen et al. 
2013). Some research indicates that the rates of progression do not differ 
between current and former smokers, while others show a slight 
improvement in the rate of decline in former smokers (Soejima, 
Yamaguchi et al. 2000, Bellomi, Rampinelli et al. 2010, Coxson, Dirksen 
et al. 2013). Recent work and computer modeling indicates that 
redistributed mechanical stress resulting from alveolar wall and 
extracellular matrix destruction may also overload the surrounding 
alveolar tissue increasing the likelihood of further destruction (Suki, 
Jesudason et al. 2011). The snowball effect of this mechanical 
breakdown may be a culmination of alveolar-capillary apoptosis due to 
oxidative stress, proteolysis, and/or failed repair, but its persistence is 
also suggestive of altered gene expression and behavior. Just as genetic 
factors play a role in disease susceptibility, it is also becoming more 
apparent that CS exposure is playing a role in dramatically altering 
intrinsic determinants of alveolar cell fate and disease progression. This 
may be due to underlying alterations in gene expression through 
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epigenetic modifications such as DNA methylation, histone modification, 
and microRNA expression but more work is needed to understand these 
context-dependent mechanisms. Still, there are several key proteins 
involved in cell fate, oxidative stress, and gene expression that are 
differentially expressed with disease, like vascular endothelial growth 
factor (VEGF), histone deactylase 2 (HDAC2), tumor suppressor protein 
p53, macrophage migration inhibitory factor (MIF), xanthine 
oxidoreductase (XOR), and nuclear factor erythroid 2-related factor 2 
(NRF2), whose dysregulation has been implicated in abnormal alveolar 
apoptosis and repair in emphysematous tissue destruction (Voelkel, 
Vandivier et al. 2006, Sussan, Rangasamy et al. 2009, Kabesch and 
Adcock 2012, Kim, Serebreni et al. 2013).  
 
1.2.5  Emphysema and Protease Imbalance 
 
The early discovery and subsequent research regarding spontaneous 
emphysema in patients with alpha-1 antitrypsin deficiency, a potent 
neutrophil elastase inhibitor, led to an initial interest in 
protease/antiprotease imbalances and effects on the extracellular 
matrixes, mainly of EndoC and EpiC, the key structural components of 
the acinus and new potential therapeutic targets. Intriguingly most 
therapies for COPD target airway constriction and inflammation; there is 
currently no specific treatment for emphysema or its progressive tissue 
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destructive, including proteolytic processes. The spontaneous airspace 
enlargement and loss of alveolar tissue in alpha-1 antitrypsin deficiency 
largely ignores the impact of CS on alveolar integrity and yields different 
pathologic features as previously noted (Abboud and Vimalanathan 
2008, Fishman, Elias et al. 2008). Nonetheless, proteases may be 
increased in COPD patients, especially current smokers or patients 
experiencing exacerbations (Fera, Abboud et al. 1986, Fujita, Nelson et 
al. 1990, Ilumets, Rytila et al. 2008). Whether this imbalance is due to 
more protease production or activation and or less production of 
antiproteases remains uncertain and the specific effect on lung function 
has not been extensively studied in humans. Both increased proteases 
and their inhibitors are detected in the sputum of COPD patients, 
particularly those experiencing an exacerbation, but these increases do 
not correlate with FEV1 responses (Cawston, Carrere et al. 2001, Mercer, 
Shute et al. 2005, Calikoglu, Unlu et al. 2006). Some evidence links the 
overproduction of proteases in response to CS to the dramatic, transient 
and long-lasting increases in the source of many proteases, innate 
immune cells such as macrophages and neutrophils (Barnes 2004, 
Hoenderdos and Condliffe 2013). Other evidence suggests that CS, and 
the associated oxidative stress, can inactivate antiproteases, specifically 
the elastolytic effects of alpha-1 antitrypsin in the bronchoalveolar lavage 
(BAL) of smokers, through post-translation modifications (PTM) (Gadek, 
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Fells et al. 1979, Carp, Miller et al. 1982, Hubbard, Ogushi et al. 1987, 
Petrache, Fijalkowska et al. 2006).  
 
1.2.6  Emphysema, Oxidative Stress, and DNA Damage 
 
The imbalance of antioxidants and oxidants, that by definition leads to 
oxidative stress, is linked with 1) numerous manifestations of COPD, 2) 
alterations in the underlying mechanisms of lung function decline, 
including alveolar-capillary damage, alveolar-capillary apoptosis, 
extracellular matrix (ECM) remodeling, inactivation of antiproteases, 
membrane lipid peroxidation, and mitochondrial respiration, and 3) the 
poor clinical and therapeutic efficacy of corticosteroids in patients with 
COPD (Abboud, Fera et al. 1985, Dalle-Donne, Giustarini et al. 2003, 
Abboud and Vimalanathan 2008, Ciencewicki, Trivedi et al. 2008, 
Louhelainen, Rytila et al. 2009, Merkwirth and Langer 2009). Further 
markers of oxidative stress, including hydrogen peroxide (H2O2), 
nitrotyrosine, 8-isoprostanes, malondialdehyde, 4-hydroxynonenal and 
4-hydroxy-2-nonenal are increased in in the lung tissue, breath, sputum 
and blood of patients with COPD (Ichinose, Sugiura et al. 2000, Paredi, 
Kharitonov et al. 2000, Rahman, van Schadewijk et al. 2002, Drost, 
Skwarski et al. 2005, Montuschi 2005, Kluchova, Petrasova et al. 2007, 
Barreiro, Peinado et al. 2010). The main cause of increased amounts of 
these reactive oxygen species (ROS) in COPD is CS, essentially a harmful 
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mix of inhaled oxidants. However the dramatic imbalance between 
oxidants and antioxidants that results can persist long after smoking 
cessation (Zhou, Yan et al. 2000). As evidenced by the persistence of 
extracellular and intracellular ROS detected in former smokers, ROS is 
also produced by mitochondrial respiration, and various inflammatory, 
airway, and alveolar-capillary cells (Le, Damico et al. 2008, Aguilera-
Aguirre, Bacsi et al. 2009, Louhelainen, Rytila et al. 2009, Damico, 
Zulueta et al. 2012, Kim, Serebreni et al. 2013). Important pulmonary 
and microvascular sources of ROS are xanthine oxidoreductase (XOR), 
uncoupled nitric oxide synthase (NOS), and NAD(P)H oxidase (Cai, 
Griendling et al. 2003, Birukov 2009, Damico, Zulueta et al. 2012). More 
specifically, XOR is a source of superoxide and hydrogen peroxide within 
pulmonary EndoC and it is elevated in human CS-induced COPD and 
emphysema (Pinamonti, Muzzoli et al. 1996, Pinamonti, Leis et al. 1998). 
Superoxide and hydrogen peroxide are abundantly produced, and while 
they are considered to be weak oxidizers, their increased production 
along with reactive nitrogen species (RNS) can parlay into the formation 
of more destructive radicals, which are increased with disease severity 
(Ichinose, Sugiura et al. 2000, Janssen-Heininger, Persinger et al. 2002, 
Van Beurden, Wielders et al. 2003, Marin-Corral, Minguella et al. 2009, 
Domej, Oettl et al. 2014, Antus and Kardos 2015).  
Oxidative stress and increased ROS are implicated in DNA damage, 
histone modification, and therefore alterations in repair processes, 
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expression of cytoprotective proteins, and production of pro-
inflammatory mediators in lung tissue and pulmonary vasculature. In 
particular the non-coding guanine rich segments of DNA, including 
promoter regions, are very susceptible to oxidative damage, and are 
repaired less efficiently (Makris, Tzanakis et al. 2008, Thomou, 
Paraskakis et al. 2009, Samara, Tzortzaki et al. 2010, Neofytou, 
Tzortzaki et al. 2012). In addition, emphysema patients and current 
smokers often have more oxidative DNA damage in the lung, as 
evidenced by the increased 8-hydroxy-2'-deoxyguanosine (8OHdG) 
double stranded DNA breaks (DSB), common by-products of oxidative 
DNA damage (Igishi, Hitsuda et al. 2003, Caramori, Adcock et al. 2011, 
Woodbine, Brunton et al. 2011, Dizdaroglu 2012, Tzortzaki, Dimakou et 
al. 2012, da Silva, da Rosa et al. 2013, Paschalaki, Starke et al. 2013). 
Single-stranded DNA lesions are more common than DSB, especially in 
non-replicating cells, but with extensive ROS-induced single-stranded 
lesions on opposite strands, the simultaneous removal of these 
bistranded lesions can give rise to DSB, before base-excision repair of 
only one lesion. This type of clustered DNA damage is very prominent in 
response to ionizing radiation (I/R), and occurs at a substantially lower 
frequency in response to endogenous ROS, making it more difficult to 
study under oxidative stress conditions (Dizdaroglu 2012). However 
recent work reveals that the repair mechanisms involving proteins like 
Ataxia telangiectasia mutated (ATM) kinase and Artemis, as well as the 
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kinetics of repair processes are fundamentally indistinguishable in ROS-
induced and I/R induced DSB, suggesting that the underlying 
characteristics of DSB formation in each condition is also similar 
(Shackelford, Innes et al. 2001, Riballo, Kühne et al. 2004, Woodbine, 
Brunton et al. 2011).   
In addition, DSB are very common in replicating cells where 
extensive or unrepaired single stranded DNA lesions, potentially from 
increased endogenous ROS, stall the DNA replication fork and trigger 
fork collapse (Pfeiffer, Goedecke et al. 2000, Chapman, Taylor et al. 
2012). This may be an important aspect in emphysematous tissue loss 
where cell damage and death by definition outpace repair and 
proliferation.  Further, DNA repair mechanisms such as DSB repair are 
increasingly inefficient with CS-induced disease severity possibly due to 
1) increased ROS-induced DNA lesions that delay or inhibit cell 
proliferation, or 2) genetic polymorphisms, causing apoptosis, 
senescence, and inflammation (Pfeiffer, Goedecke et al. 2000, Sancar, 
Lindsey-Boltz et al. 2004, Aoshiba, Zhou et al. 2012, Chapman, Taylor et 
al. 2012, Neofytou, Tzortzaki et al. 2012, da Silva 2013, Kirkham and 
Barnes 2013, Paschalaki, Starke et al. 2013, Antus and Kardos 2015). 
Notably, the promoter of vascular endothelial growth factor (VEGF) and 
the hypoxia response element (HRE) are prone to increased 8OHdG in 
lungs of COPD patients, suggesting that oxidative stress may also modify 
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cell survival and transcription in EndoC and other lung cells through 
additional and alternative mechanisms (Pastukh, Zhang et al. 2011).  
Recent research also indicates that continuous ROS production 
during and after CS is a key factor in driving inflammation and 
disrupting repair processes through the activation of redox-sensitive 
mitogen-activated protein kinases (MAPK) and transcription factors, such 
as Jun-N-terminal kinase (JNK), p38 MAPK, NRF2, and nuclear factor-
kappa Beta (NF-kappaB) (Xia, Dickens et al. 1995, Huot, Houle et al. 
1997, Ichijo, Nishida et al. 1997, Li and Karin 1999, Low, Liang et al. 
2007, Boutten, Goven et al. 2011, Kirkham and Barnes 2013). NF-
kappaB expression and activation correlates with airflow limitation, is 
increased in COPD, and is a known positive regulator of pro-
inflammatory mediators (Di Stefano, Caramori et al. 2002, Edwards, 
Bartlett et al. 2009, Lawrence 2009). Activation of p38 is linked with 
inflammatory processes, apoptosis, activation of XOR, and as with NF-
kappaB, is also increased with emphysema severity (Schieven 2005, Cai, 
Chang et al. 2006, Low, Liang et al. 2007, Le, Damico et al. 2008, Barnes 
2013, Marumo, Hoshino et al. 2014). Emerging data also suggests that 
NRF2-regulated antioxidant activity, is reduced with CS-induced 
emphysema (Goven, Boutten et al. 2008, Malhotra, Thimmulappa et al. 
2008, Suzuki, Betsuyaku et al. 2008, Malhotra, Thimmulappa et al. 
2009). Signals to these proteins are propagated through key upstream 
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redox sensitive cysteine residues on MAPK or susceptible protein 
modifiers, and in turn alter cell fate and gene transcription.  
Although it is incompletely understood, CS and ROS are also tied 
with abnormal histone regulation and therefore gene expression, possibly 
through PTM of proteins that regulate histone activity (Barnes, Ito et al. 
2004, Rahman, Marwick et al. 2004). DNA wraps around a core of 
histone proteins, which can be modified by acetylation and or 
deacetylation to allow the transcriptional machinery to access specific 
gene sequences on the DNA. To counteract and perhaps balance histone 
acetylation by histone acetyltransferases (HAT) are several histone 
deacetylases (HDAC) and in COPD, HDAC activity is significantly 
reduced, most likely due to increased ubiquitination as a result of PTM 
(Barnes, Adcock et al. 2005, Ito, Ito et al. 2005). In contrast, histone 
acetylation is significantly increased, specifically around the promoter 
regions of pro-inflammatory genes (Ito, Ito et al. 2005).  
 
1.2.7 Emphysema and Inflammation 
 
Chronic inflammation in the small airways and airspaces in the form of 
macrophages and neutrophils is a recognized COPD characteristic. 
Interestingly, the direct inhibition of alpha-1 antitrypsin is directly linked 
with a significant reduction in primary human EndoC death, suggesting 
an increased burden of neutrophils may be associated with capillary 
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pruning and EndoC caspase 3-dependent apoptosis (Petrache, 
Fijalkowska et al. 2006). Conversely elastolytic activity is increased in 
macrophages from patients with primary emphysema compared to 
patients with other primary diagnoses such as bronchitis, although this 
increased activity may purely reflect the increase in total phagocytes, as 
activity on a per cell basis does not differ (Muley, Wiebel et al. 1994, 
Abboud, Ofulue et al. 1998). Further some studies show that the degree 
of emphysema is associated with macrophage and not neutrophil burden 
(Finkelstein, Fraser et al. 1995). This is evidenced by the significant 
increase in macrophage-derived cytokines and chemokines, like tumor 
necrosis factor (TNF) alpha, and Il-8, which are increased with COPD 
severity (Keatings, Collins et al. 1996, Hirani, Antonicelli et al. 2001). 
However the burden and or persistence of macrophages in the airspace 
may also be skewed by defective clearance mechanisms. Healthy 
macrophages in the airspaces are thought to be cleared through a 
lymphatic or mucocilliary route, both of which are increasingly impaired 
due to mucus cell hyperplasia and production, and destruction of the 
pleura or lymphatic vessels respectively, although there is data to 
suggest the latter is increased in severe emphysema as part of an 
adaptive immune response (Hardavella, Tzortzaki et al. , Bhowmik, 
Chahal et al. 2009, Mori, Andersson et al. 2013).  
 Macrophages were once hypothesized to quench extracellular 
neutrophil elastase, further diminishing the impact of neutrophils on 
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disease progression, but others have since shown that macrophages are 
a source of elastase as well as other proteinases such as collagenase and 
gelatinase (Betsuyaku, Yoshioka et al. 1995, Finlay, O'Driscoll et al. 
1997, Belvisi and Bottomley 2003, Dollery, Owen et al. 2003, Barnes 
2004). These macrophage-derived sources of ECM degradation, including 
the collagenases matrix metalloprotease (MMP)1 and MMP8, the 
gelatinases MMP2 and MMP9, the elastase MMP-12 and the cysteine 
proteases or cathepsins, have been implicated in emphysema 
progression, as they are all increased in lung tissue, BAL, or ex vivo and 
BAL derived alveolar macrophages of human COPD patients, albeit at 
varying degrees depending on the studied cohort, possibly indicating 
variance due to genetic susceptibilities (Finlay, O'Driscoll et al. 1997, 
Betsuyaku, Nishimura et al. 1999, Segura-Valdez, Pardo et al. 2000, 
Imai, Dalal et al. 2001, Russell, Culpitt et al. 2002, Russell, Thorley et al. 
2002, Culpitt, Rogers et al. 2005, Molet, Belleguic et al. 2005).  
 The strongest evidence for a causal role for MMPs in emphysema 
development comes from a study in 1997 by Hautamaki et al., where 
MMP12 deletion in mice provided protection from CS-induced 
emphysema development (Hautamaki, Kobayashi et al. 1997). This 
finding has also been validated in a similar guinea model, and there may 
be polymorphisms in the MMP12 promoter that participate in differential 
phenotypes in humans; however research in human emphysema patients 
indicates an absence of MMP12 in the later stages of COPD, and 
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suggests MMP2 and MMP9 may be key elastolytic participants (Finlay, 
O'Driscoll et al. 1997, Ohnishi, Takagi et al. 1998, Betsuyaku, Nishimura 
et al. 1999, Culpitt, Maziak et al. 1999, Imai, Dalal et al. 2001, Churg, 
Wang et al. 2007, Korytina, Akhmadishina et al. 2008). However MMP12 
is known to cleave membrane bound TNF-alpha, a potent neutrophil 
chemoattractant, which is still considered a major player in ECM 
remodeling (Churg, Zay et al. 2002, Churg, Wang et al. 2003, Churg and 
Wright 2005, Lucattelli, Bartalesi et al. 2005, Elias, Kang et al. 2006). 
Intriguingly MMP12 is recently implicated in vascular injury and 
remodeling in the lung and in other disease states like scleroderma, 
suggesting it may be a contributor in dysregulated alveolar maintenance 
(Petrache, Natarajan et al. 2005, Stawski, Haines et al. 2014). Further 
the suspected longitudinal transition of MMP expression in COPD 
patients, from MMP12 to MMP9 for example, could be the result of 
evolving epigenetics and immune response to chronic CS and or 
persistent lung degradation. MMP9 is known to cleave latent 
transforming growth factor (TGF)-beta, a factor that is tied with the 
regulation of adaptive immune responses, endothelial apoptosis, and 
small airway fibrosis—a recognized characteristic of late stage 
emphysema often termed combined pulmonary fibrosis and emphysema 
(CPFE) (Wiggins, Strickland et al. 1990, Lanone, Zheng et al. 2002, 
Morris, Huang et al. 2003, Leksa, Godar et al. 2005, Wan and Flavell 
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2008, Ferrari, Cook et al. 2009, Katzenstein, Mukhopadhyay et al. 2010, 
Jankowich and Rounds 2012). 
 
1.2.8 Emphysema and Abnormal Clearance of Apoptotic Cells      
        
In addition to macrophage and neutrophil recruitment in response to CS, 
there is also an effect of CS on the infiltrating and resident alveolar cells 
that is linked with abnormal EndoC homeostasis (Vandivier, Henson et 
al. 2006, Voelkel, Vandivier et al. 2006, Thorley and Tetley 2007). CS 
impacts on macrophage phagocytic function which may lead a 
continuous cycle of infiltrating naïve macrophages and neutrophils due 
to dysregulated clearance of bacteria and dead or dying EndoC, EpiC, 
and neutrophils (Vandivier, Henson et al. 2006, Harvey, Thimmulappa et 
al. 2011). Specifically regarding vascular homeostasis, macrophages 
involved in the clearance of apoptotic EndoC and EpiC cells are also an 
important source of the EndoC survival factor, VEGF. This process, 
termed efferocytosis, is necessary for the initiation or continuation of the 
tissue repair processes but is significantly reduced in response to CS, 
oxidative stress, and in macrophages from COPD patients with a history 
of heavy chronic but not current smoking history (Hodge, Hodge et al. 
2003, Vandivier, Henson et al. 2006, Hodge, Hodge et al. 2007, Voelkel 
and MacNee 2008, Belchamber, Singh et al. 2014, Hamon, Homan et al. 
2014). This further suggests that the predominant cell infiltrate, 
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macrophages, are necessary for alveolar maintenance, whereas the 
sufficiency of the related pro-inflammatory or proteolyitc response of 
macrophages to CS on emphysematous destruction remains 
controversial. Poor efferocytosis also leads to secondary necrosis of 
uncleared apoptotic cells partly explaining the persistent inflammation 
(Silva 2010, McCubbrey and Curtis 2013). Conversely, tissue density 
determined by CT imaging, which is a means to quantify alveolar 
structure and inflammation intensity, is reduced in former smokers 
suggesting that inflammation or related secretions may not drive 
emphysema progression, although it may participate (Ashraf, Lo et al. 
2011, Mohamed Hoesein, Zanen et al. 2013, Karimi, Tornling et al. 
2014).  
 
1.2.9 Emphysema and Autoimmunity 
 
 As emphysema progresses there is a shift from an inflammatory 
environment dominated by innate immune cells like macrophages and 
neutrophils, to an enhanced adaptive immune response characterized by 
increased T lymphocytes (Aoshiba, Koinuma et al. 2004, Curtis, Freeman 
et al. 2007). This discovery has recently led to a vast expansion in 
hypotheses involving a developed autoimmunity that is pathologic in 
nature. Grumelli et al. showed that emphysema patients not currently 
suffering an exacerbation or an active infection had increased CD4 T 
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cells (Grumelli, Corry et al. 2004). Others showed that certain 
autoimmune and CD4 chemokines were increased in lungs of COPD 
patients (Panina-Bordignon, Papi et al. 2001). Interestingly memory T 
cells from smoker with COPD have a recalled immune response to elastin 
fibers, suggesting that autoimmunity may develop from the breakdown of 
the alveolar ECM (Lee, Goswami et al. 2007). In supporting models, 
Taraseviciene-Stewart et al. showed CD4 t cells target EndoC causing 
centrilobular emphysema, suggesting adaptive immune reactions may 
participate in the breakdown of the acini and endothelial apoptosis 
(Taraseviciene-Stewart, Scerbavicius et al. 2005).  
Whether this is the case in human emphysema is still unknown. 
This uncertainty remains in part because there is a disconnect between 
mouse models and human samples regarding the suspected subset of 
pathogenic CD4 T cells, termed Th17 cells, which produce interleukin 
(IL)-17 and proinflammatory mediators, that recruit innate immune cells, 
and also the subset of regulatory T cells (Treg), which may or may not 
have altered function or presence in response to CS or with disease 
progression (Grumelli, Corry et al. 2004, Lee, Goswami et al. 2007, 
Barcelo, Pons et al. 2008, Shan, Cheng et al. 2009, Dancer and Sansom 
2013, Hou, Sun et al. 2013). This hypothesis is further complicated in 
viral infections when other adaptive immune cells, like CD8 T cells, 
predominate and actively destroy infected alveolar-capillary cells (Gadgil 
and Duncan 2008).  
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The complicated multifactorial etiology of autoimmunity has led to 
high-throughput screening to discover the underlying genetic changes 
that may regulate autoimmune responses and the related inflammatory 
mediators in chronic lung and other diseases (Curtis, Freeman et al. 
2007, Gregersen and Olsson 2009, Pillai, Ge et al. 2009, Regan, 
Hokanson et al. 2010). The persistence of infections and the differential 
causes of exacerbations may also play a role in how genes are regulated 
and/or autoimmunity develops (White, Gompertz et al. 2003). However in 
stark contrast to these findings, CS-exposure in mice devoid of B and T 
cells still causes emphysema (D'Hulst A, Maes et al. 2005). Taken 
together, the experimental and clinical findings support a role for a 
dysregulated adaptive immunity and related inflammation in the 
progression of emphysema in genetically susceptible smokers, although 










1.3 Apoptosis in Emphysema 
 
Emphysema development is propelled by alveolar-capillary apoptosis 
(Yokohori, Aoshiba et al. 2004, Demedts, Demoor et al. 2006, Park, Ryter 
et al. 2007). Increased oxidative stress, inflammation and protease 
imbalances, and the associated alterations in growth factors, cell cycle, 
ECM, immune cell regulation, and extracellular death ligands, can all 
cause apoptosis through intrinsic mitochondrial pathways or through 
extrinsic death receptor-mediated pathways. Death receptor (DR) related 
apoptosis is initiated through various DR ligands including TNF alpha, 
which is increased with COPD severity (Strasser, O'Connor et al. 2000, 
Park, Ryter et al. 2007). The cascade of activation following 
phosphorylation of the intracellular receptor domain culminates in the 
cleavage and activation of FLICE (aka caspase 8) and finally caspase 3 
and or 7. The intrinsic activation of apoptosis in EndoC and EpiC is 
categorically tied with oxidative stress and subsequent DNA damage 
(Roos and Kaina 2006, Morissette, Parent et al. 2009, Damico, Simms et 
al. 2011).  
There is a considerable amount of apoptotic related research into 
emphysematous tissue destruction and remodeling focusing on the loss 
and repair of both EndoC and EpiC comprising the alveolar wall. There 
are several reports of increased alveolar wall apoptosis in patients with 
COPD compared to non-smokers and in animal models of CS-induced 
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emphysema (Yokohori, Aoshiba et al. 2004, Calabrese, Giacometti et al. 
2005, Imai, Mercer et al. 2005, Kanazawa and Yoshikawa 2005, 
Demedts, Demoor et al. 2006, Henson, Cosgrove et al. 2006, Marwick, 
Stevenson et al. 2006, Petrache, Fijalkowska et al. 2006, Petrache, 
Fijalkowska et al. 2006). This alveolar wall apoptosis further correlates 
with increases in surface area and mean airspace size but interestingly it 
is also associated with enhanced proliferation of both EndoC and EpiC, 
suggesting that the repair process is overwhelmed by CS-induced tissue 
destruction and general alveolar cell apoptosis (Yokohori, Aoshiba et al. 
2004). 
 
1.3.1  Emphysema and p53 
 
DNA damage is linked to the activation of p53 and both are increased in 
the acini of smokers and emphysema patients (Roos and Kaina 2006, 
Siganaki, Koutsopoulos et al. 2010, Caramori 2011, Aoshiba, Zhou et al. 
2012, Neofytou, Tzortzaki et al. 2012). Polymorphisms in p53 also 
correlate with disease onset and severity (Lee, Chen et al. 2006, Arif, 
Vibhuti et al. 2008). Depending on the degree of damage and its 
phosphorylation status, p53 can directly modulate members of the Bcl-2 
family of mitochondrial membrane regulators, such as the pro-apoptotic 
BAX and BAK, which are both increased in emphysema, or p53 can act 
as a transcription factor, enhancing the gene expression of apoptotic 
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protease activating factor 1 (APAF1), mediators of cell cycle arrest, and 
the pro-apoptotic Bcl-2 proteins, tBID, BAX NOXA, and PUMA (Haupt, 
Berger et al. 2003, Morissette, Vachon-Beaudoin et al. 2008, Morissette, 
Parent et al. 2009). These pro-apoptotic proteins converge on the 
mitochondrial membrane with cleaved tBID, inducing pore formation, 
disrupting the membrane potential, and causing the release of 
cytochrome c (Degenhardt, Sundararajan et al. 2002, Haupt, Berger et 
al. 2003, McDonnell, Wang et al. 2003). In addition free cytosolic p53 can 
also mediate the oligomerization of the subunits comprising the pore 
channel or directly disrupt mitochondrial membrane integrity (Chipuk, 
Bouchier-Hayes et al. 2005, Wolff, Erster et al. 2008). Cytochrome C, 
which normally is a part of the mitochondrial respiratory chain, once in 
the cytoplasm can activate caspase 9 and disrupt endoplasmic reticulum 
potential (McDonnell, Wang et al. 2003, Jin, Zhao et al. 2004). Caspase 9 
will then activate caspase 3 and or 7, ending in programmed cell death 
as in the extrinsic pathway. Activation of p53 is also associated with the 
enhanced expression and membrane trafficking of the extrinsic pathway 
associated DR, further linking p53 to many mechanisms of apoptosis in 
COPD (Bennett, Macdonald et al. 1998, Wu, Kim et al. 2000). 
 
1.3.2 Apoptosis in Emphysema: An Endothelial Focus 
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Both Endo and EpiC are key structural components of the alveoli 
and main targets of CS induced apoptosis (Morissette, Parent et al. 2009, 
Damico, Simms et al. 2011, Guarino, Cantarella et al. 2011). EpiC form 
the inner wall of the alveolar surface and have therefore been an 
appealing focus regarding CS related damage, considering the close 
proximity to noxious gas mixtures and proteases released by infiltrating 
immune cells (Mercer, Lemaître et al. 2006, Thorley and Tetley 2007). 
Moreover, type II EpiC are reportedly an important source of VEGF, 
which is necessary for EndoC maintenance and can also influence EpiC 
growth (Voelkel, Vandivier et al. 2006, Lee, Chen et al. 2007). EndoC line 
the vessels and provide structural support to the microcirculation in the 
lung, a system obligatory for bathing all alveolar components with 
nutrients. Gordon and colleagues have reported that circulating markers 
of pulmonary EndoC apoptosis are observed at higher levels in smokers 
with diminished DLCO, a physiologic manifestation of diminished 
alveolar surface area, thus providing evidence that pulmonary EndoC 
apoptosis is an early manifestation of CS-induced lung injury (Gordon, 
Gudi et al. 2011). Further the unbalanced loss of EndoC in these 
microcirculatory structures is both necessary and sufficient for disease 
progression and this would undeniably impact EpiC homeostasis 
(Kasahara, Tuder et al. 2000, Tuder, Zhen et al. 2003, Petrache, 
Natarajan et al. 2005). 
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1.3.3 Apoptosis and Growth Factors 
 
 Human emphysema is associated with diminished growth factor 
secretion in the lung, including VEGF, hepatocyte growth factor (HGF), 
fibroblast growth factor (FGF), and TGF-beta. HGF and FGF secretion 
and or receptors, which are necessary for alveolar repair processes, are 
increased with disease severity, suggesting that they may have an impact 
on vascular remodeling (Kranenburg, de Boer et al. 2002, Sauleda, 
Noguera et al. 2008). TGF-beta, which is also increased in COPD, is an 
active component in regulating inflammation, and aspects of lung 
remodeling such as angiogenesis, and apoptosis of EndoC (Leksa, Godar 
et al. 2005, Wan and Flavell 2008, Ferrari, Cook et al. 2009, Pastukh, 
Zhang et al. 2011). Further genetic polymorphisms in TGF-beta are 
associated with COPD susceptibility (Silverman, Speizer et al. 2000, 
Hersh, DeMeo et al. 2008, Konigshoff, Kneidinger et al. 2009). VEGF is 
decreased in the sputum of COPD patients and inversely correlates with 
disease severity, suggesting that impaired EndoC growth and survival 
may influence susceptibility in humans (Kanazawa and Yoshikawa 
2005).  
It has been postulated that decreased VEGF and/or signaling would 
be sufficient to induce disease (Kasahara, Tuder et al. 2001, Kanazawa, 
Asai et al. 2003). By using in situ end labeling, Segura-Valdez and 
colleagues determined that apoptotic cells in smokers with emphysema 
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were mainly EndoC, implicating both increased TGF-beta or decreased 
VEGF (Segura-Valdez, Pardo et al. 2000). In addition smoking may 
disrupt the expression or signaling of the VEGF-VEGF receptor complex 
(Marwick, Stevenson et al. 2006). In animal studies, there is more direct 
evidence of a causal relationship between EndoC apoptosis and 
development of emphysema. Kasahara and Tuder, reported that VEGF 
receptor blockade led to an apoptosis-dependent emphysematous 
remodeling; this was in the absence of inflammation but with a clear 
dependence on oxidative stress (Kasahara, Tuder et al. 2000). Taken 
together, EpiC death is hypothesized to decrease VEGF expression, 
ultimately disrupting endothelial homeostasis and resulting in 
emphysema.  
However, not to understate the importance of EpiC derived VEGF, 
the proposed dependence of EndoC apoptosis on EpiC apoptosis has not 
been directly shown. To the contrary the key finding in blocking VEGF or 
its receptors highlights the importance of EndoC homeostasis on EpiC 
death. Further in limited models where apoptosis and proliferation were 
studied simultaneously in human emphysema lung specimens, general 
alveolar wall apoptosis was increased but the majority of cells 
undergoing proliferation, as determined by proliferation cell nuclear 
antigen (PCNA), were EpiC, suggesting that EpiC VEGF production and 
or autocrine and paracrine signaling may be less prone to CS-induced 
alterations (Yokohori, Aoshiba et al. 2004, Takahashi, Nakamura et al. 
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2008). In addition, macrophages, which are also an important source of 
VEGF and the predominant cellular infiltrate into the lungs of 
emphysema patients are known to be poorly efferocytic in COPD 
patients, a process normally sufficient to enhance macrophage-derived 
VEGF (Vandivier, Henson et al. 2006, Wan, Huang et al. 2015). It should 
also be noted that until recently EndoC were not thought to produce 
VEGF, but recent evidence suggest they do and it is sufficient for steady-
state EndoC homeostasis, further highlighting the importance of EndoC 
integrity on alveolar and Endo maintenance (Maharaj, Saint-Geniez et al. 
, Lee, Chen et al. 2007). Taken together, these data highlight the 
potential contributions of non-EpiC derived VEGF, and therefore other 
potential sources of reduced VEGF leading to EndoC death with 












1.4 Animals Models of Emphysema 
 
There are several animal models of emphysema that have been developed 
and implemented to recapitulate various aspects of the complicated 
etiologies of disease onset, alveolar-capillary apoptosis, and progression. 
While some mouse strains and specific gene knockout mice, the VEGFR 
null or NRF2 null mice for example, develop spontaneous emphysema 
with age, exposures to many stimuli, including CS and proteases, are 
often used to induce disease, sometimes in tandem with postulant 
genetic deletions, with the prospect of simulating what we know about 
human emphysema, and understanding the impact of certain 
susceptibility genetic factors or candidate protein mediators.  
 
1.4.1 Elastase Model 
 
With the discovery of emphysema in patients with alpha-1 antitrypsin 
deficiency, enhanced protease expression has long been considered a 
driving factor in alveolar-capillary apoptosis, tissue degradation, and 
disease development (Laurell and Eriksson 1964, Carp, Miller et al. 
1982, Fujita, Nelson et al. 1990). The main protease that is degraded by 
alpha-1 antitrypsin is neutrophil elastase, and it degrades elastin fibers 
in the ECM of acinar cells (Hubbard, Ogushi et al. 1987). In order to 
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mimic the increase in protease production, intratracheal instillation of a 
plant protease called papain, human neutrophil elastase, or porcine 
pancreatic elastase is mainly performed on mice, rats, hamsters, and 
guinea pigs (Qian and Mitzner 1989, Tseng, Qian et al. 1992, Corteling, 
Wyss et al. 2002, Borzone, Liberona et al. 2009, Vecchiola, de la Llera et 
al. 2011, Craig, Scott et al. 2013). In mice, porcine elastase yields 
consistent and striking emphysematous damage accompanied with 
airspace enlargement, diminished alveolar surface area for gas exchange, 
declines in lung function, and immune function, which in part validate 
the model regarding relevance to human disease processes (Kuhn, Yu et 
al. 1976, Gillot, Masy et al. 1997, Fallica, Das et al. 2011, Ganesan, 
Faris et al. 2012).  
 Intratracheal or nasopharyngeal installation of elastase to induce 
emphysematous lesions is much different than the slow onset of human 
disease and may involve other mediators. This model may provide 
insights into the nature of the step-wise decline in lung function 
observed with increasingly worse exacerbations in human cases, as the 
progression that occurs after elastase clearance may be mediated by host 
inflammatory proteases (Kaplan, Kuhn et al. 1973, Kuhn and Starcher 
1980). However a large dose of elastase gives a clear picture of severe 
disease. In addition, it is a low-cost method, usually requiring one bolus 
dose of elastase to induce characteristics of human panacinar 
emphysema (Antunes and Rocco 2011). This method is often employed to 
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study the relationship of structure and function in the lung and to 
develop and or improve morphometric and stereological techniques 
(Lande and Mitzner 2006, Mitzner 2007, Fallica, Das et al. 2011, Munoz-
Barrutia, Ceresa et al. 2012, Limjunyawong, Kearson et al. 2014, 
Limjunyawong, Fallica et al. 2015). Further, given the rapid onset of 
emphysema, this is an attractive model to test specific genes and or 
proteins as well as potential therapeutic interventions that target, 
reverse, or protect against alveolar-capillary destruction (Takahashi, 
Nakamura et al. 2008). This also an appealing model in that the instilled 
elastase is cleared from the lung in 2-3 days but the alveolar damage 
persists thereafter and increases for several weeks, raising the possibility 
of developed autoimmunity as a result of ECM breakdown (Gillot, Masy 
et al. 1997, Le Guennec, Pestre et al. 2012, Kurimoto, Miyahara et al. 
2013).  
 
1.4.2 Autoimmune Model 
 
It is recognized that innate immunity responds to early exposure to CS 
and is prevalent during exacerbations but new research suggests that as 
emphysema progresses, autoimmunity is increased and dysregulated 
(Aoshiba, Koinuma et al. 2004, Curtis, Freeman et al. 2007). Evidence for 
autoimmunity in COPD was recently established, in which CD4 T cells 
from the blood of COPD patients showed a dramatic inflammatory 
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response to elastin fibers, partly validating a focus on autoreactive T cells 
as well as the protease based model (Gillot, Masy et al. 1997, Lee, 
Goswami et al. 2007, Le Guennec, Pestre et al. 2012, Kurimoto, 
Miyahara et al. 2013). In support of this role for autoimmune CD4 T cells 
in human emphysema, Taraseviciene-Stewart et al. show that rats 
immunized with human endothelial cells develop antibodies towards 
EndoC and within in weeks have signs of centrilobular emphysema, 
suggesting adaptive immune reactions may participate in the breakdown 
of the acini and endothelial apoptosis (Taraseviciene-Stewart, 
Scerbavicius et al. 2005). Interestingly the adoptive transfer of CD4 T 
cells from these immunized rats, into naive immunocompetent animals 
also results in emphysema, implicate a role for CD4 T cells in the 
targeted destruction of the alveolar EndoC. Therefore this model may fill 
the gap in knowledge as to the continued alveolar wall and EndoC 
destruction after smoking cessation. However the root cause of CD4 T 
cells initiating immune responses to self EndoC remains speculative, 
although the PTM of certain proteins, possibly due to CS, is recently 
implicated (Anderton 2004, Ryan, Nissim et al. 2014). The drawback of 
this model is that it largely avoids the slow initiation of disease onset, 
innate inflammation, and oxidative stress observed in human 
emphysema. In addition, emphysema can occur in murine models with 
recombination activating gene (RAG1) deficient mice and severe 
combined immunodeficient (SCID) mice suggesting processes involving 
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autoimmune responses in emphysema may contribute to the disease but 
are not necessary for its development.     
 
1.4.3 Cigarette Smoke Model 
 
Chronic CS exposure is the main cause of human emphysema and 
therefore a frequently used exposure method in animal models. In 
general the onset of detectable emphysema, defined by airspace 
enlargement accompanying decreased alveolar surface tissue, in mice 
takes months to a year and therefore has substantial associated 
operating costs (Fehrenbach 2006, Antunes and Rocco 2011, Leberl, 
Kratzer et al. 2013). Other species of animals including guinea pigs and 
rats are also used given there increased susceptibility to emphysematous 
remodeling, but due to the wide availability of genetic mutations, mice, 
particularly the C57BL/6, Balb/c, and A/J strains, are commonly used 
species (Leberl, Kratzer et al. 2013, Laucho-Contreras, Taylor et al. 
2015). In these mouse strains there are several varying approaches for 
smoke exposure based on ease of delivery and cost.  
 A widely used method for exposing mice is whole body exposure; 
however there are other strategies utilizing individual mouse restrainers 
for direct CS exposure to the nose which also understandably incurs a 
higher labor cost (Reduction, Bondurant et al. 2001, Leberl, Kratzer et al. 
2013). In either case the smoke delivered to the mice is a mixture of side 
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and mainstream smoke. With whole body exposure the mixture is 
approximately 80% side stream and 20% mainstream; with the direct 
nose exposure this estimated ratio is flipped (Moritsugu 2007, Leberl, 
Kratzer et al. 2013). In addition the use of modern equipment, such as 
the Teague exposure chambers, allows for total suspended particles (TSP) 
or total particulate matter (TPM) to be quantified, in order to insure 
regular dosing, and more accurate recapitulation of human main and 
side stream CS exposure (Rangasamy, Cho et al. 2004, Rangasamy, 
Misra et al. 2009, Sussan, Rangasamy et al. 2009, Simet, Sisson et al. 
2010, Leberl, Kratzer et al. 2013). While this is theoretically the closest 
model for mimicking human disease, there is a lack of consensus in the 
literature regarding the length of exposure, the “dose” of CS, particularly 
the TSP, TPM, and the amount of cigarettes used per mouse or per 
chamber per day, the type of cigarettes utilized, and the type of smoke, 
main or side stream, being delivered to the mice (Leberl, Kratzer et al. 
2013). Given that CS is a mixture of over 4000 potentially hazardous 
compounds in a gaseous form, the lack of consensus on these features 
could be a source of differential responses (Fowles and Dybing 2003, 
Rodgman and Perfetti 2013, John, Kohse et al. 2014). In addition due to 
the varying length of time it takes mice to develop CS-induced 
emphysema, the natural age-dependent alteration is lung structure may 
also make for difficult interpretation regarding the impact of CS 
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(Fehrenbach 2006, Takahashi, Fukuoka et al. 2008, Yao and Rahman 
2012).  
 Standardized reference cigarettes are available to aide in 
consistency in the field with dosing and TPM per cigarette, but other 
cigarettes are still used and the TSP and or TPM vary greatly from one 
experiment to the next. In addition, because the levels of certain oxidants 
and compounds differ in main and side stream CS, the type of smoke 
could significantly impact the patterns of inflammation, proteotlytic 
damage, declines in lung function, and the associated detection of 
emphysema (Finkelstein, Fraser et al. 1995, Nikula, March et al. 2000, 
Reduction, Bondurant et al. 2001, DeMarini 2004, Moritsugu 2007, 
Guarino, Cantarella et al. 2011, Rinaldi, Maes et al. 2012, John, Kohse 
et al. 2014). Despite these pitfalls, acute exposure in mice generally 
recapitulate many aspects of human disease processes, including DNA 
damage, dramatic increases in innate immune cell infiltration, 
alterations in immune cell function, enhanced proteolytic activity, 
enhanced oxidative stress, and increased alveolar-capillary apoptosis. 
This continues with chronic CS resulting in the irreversible loss of 
alveolar tissue, ECM destruction, pulmonary hypertension, and 
associated late stage fibrosis that characterizes human COPD (Nikula, 
March et al. 2000, Reduction, Bondurant et al. 2001, Rangasamy, Cho et 
al. 2004, Abboud and Vimalanathan 2008, Churg and Wright 2009, 
Sussan, Rangasamy et al. 2009, Barreiro, Peinado et al. 2010, Simet, 
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Sisson et al. 2010, Aoshiba, Zhou et al. 2012, Pellegrino and Antonelli 
2012, Rinaldi, Maes et al. 2012, Leberl, Kratzer et al. 2013).  
 
1.4.4 Other Inhalation Models  
 
Oxidative stress in response to cigarette or its continuance after smoking 
cessation has lead to other inhalation models, including exposure to 
zone, sulfur dioxide, or nitrogen dioxide, exclusively exploring the effects 
of environmental oxidants, production of ROS or RNS, and therefore 
oxidative damage on emphysema development (Holroyd, Eleff et al. 1997, 
Ichinose, Sugiura et al. 2000, Janssen-Heininger, Persinger et al. 2002, 
Persinger, Poynter et al. 2002, Meng, Qin et al. 2003, Groneberg and 
Chung 2004, Triantaphyllopoulos, Hussain et al. 2011, Uh, Kim et al. 
2011). Further, these noxious gases are hypothesized to be a significant 
source of exacerbated symptoms. These are interesting models, but 
require high concentrations that far exceed those detected in the 
environment for observable effects. Acute exposure to high concentration 
leads to increased alveolar wall permeability and a robust inflammatory 
response predominated by neutrophils, while longer exposures can cause 
the development of similar histopathological alterations and diffuse 
emphysematous tissue destruction observed in the later stages of COPD 
(Farone, Huang et al. 1995, Haddad, Salmon et al. 1996, Holroyd, Eleff et 
al. 1997, Kodavanti, Jackson et al. 2000, Mudway and Kelly 2000, 
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Persinger, Poynter et al. 2002, Triantaphyllopoulos, Hussain et al. 2011). 
The impact of ozone in particular seems to be on the small airways, 
causing enhanced airway hyperactivity and eventually signs of 
obstruction, as well as increases in protease production with subsequent 
loss of alveolar surface area (Tsukagoshi, Haddad et al. 1995, Mudway 
and Kelly 2000, Triantaphyllopoulos, Hussain et al. 2011). However 
ozone exposure is specifically linked with differential proteomic 
alterations compared with CS, suggesting its pathway to destroying 
tissue may not be consistent with human or murine emphysema (Uh, 
Kim et al. 2011). In addition there is a specific effect of all three gases on 
airway cells, causing hyperplasia, damage to cilia, and mucus 
hypersecretion, suggesting it may be an important model for bronchitis, 
although the use of mice may confound the translational value since they 
lack a dedicated bronchial circulation (Verloop 1949, Mitzner, Lee et al. 
2000, Groneberg and Chung 2004). Nonetheless these noxious gases and 
their secondary oxidation products provide key perspective as to the 
involvement of the oxidative stress component in disease progression but 
do not provide a full picture of emphysema or COPD. Further the 
different interspecies and intraspecies alterations may implicate 
underlying genetic susceptibilities but the duration and extent of 
exposures varies widely.  
     
1.4.5 Genetic Models 
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There is overwhelming evidence that connects susceptibility of developing 
emphysema with underlying alterations to genetic factors, including 
genetic polymorphisms and epigenetic silencing (Martorana, Brand et al. 
1993, Holroyd, Eleff et al. 1997, Wesselkamper, Prows et al. 2000, 
Hoffmann 2005, Reinhard, Meyer et al. 2005, Elias, Kang et al. 2006, 
Silverman 2006, Shapiro 2007, Hersh, DeMeo et al. 2008, Regan, 
Hokanson et al. 2010). Therefore the deletion of candidate genes that 
may regulate CS-induced disease and or result in spontaneous 
emphysema development is widely used. The targeted genetic deletions in 
mice are best selected to mirror genes that are silenced or proteins that 
are significantly decreased in human COPD (Holroyd, Eleff et al. 1997, 
Silverman, Chapman et al. 1998, Reinhard, Meyer et al. 2005, de 
Andrade 2012, Kabesch and Adcock 2012). This is perhaps recently 
exemplified in studies where the VEGF receptor and NRF2 have been 
individually knocked out in mice, to further understand their respective 
roles on aging and more specifically on EndoC, alveolar maintenance, 
and the role of antioxidants in regulating CS-induced oxidative stress 
(Kasahara, Tuder et al. 2000, Rangasamy, Cho et al. 2004). The 
spontaneous nature of emphysema in these and other genetic models 
further implicates differential gene expression in the aging process, 
suggesting that the increased severity of emphysema observed with the 
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tandem approach of genetic deletion with CS exposure is accelerating the 
aging process (MacNee 2009).  
 
 1.4.6 Summary of Mouse Models  
 
The animal models of emphysema development discussed above 
represent the most promising approaches to recapitulate what we know 
about human COPD. The elastase model is useful for understanding the 
potential contribution of protease/antiproteases imbalances but leads to 
slightly different histopathology and utilizes a time frame inconsistent 
with COPD development. The autoimmune model is an interesting 
approach to study the potential impact of altered immunity on disease 
progression observed after smoking cessation or with chronic CS, but 
similarly avoids the key aspects of disease onset and duration. The acute 
and chronic exposure of animals to CS is used to closely mimic many 
disease processes in human emphysema. Inhalation models other than 
tobacco smoke may provide information as to the specific effects of 
oxidative stress on disease development and or progression, as well as 
provide insight into the nature of non-infectious exacerbations.  
 Each of theses models carry value in understanding the 
multifactorial etiologies of emphysematous disease onset and or 
progression, but the tandem approach of CS exposure and genetic 
deletion was selected for this thesis project for several reasons. First this 
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exposure model represents the main cause of emphysema in humans 
and has been validated extensively in the literature. Secondly it allows 
accurate modeling of the acute and chronic effects of CS exposures on 
the alveolar compartment. Third it allows for the study of specific factors 
through genetic deletion, such as MIF, that may have an impact on 
emphysema, over the natural course of disease development. Thus 
understanding the underlying mechanisms of CS in tandem with 
potential novel intrinsic determinants of disease would propel the 
development and advancement of emphysema therapies, for which there 
are currently none. Fourth, MIF is an ideal candidate for targeted 
therapies, as the loss of MIF activity is implicated in normal airspace 
enlargement observed with aging, several disease processes of lung, and 
cytoprotection from CS induced apoptosis in vitro (Rosengren, Bucala et 
al. 1996, Kleemann, Kapurniotu et al. 1998, Damico, Simms et al. 2011, 
Mathew, Jacobson et al. 2013). The incorporation of MIF and MIF 









1.5 Macrophage Migration Inhibitory Factor (MIF) 
 
Historically MIF was one of the first cytokines to be discovered, and 
much research described its in vitro effects on macrophage function and 
motility, hence the common name alluding to this arresting behavior 
(Calandra and Roger 2003). In addition, MIF was thought to be secreted 
mainly from activated T lymphocytes. It was not until some 30 years after 
its discovery that MIF was cloned and still another few years before the 
recombinant protein was readily obtainable to study its structure and 
function. We now appreciate that MIF is constitutively expressed, stored, 
and secreted by many cells types that interact with the host 
environment, including macrophages, a main source during 
inflammatory responses, EndoC, EpiC, parenchymal cells, tumor cells, 
eosinophils, and glandular pituitary cells (Baugh and Bucala 2002, 
Bucala 2012). In addition MIF is found in the serum under basal 
conditions, indicating it may exert regulatory function. MIF is also 
secreted by a nonclassical ER/Golgi-independent pathway, and its 
release from preformed pools is regulated by cellular stress and 
inflammation (Weiser, Temple et al. 1989, Bernhagen, Calandra et al. 
1993, Merk, Baugh et al. 2009). Further, while MIF that is present on the 
extracellular surface of EndoC can promote monocyte arrest under flow 
conditions, and despite its name, MIF is generally recognized as 
promoting the chemotactic transmigration of leukocytes, namely 
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monocytes, into tissues (Ren, Tsui et al. 2003, Bernhagen, Krohn et al. 
2007, Simons, Grieb et al. 2011, Bucala 2012).  
MIF is now redefined as a 12.5kDa evolutionarily conserved 
pleiotropic cytokine, chemokine, hormone, and enzyme with intrinsic 
thiol-protein oxidoreductase (TPOR) activity, tautomerase activity and 
pro-inflammatory activity (Rosengren, Bucala et al. 1996, Kleemann, 
Kapurniotu et al. 1998, Chesney, Metz et al. 1999, Baugh and Bucala 
2002, Calandra and Roger 2003). In humans the MIF gene is located in 
region 1 of the q arm of chromosome 22 (22q11.2), which shares genetic 
homology with the MIF containing chromosome 10 in mice (Weiser, 
Temple et al. 1989, Calandra and Roger 2003). The MIF gene encodes a 
short 800 base mRNA that is translated into a 114 amino acid protein in 
which the sequence is 90% conserved and function is indistinguishable 
from mice to humans, suggesting that MIF has significant biological 
functions (Weiser, Temple et al. 1989, Bernhagen, Mitchell et al. 1994). 
Among these functions MIF is implicated in mechanisms that regulate 
MAPK activation, prevent apoptosis, promote cell survival, stimulate the 
expression of pro-inflammatory mediators, and block glucocorticoid 
activity, all of which are dysregulated with emphysema disease 
progression (Finkelstein, Fraser et al. 1995, Fujimoto, Kubo et al. 1999, 
Vignola, La Grutta et al. 2002, Drost, Skwarski et al. 2005, Schieven 
2005, Demedts, Demoor et al. 2006, Mercer and D'Armiento 2006, Low, 
Liang et al. 2007, Elsby, Donn et al. 2009, Barreiro, Peinado et al. 2010, 
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Shan, Yuan et al. 2012, Barnes 2013, Marumo, Hoshino et al. 2014, 
Antus and Kardos 2015). Because MIF has oxidoreductase and redox 
activity it is an attractive candidate in understanding its effect on 
oxidative stress a main component of emphysema progression. MIF is 
acutely increased in response to CS, suggesting it may have important 
protective effects (Damico, Simms et al. 2011). And lastly the anti-
apoptotic effects of MIF may be important in understanding the 
dysregulated EndoC death in emphysema.  
  
1.5.1 MIF in Endothelial Homeostasis 
 
EndoC are key components of the alveolar environment, providing the 
rest of the acini with nutrients, and they are destroyed during 
emphysema development (Kasahara, Tuder et al. 2001, Morissette, 
Parent et al. 2009, Gordon, Gudi et al. 2011, Guarino, Cantarella et al. 
2011). MIF is unique in that it can both antagonize EndoC apoptosis and 
potentiate their growth and proliferation. Exogenous MIF is an intrinsic, 
negative regulator of lipopolysaccharide (LPS)- and CS-induced apoptosis 
in human pulmonary EndoC, suggesting that the protective effects of 
MIF may be altered with disease development (Damico, Chesley et al. 
2008, Damico, Simms et al. 2011). In addition, MIF is increased in 
response to acute CS extract (CSE) and functions to antagonize EndoC 
apoptosis by blocking death signals, like TNF-alpha, from both the DR 
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and mitochondrial apoptotic pathways (Damico, Chesley et al. 2008, 
Damico, Simms et al. 2011). Specifically, MIF is a novel positive regulator 
of the FLICE-like inhibitor protein (FLIP), which functions to antagonize 
signals via the DR pathway in response to LPS (Damico, Chesley et al. 
2008). Additionally, MIF functions to suppress CS-induced p53 
expression and p53-dependent activation of the mitochondrial death 
pathway, including the uplregulation and cleavage of BID and BAX, in 
CSE-challenged EndoC (Baumann, Casaulta et al. 2003, Damico, 
Chesley et al. 2008, Damico, Simms et al. 2011). Thus, MIF antagonizes 
death signals from multiple apoptotic pathways in EndoC, by stabilizing 
intrinsic inhibitors and suppressing promoters of the apoptosis cascade.  
In addition to the anti-apoptotic effects, MIF can enhance 
endothelial proliferation in an Extracellular signal-regulated kinase (ERK) 
and or Protein kinase B (AKT) dependent manner (Amin, Volpert et al. 
2003, Lue, Thiele et al. 2007, Wadgaonkar, Somnay et al. 2008). Further, 
increased and sustained ERK1/2 activation leading to proliferation, in 
response to exogenous MIF, is dependent on a mechanism involving 
protein kinase A (PKA) and phospholipase A2 (PLA2), linking this effect of 
MIF to an extracellular receptor (Mitchell, Metz et al. 1999). This is an 
intriguing aside because PLA2 is a main target for glucocorticoids, 
endogenously produced or medically prescribed, and this type of 
treatment is often ineffective in current and former patients with varying 
degrees of emphysema or COPD (Mitchell, Metz et al. 1999, Barnes 2002, 
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Hersh, DeMeo et al. 2008, Elsby, Donn et al. 2009). This suggests that 
the acute increase in CS-induced MIF and its stabilizing effect on PLA2 
may in part explain MIFs control over glucocorticoid activity and their 
ineffectiveness in disease treatment.  
Exogenous MIF is also sufficient to upregulate the expression of 
VEGF, which is necessary for EndoC maintenance and repair, but 
reduced with disease severity (Kasahara, Tuder et al. 2000, Ren, Chan et 
al. 2004, Marwick, Stevenson et al. 2006). This may be through ERK 
dependent transactivation of hypoxia inducible factor 1 (HIF1) alpha, an 
important regulator of VEGF (Ren, Chan et al. 2004, Maity and 
Koumenis 2006, Oda, Oda et al. 2008). This relationship is most 
apparent in studies of the angiogenic potential of tumors with and 
without MIF and in neonatal respiratory distress syndrome (Kevill, 
Bhandari et al. 2008, Bucala 2012). Further, increased MIF enhances 
the chemotactic and pro-inflammatory potential of macrophages into 
areas of damage or stress and this may have 2 main effects, 1) The local 
increase of MIF counterbalances oxidative stress and prevents cell death, 
or 2) cells that die are engulfed by the infiltrating macrophages, which is 
sufficient to increase macrophage derived VEGF production (Kleemann, 
Kapurniotu et al. 1998, Lind, Trindade et al. 1999, Gregory, Morand et 
al. 2006, Vandivier, Henson et al. 2006, Damico, Simms et al. 2011, Fan, 
Hall et al. 2011).  
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1.5.2 MIF and Altered Immunity 
 
MIF has well-established pro-inflammatory functions including 
macrophage and T cell recruitment, enhancing expression of adhesion 
molecules on EndoC, and upregulating the expression of pro-
inflammatory cytokines from multiple cell types (Calandra, Bernhagen et 
al. 1995, Donnelly, Haslett et al. 1997, Bozza, Satoskar et al. 1999, 
Mitchell, Liao et al. 2002, Calandra and Roger 2003, Gregory, Morand et 
al. 2006, Bernhagen, Krohn et al. 2007, Harrison 2007, Zernecke, 
Bernhagen et al. 2008). While these functions are beyond the scope of 
this thesis, the potential dysregulation of MIF in disease could partly 
explain the altered innate and adaptive immune responses observed in 
emphysema, or other disease where MIF is altered, and validate the 
study of MIF in the modeling of emphysematous disease progression 
(Finkelstein, Fraser et al. 1995, Cosio and Guerassimov 1999, Vignola, 
La Grutta et al. 2002, Drost, Skwarski et al. 2005, Pridgeon, Bugeon et 
al. 2011, Hou, Sun et al. 2013). The acute CS-induced increase in MIF 
could therefore explain influx of predominately macrophages, which 
correlates with disease progression (Damico, Simms et al. 2011). MIF 
dysregulation with disease progression also correlates with dramatically 
distorted adaptive immunity; in disease processes like respiratory 
distress syndrome, where MIF is decreased, T cell populations are 
significantly increased as observed in later stages of emphysema 
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(Aoshiba, Koinuma et al. 2004, Rosen, Lee et al. 2006, Hodge, Nairn et 
al. 2007, Kevill, Bhandari et al. 2008, Chang, Nadigel et al. 2011, Dancer 
and Sansom 2013, Eppert, Wortham et al. 2013, Hou, Sun et al. 2013). 
In cases where MIF is significantly increased like rheumatoid arthritis 
(RA), its overexpression is coincident with the onset of autoimmune 
responses (Leech, Metz et al. 1999, Baugh, Chitnis et al. 2002, Morand, 
Leech et al. 2002, Denkinger, Metz et al. 2004). In addition and in 
possible contrast to the idea that MIF expression is protective toward CS-
induced cellular damage, MIF has been implicated as a positive regulator 
of metalloproteases (MMPs) including collagenases (MMP13 and MMP1) 
and gelatinases (MMP2, and MMP9) but not elastase (MMP12) (Meyer-
Siegler 2000, Onodera, Nishihira et al. 2002, Kong, Huang et al. 2005). 
Of the known MMPs responsive to MIF, MMP2 and MMP9, are elevated in 
human COPD and animal models of emphysema (Betsuyaku, Nishimura 
et al. 1999, Seagrave, Barr et al. 2004, Boschetto, Quintavalle et al. 
2006). 
 
1.5.3 MIF in Aging and Other Diseases 
 
MIF protein decreases in the lungs of aging mice, indirectly linking it in 
age-related airspace enlargement, a well-documented process (Verbeken, 
Cauberghs et al. 1992, Mathew, Jacobson et al. 2013, Papaioannou, 
Rossios et al. 2013). It is also recognized that genetically engineered 
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strains of mice, hypersensitive to CS, can also demonstrate evidence of 
accelerated age-dependent lung remodeling (Morris, Huang et al. 2003, 
Ruwanpura, McLeod et al. 2011). This suggests MIF may influence lung 
homeostasis, development, and or oxidative damage resulting from 
continued or prolonged smoking. In neonatal mice exposed to hyperoxia, 
both surpluses and deficits of MIF can alters neonatal alveolar 
development, suggesting that MIF concentrations are tightly regulated for 
optimal lung maturation (Sun, Choo-Wing et al. 2013). In premature 
babies increased MIF levels correlate with a polymorphism in the MIF 
promoter and is thought to confer protection from neonatal respiratory 
distress syndrome which leads to bronchopulmonary dysplasia (BPD) 
(Prencipe, Auriti et al. 2011). In contrast and highlighting the importance 
of MIF levels, MIF overexpression, which is central in the pathogenesis of 
RA, is associated with hyperplasia and overgrowth of the synovium and 
increased burden of pro-inflammatory macrophages (Santos and Morand 
2006, Kasama, Ohtsuka et al. 2010). Further in cases of sepsis, 
increased levels of MIF are associated with increased risk of lethal shock 
(Bozza, Satoskar et al. 1999). On the opposite end of the MIF spectrum, 
animal models of BPD and other disease states like ischemic cardiac 
injury and radiation-induced lung injury demonstrate that loss of MIF is 
associated with increased tissue damage (Qi, Hu et al. 2009, Prencipe, 
Auriti et al. 2011, Mathew, Jacobson et al. 2013). Further, MIF 
polymorphisms are present in other chronic lung diseases, including 
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asthma and cystic fibrosis, and correlate with disease pathogenesis, 
raising the likelihood that similar polymorphisms may confer protection 
or contribute to emphysema progression, and in fact may underlie some 
of the genetic susceptibilities suspected in CS-induce emphysema onset 
(Hoffmann 2005, Mizue, Ghani et al. 2005, Plant, Gallagher et al. 2005, 
Wu, Fu et al. 2009).  
  
1.5.4 MIF Expression and Secretion 
 
MIF is constitutively expressed and stored in preformed pools by many 
cells in the lung including EndoC, EpiC, and alveolar macrophages 
(Calandra and Roger 2003, Roger, Ding et al. 2007, Cheng, McKeown et 
al. 2010). The MIF promoter has two key response elements that can 
mediate its expression or upregulation observed with inflammation or 
oxidative stress— a sequence that binds cyclic AMP response element-
binding protein (CREB) and cyclic AMP-dependent transcription factor 
(ATF1), and a hypoxia response element (HRE) respectively (Baugh, 
Gantier et al. 2006, Elsby, Donn et al. 2009). In response to hypoxia, a 
recognized component of CS induced emphysema, HIF1-alpha will 
upregulate MIF expression through the HRE located in the MIF promoter. 
The activity of CREB or ATF1 on the MIF promoter may in part explain 
the constitutive nature of MIF expression. While polymorphisms may 
also be a source of altered MIF expression there are few other molecular 
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mechanisms that can suppress MIF transcription. MIF is susceptible to 
epigenetic silencing, by microRNA miR-451, which is upregulated in the 
circulation of human smokers suggesting one potential molecular 
mechanism of MIF suppression in COPD (Bandres, Bitarte et al. 2009, 
Liu, Jiang et al. 2013, Takahashi, Yokota et al. 2013). The MIF promoter 
is also repressed by histone deacetylase (HDAC) inhibitors, and HDAC 
expression and activity are reduced in human COPD (Yang, Chida et al. 
2006, Lugrin, Ding et al. 2009).  
 
1.5.5 MIF Structure and Function   
   
MIF has a complex structural dynamic that may help illuminate 
the many functions, binding partners, and enzymatic reactions 
attributed to it. The crystallographic structure of MIF reveals that it 
exists as a barrel-shaped 37.5kDa homotrimer with a solvent accessible 
core (Kato, Muto et al. 1996, Sun, Bernhagen et al. 1996, Dobson, 
Augustijn et al. 2009). However it is recently speculated that 
physiologically relevant quantities of MIF contain a mix of monomers, 
homodimers, or homotrimers, a balance that may be heavily influenced 
by its concentration (Sun, Swope et al. 1996, Bernhagen, Calandra et al. 
1998, Mischke, Kleemann et al. 1998). During inflammatory response, 
for example, extracellular MIF is increased which may enhance the 
probability of trimer formation and therefore shift the balance of the 
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three configurations (Swope and Lolis 1999, Fan, Rajasekaran et al. 
2013). The structure of the monomer consists of six beta strands, four of 
which form a sheet, and two alpha helices (Sun, Bernhagen et al. 1996, 
Dobson, Augustijn et al. 2009). In forming the trimeric structure two of 
the beta strands in the sheet of one monomer interact with beta strands 
on an adjacent monomer, stabilizing the complex with 3 intertwining 
beta sheets (Kato, Muto et al. 1996, Sun, Bernhagen et al. 1996). The 
homotrimer is further stabilized by hydrophobic interactions between a 
leucine residue in the beta-3 strand of one monomer with a pocket of 
other hydrophobic amino acids on the beta-2 strand of another monomer 
(El-Turk, Fauvet et al. 2012). Given these interactions, the homotrimer is 
thought to be the most stable form of MIF and functional research 
utilizing locked-trimer mutants of MIF also suggests that the active form 
of MIF that binds its putative receptors is a homotrimer (Fan, 
Rajasekaran et al. 2013). Further, the homotrimer contains catalytic 
tautomerase sites between the subunits; whether or not a biologically 
relevant substrate for this site exists remains unknown, but alterations 
to a key terminal proline (Pro2) residue within the site can reduce the 
binding capacity of MIF, suggesting this region in the trimer complex is 
necessary for at least some biological functions of MIF (Lubetsky, Swope 
et al. 1999, Lubetsky, Dios et al. 2002, Senter, Al-Abed et al. 2002, 
Fingerle-Rowson, Kaleswarapu et al. 2009). In Contrast, the monomer 
and dimer forms may be capable of binding other proteins or receptors 
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and exerting differential effects. This is perhaps exemplified in studies 
involving the reactive cysteine residues on MIF.  
  While MIF does not belong to a structural class of proteins, it is 
functionally homologous with the TPOR family of proteins, which most 
notably contains thioredoxin (TRX), which are important in redox 
signaling (Kondo, Ishii et al. 2004, Kudrin and Ray 2007). MIF contains a 
redox sensitive TPOR motif with two reactive cysteine residues, Cys57 
and Cys60, separated by two amino acids (CALC) (Mischke, Gessner et 
al. 1997, Kleemann, Kapurniotu et al. 1998, Kleemann, Mischke et al. 
1998, Kleemann, Kapurniotu et al. 1999). In the trimeric form of MIF, 
these residues are not readily accessible suggesting that the trimer may 
not have oxidoreductase activity (Sun, Bernhagen et al. 1996, Dobson, 
Augustijn et al. 2009, Luedike, Hendgen-Cotta et al. 2012). Further in 
studies utilizing single or double mutations at these sites, loss of Cys60 
resulted in total loss of redox activity, while loss of Cys57 only resulted in 
a partial reduction (Nguyen, Beck et al. 2003). Of these two cysteine 
residues, Cys60 has more surface accessibility in the monomeric form 
(Sun, Bernhagen et al. 1996, Dobson, Augustijn et al. 2009). In addition, 
monomeric MIF is approximately the same size as TRX with a remote 
structural resemblance although the fold containing the TPOR motif is 
distinctly different (Kudrin and Ray 2007). This suggests that the MIF 
monomer may actively participate in redox signaling and may have 
similar disulfide formation, protein interactions, and redox signaling as 
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other TPOR family members (Kleemann, Kapurniotu et al. 1998, 
Kleemann, Mischke et al. 1998, Kondo, Ishii et al. 2004, Nadeau, 
Charette et al. 2007). There is also a third cysteine residue on MIF, 
Cys81, which is modifiable in the monomer or trimer form (Kleemann, 
Kapurniotu et al. 1999, Jung, Seong et al. 2008, Dobson, Augustijn et al. 
2009, Luedike, Hendgen-Cotta et al. 2012). In either case modification of 
Cys81, can alter the conformation of MIF thereby altering its function. 
For example when Cys81 is S-nitrosylated (SNO), oxidioreductase 
capacity of MIF is enhanced (Luedike, Hendgen-Cotta et al. 2012). Taken 
together, these cysteine residues are key to some of MIF’s biological 
functions, although more work is needed to understand the in vivo 
conformations of MIF and their impact on downstream signaling.  
 
1.5.6 MIF Protein-Protein Interactions  
 
In addition to altering and conferring function, the reactive cysteine 
residues on MIF are also sufficient for protein-protein interactions. MIF 
can bind to intracellular proteins as an endogenous protein, or via 
internalization into the cell. The recognized intracellular receptor for MIF 
is the cysteine-rich c-Jun activation domain binding protein-1 (JAB1), 
also known as subunit 5 (CSN5) of the COP9 signalosome, which 
through its downstream target, activator protein 1 (AP1), can modulate 
cell proliferation, differentiation, and apoptosis (Hwang, Ryu et al. 2004, 
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Burger-Kentischer, Finkelmeier et al. 2005, Lue, Thiele et al. 2007). The 
peptide region on MIF spanning amino acids 50-65, which contains the 
TPOR region, is necessary for the JAB1 interaction (Burger-Kentischer, 
Finkelmeier et al. 2005). Some research suggests that the Cys60 residue 
may be key for a strong interaction but not essential for binding 
(Kleemann, Hausser et al. 2000, Nguyen, Beck et al. 2003). Recent 
research also suggests that Cys81 allosterically regulates the binding 
capacity of this TPOR spanning region on MIF. Mutating or deleting 
Cys81 results in significantly less JAB1 binding and SNO-Cys81 
enhances it (Luedike, Hendgen-Cotta et al. 2012). Cys81 is further 
implicated in the ability of MIF to directly bind and inhibit p53 (Jung, 
Seong et al. 2008). Although there is evidence that JAB1 also binds p53 
and may act as a molecular bridge, recent data suggests that Cys81 
forms a disulfide linkage with Cys242 on p53 (Chamovitz and Segal 
2001, Lee, Oh et al. 2006, Oh, Lee et al. 2006, Jung, Seong et al. 2008, 
Jung, Seong et al. 2008). However given the importance of Cys81 on MIF 
structure, conformational changes have not yet been ruled out in MIF-
p53 binding. Interestingly, nucleoside diphosphate kinase 1 (NM23-H1), 
which binds to Cys60 on MIF, negatively regulates the ability of MIF to 
suppress p53, suggesting that NM23-H1 binding is competitive for the 
same region on MIF (Jung, Seong et al. 2008). Nonetheless these cysteine 
residues are critical for many intracellular protein interactions with MIF 
and while this is still an ongoing area of research, cysteine interactions 
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are further implicated in MIF binding with the proapoptotic Bcl-
2/adenovirus E1B 19 kDa-interacting protein 2-like (BNIPL), the thiol 
specific antioxidant proliferation associated gene (PAG), and the 
hepatotrophic growth factor hepatopoietin (HPO) (Jung, Kim et al. 2001, 
Shen, Hu et al. 2003, Li, Lu et al. 2004). 
Binding of extracellular MIF to its cognate receptors is thought to 
be independent of the cysteine residues, and dependent on the trimeric 
structure. This is most evident in studies utilizes a mutant form of MIF 
that is locked in a trimeric state through an intersubunit disulfide bond; 
the locked trimer of MIF binds CD74 and activates downstream signals 
(Fan, Rajasekaran et al. 2013). Interestingly CD74 is the extracellular 
invariant chain of major histocompatibility complex II (MHCII), which 
normally binds and facilitates shuttling of MHCII to the surface, and MIF 
shares structural similarities with the peptide-binding region of MHCs 
(Thiele and Bernhagen 2005, Bucala 2012). In this cognate role CD74 
interacts with MHCII as a trimer. In this trimeric state CD74 shares 
rotational symmetry with the MIF trimer, and this may help shed light on 
the importance of the MIF intersubunit tautomerase sites on CD74 
binding (Lubetsky, Swope et al. 1999, Dobson, Augustijn et al. 2009, 
Fingerle-Rowson, Kaleswarapu et al. 2009, Schwartz, Lue et al. 2009). 
Further MIF may contribute in class II antigen presentation by binding 
HLA-DP molecules and processing antigen peptides (Potolicchio, 
Santambrogio et al. 2003). The MIF monomer also shares remote 
! 70!
structural similarities with the chemokine dimer CXCL8, implicating 
extracellular binding of different forms of MIF on intracellular signaling 
pathways; MIF is known to bind the chemokine receptors CXCR2 (CXCL8 
receptor) and CXCR4, which is sufficient to induce leukocyte 
recruitment, tying the secretion of MIF to inflammatory responses 
(Bernhagen, Krohn et al. 2007, Bucala 2012, Schwartz, Kruttgen et al. 
2012).  
Conversely more studies are needed to elucidate whether these 
effects may also be mediated through the efficient endocytosis of MIF into 
certain cells. Intriguingly, MIF has been recently shown to bind its TPOR 
family member TRX on the extracellular surface, which mediates its 
internalization and inhibits some of the MIF-associated pro-inflammatory 
activity (Son, Kato et al. 2009). However the formation of chemokine 
receptor heterodimers, or dimerization with CD74, specifically 
CD74/CXCR4, is also implicated in MIF endocytosis involving clathrin 
and dynamin-dependent processes (Schwartz, Kruttgen et al. 2012). 
More work is needed to elucidate this complicated picture of MIF 
structural dynamics and the resulting differential binding capacities or 
behaviors with the formation, binding, and internalization capacities of 
the extracellular receptors, which may also vary depending on the 
stimulus or type of response being elicited.  
  
1.5.7 MIF and Transcription Factors  
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Through its effects on cytosolic p53, intracellular MIF can 
ultimately alter cell fate decisions by modulating the stability of nuclear 
p53 and other transcription factors, including HIF1 alpha (Lee, Oh et al. 
2006, Jung, Seong et al. 2008, Oda, Oda et al. 2008). Further, through 
JAB1 binding, MIF can alter HIF1-alpha, p53, AP1, Progesterone 
receptor- (PR), and glucocorticoid receptor (GCR)-related transcription 
and may also enhance the major transcriptional regulator of the 
antioxidant response element (ARE), NRF2, leading to secondary effects 
on antioxidant gene expression and regulatory activity towards oxidative 
stress (Bianchi, Denti et al. 2000, Chauchereau, Georgiakaki et al. 2000, 
Kleemann, Hausser et al. 2000, Chamovitz and Segal 2001, Bae, Ahn et 
al. 2002, Hwang, Ryu et al. 2004, Lee, Oh et al. 2006, Oh, Lee et al. 
2006, Villeneuve, Lau et al. 2010). The antagonism of p53 by MIF, leads 
to a reduction in the pro-apoptotic genes regulated by p53 (discussed 
above in section 1.3.1) and therefore has a pro-survival effect. In addition 
to the hypoxic upregulation of MIF expression, MIF can stabilize HIF1-
alpha by preventing the p53-dependent ubiquitination of HIF1-alpha 
(Oda, Oda et al. 2008, Simons, Grieb et al. 2011). This stabilizing effect 
on HIF1-alpha may be sufficient to maintain vascular homeostasis in the 
lung, as VEGF and glucose transport are increased as a result of is 
transcriptional activity (Xiao, Zeng et al. 2006, Oda, Oda et al. 2008, 
Song, Wang et al. 2009). The effect of MIF on JAB1 dependent AP1 
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transactivation is also straightforward; JAB1 stabilizes c-jun protein 
binding to AP1 sites, thereby acting as a coactivator for AP1 
transcription, and MIF binding to JAB1 antagonizes this function, 
altering cell growth, proliferation, and or apoptosis-related protein 
expression depending on the cellular context (Bianchi, Denti et al. 2000, 
Kleemann, Hausser et al. 2000, Hwang, Ryu et al. 2004). JAB1 also 
directly interacts with PR, GCR, and to an extent NF-kappaB by 
stabilizing their association with nuclear receptor coactivator 1 (NCOA1), 
but the effects of MIF on JAB1 regarding these transcription factors, 
while plausible, remains ill defined (Claret, Hibi et al. 1996, Kleemann, 
Hausser et al. 2000, Chamovitz and Segal 2001). 
The hypothesis of MIF binding JAB1 to affect NRF2 stability is still 
controversial. The COP9 signalosome, to which JAB1 associates, is 
involved in the deneddylation of proteins (Schmaler and Dubiel 2010). 
Neddylin (NEDD8) stabilizes cullins, allowing for activation of associated 
ubiquitin ligases (E3) (Lyapina 2001, Cope 2002, Zheng 2002, Yamoah, 
Wu et al. 2005). Kelch-like ECH-associated protein 1 (KEAP1) tethers 
NRF2 to these cullin scaffolds, and when neddylated, the E3 ligase 
targets NRF2 for ubiquitination (Villeneuve, Lau et al. 2010). In order for 
this complex to efficiently degrade more cytosolic NRF2 it must cycle 
apart and back together (Chamovitz and Segal 2001, Pintard 2003). 
JAB1, as part of the signalosome, is hypothesized to remove NEDD8, 
destabilizing the cullin complex in order for KEAP1 to bind another NRF2 
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(Cope 2002, Villeneuve, Lau et al. 2010). In the presence of ubiquitin-
conjugating enzyme E2M (UBC12) the complex will be re-neddylated, 
stabilizing the complex once again, allowing the cycle to continue 
(Chamovitz and Segal 2001, Schmaler and Dubiel 2010, Villeneuve, Lau 
et al. 2010). However, it is not known whether MIF interacts with JAB1 
as a single protein or as part of the multi-protein complex (COP9 
signalosome) or how MIF may modulate these relative pools of JAB1. 
Under the premise that MIF antagonizes JAB1 activity, this scenario 
paints a picture whereby MIF would stabilize NRF2, by preventing its 
rapid targeting for proteosomal degradation. Taken together intracellular 
MIF can modulate gene transcription by regulating several key 
transcription factors involved in cell fate.  
 
1.5.8  MIF and Intracellular Signaling Pathways 
 
As described above MIF can alter fundamental pathways involved in cell-
fate through extracellular reception, as an endogenous protein, or 
through internalization via an ill-defined endocytic route. Depending on 
how MIF is received by a given cell may determine the response, which 
could also be functionally distinct and or conflicting within a single cell 
type or between cell types. For example, CD74, in conjunction with 
CD44, is capable of transducing the extracellular binding of MIF into 
activation of intracellular kinase cascades involved in cell survival, 
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including JNK, p38, ERK1/2, and AKT (Santos, Lacey et al. 2004, Shi, 
Leng et al. 2006, Starlets, Gore et al. 2006, Qi, Hu et al. 2009, Sanchez-
Nino, Sanz et al. 2009). However CD74 has not been identified on EndoC 
and other cells, suggesting the impact of MIF, at least on EndoC survival 
is through a different pathway or absent in these cell types. In addition 
p38 is likely still modified in MIF dependent manner but by means other 
than CD74. XOR for example, which is increased with disease severity 
and an important source of ROS, is activated downstream of p38 in 
human microvascular EndoC (HMVEC) which lack CD74 (Pinamonti, 
Muzzoli et al. 1996, Pinamonti, Leis et al. 1998, Le, Damico et al. 2008, 
Kim, Serebreni et al. 2013). Although the internalization of MIF, either 
through receptor ligand interaction or pinocytosis when its 
concentrations are high, is not well studied, MIF is however hypothesized 
to act freely in the cytosol versus in an endolysosomal compartment 
because its oxidoreductase activity is optimal at neutral pH (Potolicchio, 
Santambrogio et al. 2003, Kudrin and Ray 2007). Theoretically free 
cytosolic MIF could then interact with redox sensitive MAP3K and the 
associated pathways. However, the resulting pathway activations may be 
entirely different given that extracellular stimulation of CD74 is likely 
with a MIF trimer and the intracellular alterations are likely mediated 
through the TPOR site and oxidoreductase activity of MIF. 
  The ability of MIF to antagonize JAB1 may also allude to one 
possible mechanism by which MIF exerts its protective effects, through 
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the NRF2 related mechanism discussed above for example. However 
there is conflicting evidence that may in part be due to the context of this 
cellular interaction between MIF and JAB1. They both stabilize HIF1-
alpha, albeit through different mechanisms, but this raises the question 
of whether their relationship is purely antagonistic (Bae, Ahn et al. 2002, 
Oda, Oda et al. 2008, Simons, Grieb et al. 2011). JAB1, independent of 
the COP9 signalosome, inhibits the cyclin dependent kinase (CDK) 
inhibitor p27KIP1, which can induce G1 cell cycle arrest (Tomoda, 
Kubota et al. 1999). Exogenously applied MIF is internalized where it 
binds with cytosolic JAB1 near the plasma membrane and inhibits the 
control of JAB1 over p27KIP1, essentially stabilizing p27KIP1 and G1 cell 
cycle arrest (Tomoda, Kubota et al. 1999, Kleemann, Hausser et al. 
2000). In addition, perhaps tying in with the JAB1-related regulation of 
AP1 transcription, JAB1 enhances JNK activity and downstream c-jun 
phosphorylation; MIF blocks this JAB1–dependent effect, possibly 
disrupting cell growth and or proliferation. However the exact mechanism 
remains ill-defined, as MIF and JAB1 do not possess kinase activity and 
do not directly associate with JNK (Tomoda, Kubota et al. 1999, 
Kleemann, Hausser et al. 2000). Further this regulation of the MAPK 
pathways contradicts signaling mediated through extracellular receptors 
since exogenous MIF is mostly reported as a positive regulator of cell 
survival and proliferation. Nonetheless, MIF, through its TPOR motif may 
alter the function of the MAPK kinase kinases (MAP3K), which are known 
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to be sensitive to oxidative stress. This hypothesis could also partially 
explain JAB1 control over JNK activity, as JAB1 can also directly 
associate with TRX a known regulator of MAP3K (Burger-Kentischer, 
Finkelmeier et al. 2005, Kudrin and Ray 2007).  
 JAB1 appears to have promiscuous cell behavior and binding, not 
only modulating transcription factors in the nucleus and protein activity 
in the cytosol, but redundancy in binding the known MIF-binding 
partners, like p53, and HPO (Wang, Lu et al. , Lu, Li et al. 2002, Lee, Oh 
et al. 2006). JAB1 can bind p53 and as part of the COP9 signalosome it 
can mediate the degradation of p53 (Bech-Otschir 2001, Lee, Oh et al. 
2006). HPO appears to stabilize JAB1 effects on AP1, which is in contrast 
to MIF. Intriguingly the MIF-JAB1 complex is detectable in the cytosol, 
but it is not known whether this complex, while together, has signaling 
or binding functionality as a cytosolic and or transcription factor similar 
to the individual capacities of MIF and JAB (Kleemann 2000, Bech-
Otschir 2001, Chamovitz and Segal 2001, Lee, Oh et al. 2006, Kudrin 
and Ray 2007). Given the differential regulation of JAB1 by MIF and HPO 
it is conceivable this may be due to differential binding. In addition the 
promiscuous activity of JAB1 may underlie its reportedly divided role in 
inducing or protecting cells from apoptosis (Tomoda, Yoneda-Kato et al. 
2004, Hallstrom and Nevins 2006, Liu, Pan et al. 2008, Damico, Simms 
et al. 2011). Further, MIF may also have the capacity for multiple and 
simultaneous interactions as both the TPOR motif and Cys81 are 
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involved in binding. However further work is needed to uncover the 
complex networking of these cysteine-rich and redox-sensitive proteins 
when their cognate intracellular locations are in flux, especially in the 
context of specific stimuli like CS, which provokes the associated redox 
reactions.  
 
1.5.9  MIF Deficient Mice 
  
Deletion of the MIF gene from the mouse genome was completed in 1999 
by Bozza et al, in order to better understand the role of MIF in sepsis 
(Bozza, Satoskar et al. 1999, Calandra and Roger 2003). It was reported 
that Mif -/- mice are healthy, lacking any apparent abnormalities or 
growth and developmental deficiencies. Since then Mif -/- mice have been 
utilized extensively to better understand its role in many inflammatory, 
autoimmune, and exposure-related disease processes especially where 
human MIF polymorphisms correlate with disease severity. In recent 
studies, we now understand that MIF may be involved in normal lung 
development and antagonize the natural aging of the lung (Mathew, 
Jacobson et al. 2013). Given the role of MIF polymorphism in other 
chronic lung diseases, in vitro data implicating MIF in pulmonary 
vascular homeostasis, and the potential cytoprotection conferred through 
its oxidoreductase activity we have employed Mif -/- mice to elucidate its 
role in CS-induced lung injury, hypothesizing that MIF expression is 
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1.6 Thesis Summary 
 
Emphysema is a common form of COPD that contributes to significant 
morbidity, mortality, and healthcare cost in the United States. CS is the 
most common cause of emphysema but there are clear genetic risk 
factors, such as alpha-1 antitrypsin deficiency, that inform our 
understanding of the cellular and molecular mechanisms of 
emphysematous tissue destruction. However the relationship between 
intrinsic determinants of disease and CS exposure history is not well 
understood. In addition there are currently no therapies directed at 
ameliorating or curtailing the persistent nature of alveolar tissue loss 
observed in emphysema.  
Endo and EpiC are key structural components of the alveoli and 
principal targets of CS-induced apoptosis leading to emphysematous 
tissue destruction. This alveolar wall apoptosis correlates with increases 
in surface area and mean airspace size but is associated with enhanced 
proliferation of both EndoC and EpiC, suggesting that the repair process 
is overwhelmed by CS-induced tissue destruction and apoptosis. This 
disproportionate apoptosis is necessary for emphysema and EndoC 
apoptosis is sufficient to induce emphysematous lung destruction. In 
addition, the associated increases in oxidative stress, inflammation, and 
a protease/anti-protease imbalance all promote EndoC apoptosis and all 
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are implicated in loss of acinar structures, further emphasizing apoptosis 
as a nodal point CS-induced emphysema pathogenesis.  
Recognizing CS is a mixture of many extrinisic factors and 
oxidants that may alter and or contribute to emphysema development 
and severity, the identification of the pathways and intrinsic 
determinants of CS-induced apoptosis may further the understanding of 
disease pathogenesis for therapeutic interventions. However, apoptosis 
persists after cessation of chronic CS, indicating that protective 
mechanisms may be significantly or irreversibly impaired. This is evident 
from the continued exacerbations of oxidative stress in former smokers 
and patients with emphysema. In addition oxidative stress may underlie 
many of the disease manifestations like protease imbalance and 
inflammation. Therefore, understanding functional relationships between 
apoptosis, oxidative stress, and intrinsic determinants of emphysema 
pathogenesis is critical for therapy.  
MIF is one intrinsic factor that is acutely increased in response to 
CS in vitro and antagonizes CS-induced EndoC apoptosis. This suggests 
that the cytoprotective effects of MIF may be altered or diminished with 
disease severity. The multiple functions of MIF as a cytokine and enzyme 
reveal a critical role for MIF in enhancing acute CS-induced 
inflammatory responses and modulating oxidant and antioxidant 
reactions through its redox sensitive cysteine residues, both key 
characteristics in emphysema pathogenesis. MIF also interacts with 
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many proteins and directly or indirectly modulates transcription factors 
that are linked to and are dysregulated in emphysema. In addition there 
are other lung diseases where polymorphisms in the MIF promoter 
correlate with disease severity suggesting that the levels of MIF may be 
critical in maintaining lung and alveolar EndoC maintenance. Therefore 
the study of emphysema utilizing a combination of genetic and exposure 
models may uncover a novel role for MIF in disease pathogenesis and 
open the door for new therapeutic strategies targeting oxidative stress 
and tissue destruction.  
 
1.6.1 Hypothesis and Aims 
 
The overarching hypothesis is that MIF deficiency will exacerbate CS-










1.6.2 Specific Aims 
Aim 1: To test the hypothesis that MIF impacts on the severity of 
CS-induced EndoC injury in vivo and influences emphysematous 
tissue remodeling. 
To disrupt MIF signaling, Mif -/- mice were examined following acute and 
chronic CS-exposure. To examine the effects of MIF deficiency 
immunohistochemistry, apoptosis-related protein expression, and DNA-
damage were assessed in comparison to wild type animals. 
Aim 2: To test the hypothesis that MIF impacts on CS-mediated 
cytotoxicity in lung by regulating ROS production, in part, via XOR.  
Mif -/- mice were exposed to acute CS and examined for alterations in 
XOR activity and expression. A combination of in vitro, in vivo, and cell 
free functional assays and immunohistochemistry were employed to 
uncover mechanisms by which MIF alters XOR activity.  
Aim3: To test the hypothesis that MIF regulates antioxidant 
responses by impacting on NRF2 stability  
Mif -/- mice were exposed to acute CS and examined for alterations in 
NRF2 activity and related gene expression. In vitro protein expression 
and functional assays were also utilized to uncover alterations in NRF2 








Description FEV1 (% Predicted) FEV1/FVC (%) 
1 Mild 80 <70 
2 Moderate 50-80 <70 
3 Severe 30-50 <70 
4 Very Severe 
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Chapter 2: Materials and Methods 
 
2.1 Experimental Models 
 
2.1.1 Human Subjects 
 
 All study protocols related to human studies were approved by the 
Institutional Review Board of the Johns Hopkins University. Written, 
informed consent was obtained from all participants at the time of 
sample collection. Patients with COPD were recruited from clinical 
populations at the Johns Hopkins Hospital, Johns Hopkins Bayview 
Medical Center and from the NHLBI Lung Tissue Research Consortium. 
Healthy, non-smoking subjects supplied serum for control reference.  
 
2.1.2 Animals and Treatments 
 
All animal protocols were conducted as approved by the Johns Hopkins 
University Institutional Animal Care and Use Committee. MIF-/- mice 
with a C57BL/6 background were generated as previously described 
(Bozza, Satoskar et al. 1999). Mif-/- and Mif+/+ C57BL/6 mice were 
housed under controlled conditions for temperature and humidity using 
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a 12-hour light/dark cycle. At 8-10 weeks of age, mice were exposed to 
CS or filtered air. CS exposure was carried out as previously described 
(Sussan, Rangasamy et al. 2009) for 5 hours/day, 5 days/week, for 3 
days, or 6 months. Briefly, 2R4F reference cigarettes (Tobacco Research 
Institute, University of Kentucky) were burned using a smoke machine 
(Model TE-10, Teague Enterprises). The smoke machine was adjusted to 
produce a mixture of side stream and mainstream smoke as previously 
described (Rangasamy, Cho et al. 2004) with minimal adjustments. 
Chamber atmosphere was monitored for total suspended particulates 
and carbon monoxide, with concentrations of 150 mg/m3 and 750 ppm, 
respectively. In pharmacologic studies mice were injected 
intraperitoneally with 2 mg/kg of a selective pyridinyl imidazole inhibitor, 
SB203580 (LC8 Laboratories, Woburn MA), dissolved at 0.4 mg/ml in 1% 
DMSO in sterile saline or carrier alone (vehicle) as previously described 
(Le, Damico et al. 2008), with minor modifications.  
 
2.1.3 Cells and Reagents 
 
Human and rat lung microvascular EndoC (HLMVEC, CC2527, Lonza, 
MD and RLMVEC, RA6011, Cell Biologics, IL, respectively) were cultured 
and maintained in EGMV-2 (Lonza, MD) or (Basal Media supplemented 
with M1266, Cell Biologics, IL) from passage 4-9. Recombinant MIF 
(rMIF, R&D Systems, Minneapolis, MN), On-target control siRNA and MIF 
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siRNA (Dharmacon, Lafayette, CO), ASK1 siRNA (Dharmacon, Lafayette, 
CO), and cigarette smoke extract (CSE) were used as previously 
described (Damico, Simms et al. 2011). Briefly, at 50% confluence, cells 
were washed with PBS, and bathed with optimem reduced serum media 
(Life Technologies, Grande Island, NY) for transfection of siRNAs. 
Geneporter 2 transfection reagent (GenLantis, San Diego, CA) was 
optimized for lipid based transfections and after 4 hours, complete media 
was added to the cells. Naïve cells, transfected cells or cells receiving 
rMIF were exposed to CSE for 5-45minutes, 4, 8, 24 and 48hrs hours, 
after which lysates and supernatants were collected for analysis. 
 
2.2 Lung Mechanics and Morphometry 
 
Fifteen hours after the last CS exposure, mice were anesthetized with 
ketamine/xylazine (75mg/kg, 15mg/kg). Under deep anesthesia, mice 
were tracheostomized, and the lungs mechanically ventilated with a 
Flexivent (SCIREQ, Montreal, Quebec, Canada) to measure lung 
resistance and elastance. Once under mechanical ventilation, mice 
received a bolus of the paralytic succinylcholine intramuscularly. Mice 
were ventilated at 150 breaths per minute, and lung function parameters 
were determined during a 2 second breath hold with a 2.5-Hz sinusoidal 
oscillation.  
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Subsequent to lung mechanics, bronchoalveolar lavage was 
performed on the right lung, which was removed immediately, rinsed in 
cold PBS, and flash frozen for RNA and protein analysis. The left lung 
was inflated with a warm 1% agarose under pressure (30 cm H2O) and 
submerged in zinc buffered formalin (Z-fix, Anatech LTD, Battle Creek, 
MI) for 2 days. The fixed lung volumes were measured by water 
displacement after which the left lung was divided into 3 sections as 
previously described (Mitzner, Fallica et al. 2008). Briefly, the cranial 1-
2mm was removed from the left lung cutting along the transverse plane. 
Moving down the cranial-caudal axis, 2-3mm thick transverse sections 
were cut, removing approximately 1mm in between each section. The 
caudal-most portion was discarded with the apex and 1mm thick 
spacers, resulting in three 2-3mm thick lung sections, cranial, middle, 
and caudal, which were embedded cut side down in paraffin for thin 
sectioning via microtome.  
For morphometric analysis, lung slices were stained with 
hematoxylin and eosin (H&E), and systematic random sampling of each 
section was performed to obtain unbiased representative pictures of each 
lung. A line probe was employed to assess tissue ratio and mean chord 
length using the stereology tool, STEPanizer (Tschanz, Burri et al. 2011). 
The ends of the probes were used to estimate air to tissue ratios. The 
number of intercepts, or points where septal tissue bordering airspace 
intersects the line probe, was also recorded. After calibrating for the 
! 130!
length of the line probe, we used a ratio of points hitting airspace (Pa) to 
intercepts to estimate mean chord length. The number of intercepts 
counted is proportional to the alveolar surface density and, therefore, we 
were able to estimate whole lung alveolar surface area as previously 




Cleaved Caspase-3 ± Thrombomodulin or ± Tomato Lectin: Unstained 
thin lung sections from paraffin blocks were deparaffinized using xylenes 
and slowly hydrated with washes of decreasing ethanol percentage. The 
lung sections were blocked with a 10% donkey serum with BSA and 
Tween for 1hour. After blocking rabbit anti-mouse cleaved caspase 3 
(#9661, Cell Signaling, Boston, MA) was added to the sections with or 
without goat anti-mouse thrombomodulin (#AF3894, R&D Systems, 
Minneapolis, MN) as previously described (Le, Damico et al. 2008) and 
incubated overnight in a BSA/triton solution. After thoroughly washing, 
the secondary antibody, donkey anti-rabbit Alexa Fluor 594, was added 
for 2 hours at room temperature and for co-staining investigations, 
donkey anti-goat Alexa Fluor 488 or the endothelial specific marker 
tomato lectin (DL-1177, Vector Labs, Burlingame, CA) was also added.  
Lung sections were washed and rinsed with SlowFade anti-fade kit 
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(Invitrogen/ Life Technologies, Carlsbad, CA) after which Vectashield 
with DAPI (Vector Labs, Burlingame, CA) was applied to each slide 
immediately before adding a coverslip. Lung slices were immediately 
imaged using a Nikon microscope with a mounted camera. All images 
were acquired and analyzed in a blinded fashion.  
γH2AX ± Isolectin GS-IB4: Thin lung sections from paraffin blocks 
were heated for 1hr at 60°C, deparaffinized using xylenes, and hydrated 
using washes of decreasing ethanol percentage and deionized water. For 
antigen retrieval (Vector reagent H3300, Burlingame, CA) the slides were 
placed in a steam cooker for 40 minutes. After heating, temperatures 
were normalized and slides were further cooled in distilled water. Each 
slice of tissue was outlined with a pap pen and incubations were 
completed in accordance with a mouse on mouse kit (MOM kit, Millipore 
Corp., Billerica, MA). Mouse Ig Blocking Reagent was applied for 1 hr. 
After washing, slides were incubated with MOM diluent first, and then 
incubated with anti-mouse γH2AX in MOM diluent overnight. Again 
washing was performed and the sections were incubated with goat anti-
mouse Alexa Fluor 488 antibody for 1 hour or overnight with isolectin 
GS-IB4 conjugated with Alexa Fluor 568. Hoechst stain (Invitrogen/ Life 
Technologies, Carlsbad, CA) was carried out during the wash phase for 
the detection of nuclei. SlowFade was applied to each slide immediately 
before adding a coverslip. Lung slices were immediately imaged using a 
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Nikon microscope with a mounted camera. All images were acquired and 
analyzed in a blinded fashion. 
 Phospho-p38: Unstained thin lung sections from paraffin blocks 
were deparaffinized using xylenes and slowly hydrated with washes of 
decreasing ethanol percentage. The lung sections were blocked with a 
10% donkey serum with BSA and Triton for 1 hour. After blocking mouse 
lung sections, rabbit anti-mouse phospho-p38 (SC-17852-R, Santa Cruz 
Biotechnology, Santa Cruz, CA) was added to the sections and incubated 
overnight in a BSA/triton solution. After thoroughly washing, the 
secondary antibody, donkey anti-rabbit Alexa Fluor 488, was added for 1 
hour at room temperature. 
XOR ± PECAM: For human lung sections, rabbit anti-human XOR 
(SC-20991, Santa Cruz Biotechnology, Santa Cruz, CA), and goat anti-
human PECAM (SC-1506, Santa Cruz Biotechnology, Santa Cruz, CA) 
were added as the primaries, whereas, donkey anti-goat Alexa Fluor 488 
and donkey anti-rabbit Alexa Fluor 594 were used as secondaries. DAPI 
(Invitrogen, Eugene, Oregon) was added to the wash and lung sections 
were preserved with SlowFade (Invitrogen/ Life Technologies, Carlsbad, 
CA) immediately before adding a coverslip. Lung slices were immediately 
imaged using a Nikon microscope with a mounted camera. All images 
were acquired and analyzed in a blinded fashion. 
 
2.4 ROS Sensitive Indicators 
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Dihydroethidium (D-1168, Life Technologies, Carlsbad, CA) staining was 
performed as previously described (Jankov et al. 2007). Mice lungs were 
flushed with saline and inflated with Tissue-Tek CRYO-OCT compound 
diluted 1:3 in PBS containing 20% w/v sucrose. Inflated lungs were cryo-
frozen in molds containing OCT compound and stored at -80C. 
Transverse lung sections were mounted on super frost plus slides 
(Fischer Scientific, Waltham, MA), incubated with PBS or appropriate 
drugs (50uM diphenylene iodonium, Cat. # D2926, or 2mM N-Acetyl-L-
cysteine, Cat. # A7250, Sigma Chemical Co., St. Louis, MO) for 30 
minutes. Drugs were washed off with PBS, and slides were incubated 
with 10uM dihydroethidium (DHE) for 30 minutes after which slides were 
mounted with Slow Fade Gold (# S36936, Life Technologies, Carlsbad, 
CA) and imaged immediately. Pictures of parenchymal tissue were taken 
using a Zeiss fluorescent microscope. 2',7'-dichlorodihydrofluorescein 
diacetate (H2DCFDA, # D-399, Life Technologies, Carlsbad, CA) staining 
was performed on HLMVEC per manufactures recommendations. Briefly, 
HLMVEC were loaded with H2DCFDA (10mM in Hanks with 10mM 
HEPES, pH7.4) for 45 minutes and subsequently incubated with rMIF 
(100ng/ml), carrier, or NAC (2mM). post-CS extract (20%V/V) addition, 
fluorescent intensity (495 /520 nm) was assessed  every 5 minutes.   An 
increase in DCF fluoresces was quantified as the ratio of the post-





Supernatants from Human microvascular EndoC exposed to 4, 8, 24, 
and 48 hrs CSE or PBS were analyzed using a solid phase sandwich MIF 
ELISA (R&D Systems, Minneapolis, MN) as previously described (Fallica, 
Boyer et al. 2014) and per manufacturer’s specifications.  
 
2.6 Western Blotting 
 
For tissue derived protein quantification, lungs were washed in cold PBS 
and placed in lysis buffer (Cell Signaling, Boston, MA) with protease 
inhibitors (Sigma Chemical Co., St. Louis, MO; P8340). Tissue lysis 
beads (Next Advance, NY, USA; PINKE5) were added to the lung samples 
and proteins were liberated via homogenization. SDS–PAGE separated 
proteins were electrophoretically transferred to a polyvinylidene 
difluoride membrane (Millipore Corp., Billerica, MA). Specific proteins 
were detected with the following antibodies: caspase-3 (# 9662, Cell 
Signaling, Boston, MA), anti-cleaved caspase-3 (# 9661, Cell Signaling, 
Boston, MA), anti-p53 (# 9662, Cell Signaling, Boston, MA), γH2AX (# 
05–636, Millipore Corp., Billerica, MA), HSP90 (4874, Cell Signaling, 
Boston, MA), p-p38 (9215s, Cell Signaling, Danvers, MA), p38 (9212s, 
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Cell Signaling, Danvers, MA), ASK1 (8662s, Cell Signaling, Danvers, MA), 
XOR (22006, Santa Cruz Biotechnology, Santa Cruz, CA) Cleaved 
caspase (9661s, Cell Signaling, Danvers, MA), MIF (20121, Santa Cruz 
Biotechnology, Santa Cruz, CA) and beta actin (13157, Santa Cruz 
Biotechnology, Santa Cruz, CA). HRP-conjugated secondary antibodies 
were used to amplify the primary signal and the protein/antibody 
complexes were detected by chemiluminescence (ECL; Amersham 
Pharmacia Biotech, Piscataway, NJ). 
 
2.7 RNA Extraction and qPCR 
 
Total RNA was isolated and purified from lung tissue using TRIzol 
reagent (Invitrogen/ Life Technologies, Carlsbad, CA), and components of 
an RNeasy kit (Qiagen, Valencia, CA) respectively. Complementary DNA 
was generated by using an RT2 FirstStrand cDNA kit (SAbioscience/ 
Qiagen, Valencia, CA). Gene expression was measured by utilizing mouse 
primers (IDT, San Jose, CA) for MIF (5’-TGGGTCACACCGCGCTTTGT-3’,5’-
TGCGATGTACTGTGCGGGCT-3’), p53 (5’-ACAGCAGGGCTCACTCCAGCTACC-3’, 5’-
AGCAGAAGGGACCGGGAGGATT-3’), heme oxygenase-1 (HO1) (5’-
GGCCACCAAGGAGGTACACAT-3’,5’-TGGGGCATAGACTGGGTTCT-3’), NADPH 
dehydrogenase quinone 1 (NQO1) (5’-AGCCAATCAGCGTTCGGTAT-3’,5’-
GTAGTTGAATGATGTCTTCTCTGAAT-3’), glutathione peroxidase 2 (GPX2) (5’-
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CCCTTCCGTCGCTACAGCCG-3’, 5’-TCCCAGGGTCTCCCGAGGGTA-3’) beta actin 
(5’ACGGCTCCGGCATGTGCAAA-3’, 5’-ACCATCACACCCTGGTGCCT-3’) and human 
primers Glyceraldehyde 3-phosphate dehydrogenase (5’-
AATGCCAGCCCCAGCGTCAAA-3’, 5’-TGTCCCCACTGCCAACGTGTCA-3’) with the 
SYBR green method.  
 Human oxidative stress and antioxidant defense PCR array 
(SAbioscience/ Qiagen, Valencia, CA) were used per manufacturer’s 
specifications. 
  
2.8 Pterin Assay 
 
The measurement of XOR enzymatic activity was performed on mouse 
lung homogenates using a fluorometric assay based on the conversion of 
pterin to its fluorescent product isoxanthopterin as previously described 
(Kayyali, Budhiraja et al. 2003). Lung tissue was homogenized with 
pterin buffer containing 50mM KH2PO4, 10mM DTT, and 0.18mg/mL 
PMSF. Lysates were centrifuged at 13,000g for 15 minutes at 4°C and 
the supernatants were used in the assay immediately before 
measurement. 
 
2.9 Kinase Assay 
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MIF and ASK1 interactions were tested using a cell free ASK1 kinase 
enzyme system (Promega, Madison, WI), whereby ASK1 in the presence of 
a substrate protein MBP, and ATP will phosphorylate MBP, converting 
ATP to ADP. After quenching any remaining ATP following a reaction 
period, the remaining ADP is converted back to ATP and coupled to a 
luciferase/luciferin reaction producing light (ADP-Glo assay, Promega, 
Madison, WI). The manufacturer’s protocol was followed for setting up 
controls and determining the IC50 values for inhibitors. With this assay 
system rMIF was titrated across several dilutions in triplicate with ASK1 
and the formation of ADP was subsequently measured.   
 
2.10 Caspase 3 Activity Assay 
 
After CS exposure Mif+/+ and Mif-/- lung homogenates were collected and 
directly plated in triplicate on a white-bottom 96-well plate. Homogenates 
were probed for caspase 3/7 activity using the Caspase-Glo 3/7 assay 
(G8091, Promega, Madison, WI) following manufacturers guidelines. 
Briefly the Caspase-Glo substrate and buffer were combined and equal 
volumes of this Glo reagent and lung sample were combined in each well. 
In the presence of the Glo reagent, active caspase 3/7 will cleave from 
the substrate and generate luminescent signal, produced by luciferase. 
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2.11 NRF2 Dual Luciferase Assay 
 
An antioxidant response element (ARE) reporter, containing a mixture of 
a Nrf2-responsive luciferase construct and a constitutively expressing 
Renilla construct were transfected into rat microvascular EndoC. The 
Nrf2-responsive luciferase construct encodes the firefly luciferase 
reporter gene under the control of a minimal CMV promoter and tandem 
repeats of the ARE transcriptional response element. After a 24 hour 
period cells were lysed with a passive lysis buffer, and subjected to a one 
freeze-thaw cycle before NRF2 reporter activity was analyzed using the 
manufacturers guidelines for the Dual-Luciferase Reporter Assay System 
(E1910 Promega, Madison, WI).  In separate approaches NRF2 activity 
was measured in the presence of rMIF (100ng/ml) or in the presence of 
siRNA targeting JAB1.    
 
2.12 Statistical Analysis 
 
For comparisons among groups of normally distributed data sets, the 
student's t test or ANOVA with post hoc Bonferroni correction was used. 
For non-normally distributed data, the Mann Whitney or Kruskal-Wallis 
test with post-hoc Bonferonni correction was used. Values are presented 
as means ± standard error.  
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Cigarette smoke (CS) is the most common cause of chronic obstructive 
pulmonary diseases (COPD) including emphysema. CS exposure impacts 
all cell types within the airways and lung parenchyma, causing alveolar 
tissue destruction through four mechanisms: 1) oxidative stress, 2) 
inflammation, 3) protease-induced degradation of the extracellular 
matrix, and 4) enhanced alveolar epithelial and endothelial cell (EndoC) 
apoptosis. Studies in human pulmonary EndoC demonstrate that 
macrophage migration inhibitor factor (MIF) antagonizes CS-induced 
apoptosis. Here we used human microvascular EndoC, an animal model 
of emphysema (mice challenged with chronic CS), and patient serum 
samples to address both the capacity of CS to alter MIF expression and 
the effects of MIF on disease severity. We demonstrate significantly 
reduced serum MIF levels in patients with COPD. In the murine model, 
chronic CS exposure resulted in decreased MIF mRNA and protein 
expression in the intact lung. MIF deficiency (Mif-/-) potentiated the 
toxicity of CS exposure in vivo via increased apoptosis of EndoC resulting 
in enhanced CS-induced tissue remodeling. This was linked to MIF’s 
capacity to shield against double stranded DNA damage and suppress 
p53 expression. Taken together, MIF appears to antagonize CS-induced 




suppressing EndoC DNA damage and controlling p53-mediated 
apoptosis, highlighting a critical role of MIF in EndoC homeostasis within 



















In humans, pulmonary EndoC apoptosis represents an early event in 
cigarette smoke (CS)-induced lung pathology, preceding other physiologic 
manifestations of obstructive disease (Gordon, Gudi et al.). Numerous 
studies have identified increased EndoC apoptosis in human 
COPD/emphysema, and animal studies support a causal link between 
cell death and airspace remodeling (Calabrese, Giacometti et al. 2005, 
Kanazawa and Yoshikawa 2005, Henson, Cosgrove et al. 2006). 
Importantly, the targeted induction of EndoC death is sufficient to 
promote apoptosis of both EndoC and type II alveolar epithelial cells 
within the alveolar-capillary unit, with the net result being 
emphysematous tissue remodeling (Giordano, Lahdenranta et al. 2008). 
Thus, there is a critical interdependence between alveolar epithelial and 
microvascular EndoC in the maintenance of airspace structure, and loss 
of EndoC within the lung directly contributes to emphysematous 
remodeling. Despite these clinical and pre-clinical observations, 
understanding of the molecular basis of CS-induced EndoC apoptosis 
remains incomplete. We sought to identify and characterize intrinsic 
molecular regulators of alveolar-capillary homeostasis and define their 
contribution to disease severity and CS-induced tissue destruction.  
Macrophage migration inhibitor factor (MIF) is a pleiotropic 




activities (Rosengren, Bucala et al. 1996, Kleemann, Kapurniotu et al. 
1998). It is constitutively expressed by multiple cell types including 
pulmonary microvascular EndoC (Damico, Chesley et al. 2008), vascular 
smooth muscle (Zhang, Shen et al. 2012), fibroblasts (Zhang, Talwar et 
al. 2012) and bronchial epithelium (Kobayashi, Nasuhara et al. 2006) 
within the lung. Further, it is produced by multiple leukocytes, including 
both B and T cells (Bloom and Shevach 1975) and macrophages 
(Calandra, Bernhagen et al. 1994), and is secreted by both the anterior 
pituitary gland (Bernhagen, Calandra et al. 1993) and pancreas (Waeber, 
Calandra et al. 1997). MIF is found in the serum under basal conditions 
and elevated circulating levels of MIF have been observed in humans in 
both acute and chronic inflammatory disease states (Morand 2005). 
Extracellular MIF is capable of engaging multiple recognized cell surface 
receptors, functioning in an autocrine or paracrine manner to activate 
signaling kinases, such as extracellular signal-related kinase (ERK), AKT, 
and AMP-Activated Protein Kinase (AMPK). Each of these kinases has 
been linked to pro-survival pathways. Additionally, intracellular pools of 
MIF modulate the stability of transcription factors, including hypoxia 
inducible factor 1 alpha (HIF1a) (Oda, Oda et al. 2008), p53 (Jung, Seong 
et al. 2008), and, as recent research shows, possibly nuclear factor 
(erythroid-derived 2)-like 2 (NRF2) (Mathew, Jacobson et al. 2013), 
leading to secondary effects on gene expression. These three 




environmental stimuli (i.e. hypoxia, DNA damage, and increased reactive 
oxygen species, respectively) and thus are critical determinants of 
homeostatic responses to intracellular or extracellular stressors. Animal 
models of ischemic cardiac injury, bronchopulmonary dysplasia (BPD), 
and radiation-induced lung injury (Qi, Hu et al. 2009, Prencipe, Auriti et 
al. 2011, Mathew, Jacobson et al. 2013) demonstrate that loss of MIF is 
associated with increased tissue damage. We have previously identified 
MIF as a modulator of the sensitivity of CS-induced human lung EndoC 
apoptosis in vitro (Damico, Simms et al. 2011) antagonizing p53-
dependent activation of the mitochondrial apoptotic pathway. Thus, we 
hypothesize MIF will impact on the severity of CS-induced EndoC injury 
in vivo and thus influence emphysematous tissue remodeling through its 
effects on alveolar-capillary homeostasis.  
The present study identifies MIF as a novel modifier of disease 
severity in CS-induced injury and emphysematous remodeling and 
provides evidence that MIF is a critical determinant of lung EndoC 
homeostasis in the face of oxidative injury. Further, it shows that MIF 
acts predominantly in EndoC within the alveolar-capillary unit to 
antagonize DNA damage and to suppress subsequent p53 induction; 
thus preventing EndoC cell death and apoptosis-mediated tissue 
remodeling. Here, we demonstrate for the first time that serum MIF is 




the most severe disease, implicating relative MIF deficiency in the 




















3.3.1 MIF levels are significantly reduced in humans with COPD 
 
We have previously demonstrated that MIF modifies EndoC injury in vitro 
in response to acute CS exposure by antagonizing p53-mediated 
mitochondrial apoptosis (Damico, Simms et al. 2011). To explore if 
alterations in MIF occur in the context of human COPD, we quantified 
circulating MIF levels in the serum of normal controls (n=18) and in 
subjects with COPD. This was defined by irreversible airflows obstruction 
(i.e., FEV1/FVC ratio of less than 0.7 and an FEV1 less than 90% 
predicted, n=32). Patient demographics are in Table 3-1. Serum MIF 
levels were significantly lower in patients with COPD compared to 
healthy, non-smoking controls (950 pg/ml vs. 1541 pg/ml, P=0.03) 
(Figure 3-1A).  
To begin to address the relationship between MIF and disease 
severity, the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria was used to further classify patients in COPD cohort as 
previously described (Mannino and Braman 2007). In this cross-sectional 
analysis, patients with severe COPD (GOLD Stage IV) had significantly 
lower circulating MIF than subjects with less severe COPD (GOLD II and 
III) (P=0.03) (Figure 3-1B). Thus, we observed significantly lower 
circulating MIF in patients with COPD and this was most pronounced in 





3.3.2 Chronic smoke alters MIF expression in the intact lung 
 
To address the effects of chronic CS exposure on MIF expression in vivo, 
wild type C57BL/6 mice were randomized to exposure with filtered air or 
CS for 6 months. Whole lung homogenates were analyzed for MIF mRNA 
and protein. Chronic CS exposure resulted in a significant decrease in 
total lung MIF mRNA (Figure 3-2A). Similarly, MIF protein expression 
was significantly decreased with chronic CS relative to air controls 
(Figure 3-2B and C). These changes in MIF expression were associated 
with enhanced activation of caspase-3 (Figure 3-2D), a marker of CS-
induced apoptosis in the lung. Thus, MIF mRNA and protein expression 
were significantly decreased in the setting of chronic CS exposure in the 
intact murine lung coincident with activation of the apoptotic pathway. 
 
3.3.3 MIF suppresses cigarette smoke-induced DNA damage in 
vivo 
 
Cell culture, animal data (Kim, Serebreni et al. 2013), and human 
pathology (Pastukh, Zhang et al. 2011) demonstrate double stranded 
DNA breaks (DSB) as one mechanism of CS-induced cellular injury in the 




in the form of apoptosis, orchestrated by the transcription factor, p53, a 
major effector of the DNA damage response (Niida and Nakanishi 2006). 
In response to DSB, histone H2AX is phosphorylated (termed γH2AX) by 
the ataxia telangiectasia mutated (ATM) kinase; making γH2AX a marker 
of both DSB and ATM kinase activity. To test if MIF functions to 
suppress DNA damage in the face of CS, Mif+/+ and Mif-/- mice were 
randomized to air or CS for 0.5 months, and lung γH2AX levels were 
analyzed by immunohistochemistry and Western blot. In air-exposed 
mice, basal in situ staining for γH2AX was minimal and similar between 
genotypes. In contrast, Mif-/- animals demonstrated significantly 
increased numbers of γH2AX positive cells in lung parenchyma compared 
to Mif+/+ mice following exposure to CS (13.6+2.2 vs. 2.5+1.7 cells/high 
power field, P<0.05) (Figure 3-3A and B). This was confirmed by Western 
blot analysis (Figure 3-4A and B).  
 Microvascular EndoC are susceptible to CS-induced DSB in vitro 
(Kim, Serebreni et al. 2013), thus we evaluated the extent of DNA damage 
in EndoC in vivo. Using lectins which bind alveolar (microvascular) 
EndoC and not extraalveolar (macrovascular), we co-stained 
microvascular EndoC and γH2AX by immunofluorescent microscopy 
(King, Hamil et al. 2004). In vivo, the majority of cells with CS-induced 
DSB in Mif-/- mice were microvascular EndoC (Figure 3-3C and D). This 
differed significantly with Mif+/+ both in absolute numbers and as a 




large blood vessels (identified on phase contrast). Therefore, MIF 
deficiency potentiated CS-induced DSB and ATM kinase activation within 
microvascular EndoC in the intact lung. 
 
3.3.4 MIF suppresses cigarette smoke-mediated p53 expression 
in vivo 
 
ATM kinase is a well-established positive regulator of p53 expression. We 
next asked if the enhanced ATM kinase activity, as reflected by increased 
γH2AX (Figure 3-3), was associated with increased p53 expression in 
vivo. Protein and mRNA were extracted from the lung of CS-exposed Mif-/- 
and Mif+/+ mice and p53 expression was quantified via Western blotting 
and qPCR (Figure 3-5) both were significantly enhanced in CS-exposed 
Mif-/- mice relative to CS-exposed Mif+/+ or air-exposed animals. CS-
induced p53 expression is ATM-kinase-dependent (Kim, Serebreni et al. 
2013) and p53 triggers activation of pro-apoptotic BAX and EndoC death 
via the mitochondrial apoptotic pathway (Damico, Simms et al. 2011). 
MIF functions upstream of ATM kinase. Thus, ATM kinase provides a 
molecular link between MIF effects in response to CS and p53 
expression.  
 





Based on the observed effects of MIF on p53-dependent human EndoC 
apoptosis in response to CS in vitro (Damico, Simms et al. 2011), we 
rationalized that increased p53 would be linked to increased cell 
apoptosis in vivo. To test this, lung sections from air and CS-exposed (0.5 
and 6 months) mice were stained for cleaved caspase-3, the enzymatic 
effector of apoptosis (Figure 3-6A and B). In situ quantification 
demonstrated a significantly increased number of cleaved caspase-3 
positive cells in the parenchyma of Mif-/- mice challenged with CS 
compared to Mif+/+ animals exposed in parallel (upper panels of Figure 3-
6C and D). There was no difference in the frequency of cleaved caspase-3 
positive cells between genotypes under basal conditions (air-exposed) 
when comparing age-matched mice. In the presence of MIF, short-term 
exposure to CS was sufficient to increase apoptosis above air-exposed, 
age-matched mice (3.4/HPF vs. 7.1/HPF, P=0.02) (Figure 3-6C upper 
panel). This increase in cell death was lost by 6 months of CS exposure 
(5.4 /HPF vs. 6.2/HPF, P=0.2) (Figure 3-6D upper panel) with basal 
frequencies of apoptosis being higher in the lungs of these older mice. In 
contrast, there was a significant increase in CS-induced apoptosis within 
the parenchyma of Mif-/- mice at 0.5 months (2.5/HPF vs. 15/HPF, 
P<0.0001) (Figure 3-6C upper panel), which trended down by 6 months 
(Figure 3-6D upper panel), but remained elevated above air-exposed 
littermates (5.2/HPF vs. 7.3/HPF, P=0.002). Thus, the absence of MIF 




exposure without demonstrable differences in air-exposed animals, 
further implicating MIF in cytoprotective responses in the lung following 
oxidative challenge. 
 
3.3.6 MIF antagonizes cigarette-smoke induced endothelial 
apoptosis in the intact lung  
 
To address the contribution of MIF to EndoC apoptosis, we performed co-
immunohistochemistry for both cleaved caspase-3 and the EndoC 
marker, thrombomodulin (Kasahara, Tuder et al. 2000) (Middle panels of 
Figure 3-6C and D). In the presence of MIF (Mif+/+ animals) there was a 
relative resistance of microvascular EndoC following subacute exposures 
to CS with no significant difference in EndoC apoptosis observed relative 
to age-matched air-exposed animals. After prolonged exposure to CS (6 
months), there was a trend towards an increase in microvascular EndoC 
apoptosis, which did not meet statistical significance (1.8/HPF vs 
2.7/HPF, P=0.07) (Figure 3-6D middle panel). In the absence of MIF, 
there were no differences at baseline (air-exposed) after 0.5 months or 6 
months exposure relative to Mif+/+ mice (Figure 3-6D middle panel). In 
contrast, exposure to both short-term and prolonged CS resulted in 
significant increases in microvascular EndoC apoptosis in Mif-/- mice 
when compared to Mif+/+ mice (1.8/HPF vs. 9.8/HPF at 0.5 months, 




of Figure 3-6C and D).  
Non-EndoC apoptosis was significantly increased after 0.5 months 
of CS exposure (1.6/HPF vs. 5.5/HPF, P=0.01); however there was no 
difference between genotypes (5.5/HPF vs. 5.1/HPF, P=0.8). Despite the 
apparent lower mean in the knockout mice, there was not a statistically 
significant difference between genotypes at baseline (1.6/HPF vs. 
0.2/HPF, P=0.07) (Figure 3-5C lower panel). After 6 months, the 
frequency of apoptosis in non-EndoC did not differ between exposures or 
genotypes (Figure 3-6D lower panel). Thus, MIF deficiency preferentially 
enhanced microvascular EndoC sensitivity to CS-induced apoptosis in 
the intact lung.  
 
3.3.7 MIF-deficiency enhances cigarette smoke-induced tissue 
remodeling 
 
In order to test the hypothesis that MIF modifies the severity of CS-
induced emphysematous tissue remodeling, Mif+/+ and Mif-/- mice were 
randomized to prolonged CS exposure (6 months, 5 days/week) or 
filtered air for the same duration of time. Lung tissue was subjected to 
morphometric analysis under basal conditions (air-exposed, age-matched 
animals) and in the setting of chronic CS. Using systematic random 




alterations in tissue architecture, with quantification of airspace 
enlargement defined by increased mean chord length (Lm).  
Baseline analysis revealed a modest, but statistically significant, 
increase in the cranial and middle Lm in Mif-/- mice relative to age-
matched Mif+/+ mice (29.7 vs. 32.0, P=0.01, and 30.2 vs. 32.4, P=0.02, 
respectively) (Figure 3-7). Thus, in the absence of MIF there were 
statistically significant differences in airspace morphology under basal 
conditions, which may reflect a contribution of MIF in normal lung 
development and/or in the maintenance of lung structure with aging.  
In response to CS, airspace enlargement was visually detected in 
caudal regions regardless of genotype (Figure 3-8A-D and Figure 3-9) and 
morphometric analysis confirmed that tissue remodeling in response to 
CS predominated in the caudal regions, highlighting a heterogeneous 
distribution of airspace enlargement and enhanced lower lung damage 
due to CS in this model (Figure 3-8A-D). In response to CS, airspace 
enlargement in Mif+/+ mice was significant in the cranial and middle lung 
regions (29.7 vs. 31, P=0.03, and 30.3 vs. 32.5, P=0.04, respectively) 
(Figure 3-7 and Figure 3-9), and tended to be enlarged in the caudal 
regions (31.0 vs. 33.2, P=0.07) relative to air controls.  
Regional remodeling was significantly enhanced in the absence of 
MIF. In Mif-/- mice, the caudal lung demonstrated significant increases in 
Lm when compared with CS-exposed Mif+/+ mice (33.2 vs. 36.5, P=0.007) 




3-9). Even after adjusting for multiple comparisons, Mif-/- mice exposed 
to CS demonstrated a significant increase in the absolute Lm relative to 
smoke challenged Mif+/+ mice (P<0.008) (Figure 3-7 and Figure 3-8). In 
addition to the effects observed in absolute Lm in response to CS, 
quantification of the relative change in Lm highlighted the effects of both 
MIF deficiency and CS exposure on airspace enlargement (Figure 3-8F). 
The calculated mean whole lung alveolar surface area (Sav) (Demedts, 
Demoor et al. 2006) did not differ between genotypes at baseline and was 
lower in Mif-/- mice following smoke. This did not reach statistical 
significance secondary to large variability in the values (P=0.09) (Table 3-
2). Importantly, the validity of the calculated Sav requires homogeneity of 
remodeling throughout the lung, a condition present at baseline but not 














Table 1.   Patient Demographics 
  
Healthy 
controls Group I-II Group III Group IV 
Patients 
(n) 18 18 10 7 
Mean Age 50 55 61.5 60.7 
95% CI 46.5-53.6 50.6-59.4 53.7-69.3 55.9-65.5 
Males, n 10 9 6 5 















































369.6 ± 8.2 374.6 ± 23.6 375.5 ± 30.8 318.8 ± 14.9*
VL ± SEM 
(g)
0.305 ± 0.05 0.28 ± 0.01 0.272 ± 0.01 0.302 ± 0.03
n
CS-related airspace Lung Characteristics
Mif +/+ Air Mif -/- Air Mif +/+ CS Mif -/- CS







Figure 3-1. Serum MIF concentrations are reduced in patients with 
severe COPD. Serum MIF levels were significantly reduced in subjects 
with COPD when compared with non-smokers (left panel). In patients 
with COPD, serum MIF was significantly reduced in severe, GOLD IV 
















Figure 3-2. Chronic smoke alters MIF expression in the intact lung. 
Wild type C57BL/6 mice were exposed to CS or filtered air. Gene 
expression and Western blotting were utilized to study alterations in MIF 
and cleaved caspase-3. Lung MIF mRNA was significantly reduced 
following exposure to CS (A). Tissue MIF was significantly decreased with 
chronic CS relative to air controls (B). The resulting protein intensities 
were normalized to beta actin (C). Chronic CS was associated with 
enhanced cleavage of caspase-3 relative to air controls (D). n=5 per arm. 














Figure 3-3. MIF antagonizes CS-induced EndoC double stranded DNA 
breaks (DSB) in vivo. Lungs from Mif+/+ and Mif-/- animals exposed to 
filtered air or CS for 0.5 months were harvested and sectioned for 
immunohistochemistry (A and C). MIF deficient mice exposed to CS 
demonstrated a significant increase in γH2AX positive parenchymal cells 
relative to air-exposed Mif-/- and CS challenged Mif+/+ mice (A and B). Mif-
/- mice had significantly higher γH2AX positive EndoC as detected by co-
localization of isolectin staining (red) (C and D). n=5 per arm. Values are 





Figure 3-4.  MIF antagonizes CS-induced EndoC double stranded 
DNA breaks (DSB) in vivo. Lungs from Mif+/+ and Mif-/- animals exposed 
to filtered air or CS for 15 days were harvested and homogenized for  
Western blot analysis (B). Densitometric analysis showed samples probed 
with anti-γH2AX antibody had a significant increase in γH2AX levels after 
CS exposure in Mif-/- animals relative to Mif+/+ (A). n=5 per arm. Values 
are expressed as mean ± SEM. 
 
 
Figure 3-5. CS-induced p53 expression is increased in the absence of 
MIF. Lungs from Mif+/+ and Mif-/- animals exposed to filtered air or CS for 
0.5 months were harvested and homogenized for Western blotting (A and 
B) and gene expression (C). Relative p53 protein expression was 
increased in Mif-/- mice exposed to CS (A). Representative Western blot 
(B). n=5-6 per arm. There was a significant increase in p53 mRNA in Mif-









Figure 3-6. Caspase-3 expression is increased in the absence of MIF 
with sub-acute and chronic CS exposure. Lungs from Mif+/+ and Mif-/- 
animals exposed to filtered air or CS for 0.5 or 6 months were harvested 
and sectioned for immunohistochemistry. Representative fluorescent 
microscopy images are shown of cleaved caspase-3 (red) and 
thrombomodulin (green) in the lung (A and B). The frequency of cleaved 
caspase-3 positive parenchymal cells was significantly increased in Mif-/- 
vs. Mif+/+ mice exposed to 0.5 months CS (P<0.05) (C upper panel), and 
with 6 months of CS (P<0.05) (D upper panel). The majority of caspase-3 
positive cells in Mif-/-exposed to 0.5 or 6 months CS were EndoC (both 
with P<0.05) (middle panels of C and D). Non EndoC were enhanced with 
0.5 months with exposure (P<0.05) and this did not differ with genoptype 
(lower panels of C and D). No differences were observed under basal 
conditions independent of genotype (n=5-8 per arm) Nuclei were stained 




Figure 3-7. Regional differences in cigarette smoke-induced 
emphysematous tissue remodeling in vivo. Representative images of 
lung regions in CS-exposed mice highlight the significant increase in 
caudal airspace remodeling. Mif+/+ and Mif-/- mice were randomized to 
filtered air or chronic CS and harvested for morphometric analysis as 
detailed in Materials and Methods. In air exposed animals, there were no 
significant regional differences in Lm between the cranial and caudal 
zones or between genotypes (A&C, D&F). Following CS exposure, caudal 
Lm was significantly different from cranial Lm and this difference from 
cranial Lm was more pronounced in the middle and caudal Mif-/-lung 




Figure 3-8. MIF deficiency leads to increased sensitivity to 
emphysematous remodeling in vivo. Lungs from Mif+/+ and Mif-/- 
animals exposed to filtered air or CS for 6 months were sectioned for 
morphometry. Differences in alveolar remodeling in Mif+/+ vs. Mif-/- mice 
are visually apparent in CS exposed caudal lung regions (C & D 
respectively) compared with air-exposed mice (A & B respectively). Mif-/- 
mice had significantly higher Lm in the caudal lung regions than Mif+/+ 
when exposed to CS (E) and the change in Lm from baseline was 








Figure 3-9.  Effects of MIF loss and CS on the Lm of cranial and 
middle lung regions. Lungs from Mif+/+ and Mif-/- animals exposed to 
filtered air or CS for 6 months were sectioned for morphometry. By 
simple comparisons, cranial and middle lung regions were different at 
baseline between genotypes. In response to CS, middle lung regions had 
significantly increased Lm in Mif+/+ (P<0.05) and Mif-/-(P<0.001) mice. CS-
induced increases in Mif-/- middle lungs displayed more than an additive 
effect of MIF deficiency and CS. No effect was observed in the cranial 
regions in Mif-/- mice, while there was a small effect in Mif+/+ mice 
(P<0.05).   
 
Figure 3-10.  Sub-acute CS does not differentially alter macrophage 
viability or frequency in the absence of MIF. Mif+/+ and Mif-/- mice 
were exposed to 15 days of air or CS, after which BALF and lung tissue 









Figure 3-11.  Matrix Metalloproteinases are not regulated by MIF in 
response to CS.  Serum from Mif+/+ and Mif-/- animals exposed to filtered 
air or chronic CS were harvested and homogenized for zymogram 








Figure 3-12. BALF cell count and differentials in Mif+/+ and Mif-/- mice 
exposed CS. Mif+/+ and Mif-/- mice were exposed to 3 days of air or CS, 
after which BALF was extracted and analyzed for differential cell counts. 
There was a significant effect of CS exposure on total cell count with a 









Emphysema, a common form of COPD, contributes to an estimated 2.5 
million deaths and a health care cost approaching 38.8 billion dollars 
annually in the United States alone (Foster, Miller et al. 2006). It is a 
debilitating disease characterized by the irreversible destruction of the 
lung architecture with enlargement of the airspaces driven by enhanced 
apoptosis (Demedts, Demoor et al. 2006). Targeted EndoC apoptosis is 
sufficient to induce emphysema (Giordano, Lahdenranta et al. 2008) 
while pharmacologic blockade prevents disease, arguing that EndoC 
apoptosis is both sufficient and necessary for development of emphysema 
(Kasahara, Tuder et al. 2000, Tuder, Petrache et al. 2003). Further, loss 
of EndoC viability is sufficient to induce apoptosis of type II alveolar 
epithelial cells (Giordano, Lahdenranta et al. 2008), highlighting the 
contribution of EndoC homeostasis in the maintenance of normal 
alveolar structure. We set out to identify new molecular determinants of 
EndoC apoptosis and survival in response to CS (Damico, Simms et al. 
2011, Kim, Serebreni et al. 2013) predicting that such factors could 
represent novel determinants of disease severity and pathologic tissue 
remodeling. The capacity of MIF to regulate the sensitivity of human 
pulmonary EndoC to CS in vitro made it an attractive candidate. Our 
work provides evidence of altered MIF expression in murine and human 
CS-induced lung disease and links enhanced disease severity to the loss 




microvascular EndoC within the lung, potentiating CS-induced tissue 
remodeling.  
Here, we provide the first evidence that patients with COPD have 
diminished serum MIF relative to normal controls (non-smokers). 
Further, we demonstrate that patient with severe disease (GOLD stage IV 
COPD) have markedly lower circulating MIF than those with milder 
disease. It remains to be determined if this is a cause or consequence in 
human disease, which cannot be specifically addressed in a cross-
sectional study design such as this. However, in our animal and human 
EndoC studies, MIF levels inversely correlate with cellular injury and 
tissue remodeling, implicating a causal relationship in humans rather 
than an epiphenomenon. Our results suggest the possibility that 
individual variability in MIF expression, which is genetically determined 
(Baugh, Chitnis et al. 2002), could account for the clinical heterogeneity 
in susceptibility to CS-induced emphysematous pathology in humans.  
In our animal model, we have demonstrated CS-induced DNA 
damage in the lung parenchyma that is antagonized by MIF. Further, our 
data indicated that MIF functions predominantly to maintain 
homeostasis of microvascular EndoC. In the absence of MIF, there was 
increased DSB, leading to increased ATM kinase-dependent p53 
expression. As a consequence, MIF deficiency exacerbated CS-induced 
lung cell death. The cytoprotective effects of MIF in the context of CS 




primary targets of DSB and apoptosis in the absence of MIF. CS-induced 
EndoC apoptosis was observed rapidly (0.5 months), at a higher 
frequency (approaching 5-fold great), and persistently (6 months) in Mif-/- 
mice compared to Mif+/+ animals. This occurred without evidence of basal 
differences in age-matched mice. Importantly, there was no difference 
between the frequencies of CS-induced non-EndoC death between 
genotypes, again pointing to the enhanced dependence of microvascular 
EndoC on MIF in the setting of CS. The enhanced EndoC apoptosis, was 
linked to increased emphysematous tissue destruction manifested by a 
significant increase in mean chord length in the lower lung zones (i.e. 
middle and caudal regions).  
The alveolar-capillary structure is composed of multiple cell types. 
In addition to the contribution of microvascular EndoC, the alveolar wall 
is composed predominantly of type I and II epithelial cells (pneumocytes). 
Homeostasis of both EndoC and pneumocytes are necessary for 
maintenance of normal alveolar structure. Both cell types are also 
destroyed during human emphysematous remodeling. Our in vivo data 
indicates microvascular EndoC represent the major cellular target of 
DNA damage and apoptosis in the absence MIF. Others have shown that 
targeted killing of EndoC in the lung is sufficient to trigger apoptosis of 
type II pneumocytes (Giordano, Lahdenranta et al. 2008). Thus, it is 
possible that loss of these cells in the alveolus may be a consequence of 




while we observed apoptosis in other cell types in the lung parenchyma, 
this did not differ as a function of MIF expression. MIF deficiency has 
also been linked to decreased macrophage viability (Mitchell, Liao et al. 
2002) and macrophage numbers are significantly altered in both COPD 
patients and in animal models of CS-induced lung disease (Holloway and 
Donnelly 2013). Thus, we specifically assessed macrophage numbers, 
activation status, and/or viability. While we observed an increase in 
macrophage frequency in the bronchoalveolar fluid (BALF) following 
short-term CS exposure, this did not differ between genotypes (Figure 3-
10). Viability of both naive (CD11b+) and activated (CD11c+) f4/80+ 
macrophages in the BALF and lung tissue increased following CS (Figure 
3-11) and again was not altered by MIF expression. Thus, MIF’s effects 
on macrophage number, viability, or activation status do not contribute 
to CS-induced tissue injury or remodeling in our model.  
Under normal physiologic conditions, MIF is detectable in the 
circulation. It is produced and secreted by numerous cell types and 
tissues and functions via autocrine and paracrine effects. While we 
demonstrate that MIF expression decreases in the lung with chronic 
smoke and is lower in the circulation of patients with COPD, at this point 
it remains to be determined if MIF expression is reduced systemically or 
in a subset of cells/tissues in the context of disease. Such information 
will be critical to define the mechanism(s) by which MIF is decreased in 




sources of MIF, low circulating levels predictably impact EndoC which 
are in direct contact with the blood. Our murine data indicates that MIF 
mRNA is globally reduced in the lung following chronic smoke exposure. 
There are few defined molecular mechanisms to suppress MIF 
transcription.  MIF is however sensitive to epigenetic silencing. MicroRNA 
miR-451 can suppress MIF expression (Bandres, Bitarte et al. 2009) and 
intriguingly this microRNA is upregulated in the circulation of human 
smokers (Takahashi, Yokota et al. 2013) suggesting one potential 
molecular mechanism of MIF suppression in COPD. Additionally, the MIF 
promoter is repressed by histone deacetylase (HDAC) inhibitors (Lugrin, 
Ding et al. 2009). Both HDAC expression and activity are reduced in 
human COPD (Yang, Chida et al. 2006) suggesting a second potential 
molecular mechanism to account for the decline in MIF observed.  
MIF has well-established pro-inflammatory functions and has been 
implicated as a positive regulator of metalloproteases (MMPs) including 
collagenases (MMP13 (Onodera, Nishihira et al. 2002) and MMP1 (Kong, 
Huang et al. 2005)) and gelatinases (MMP2 (Meyer-Siegler 2000), and 
MMP9 (Onodera, Nishihira et al. 2002)) but not elastase (MMP12). Of the 
known MMPs responsive to MIF, MMP2 and MMP9, are elevated in 
human COPD (Betsuyaku, Nishimura et al. 1999, Boschetto, Quintavalle 
et al. 2006) and animal models of emphysema (Seagrave, Barr et al. 
2004). Despite these potential molecular targets of MIF in CS-induced 




inflammatory cytokine tumor necrosis factor alpha (TNFa) expression or 
MMP2/MMP9 in our model by qPCR (data not shown) or zymography, 
respectively (Figure 3-12) based on genotype. Further, we did not detect 
altered total BAL cell counts between genotypes, though lymphocyte 
numbers were differentially affected by CS (Figure 3-10). Thus, our loss-
of-function and clinical data argue against a model in which the pro-
inflammatory functions of MIF promote COPD pathology.  
Airspace enlargement is a well-documented age-related process 
(Verbeken, Cauberghs et al. 1992, Papaioannou, Rossios et al. 2013) and 
it is recognized that genetically engineered strains of mice, hypersensitive 
to CS, can also demonstrate evidence of accelerated age-dependent lung 
remodeling (Morris, Huang et al. 2003, Ruwanpura, McLeod et al. 2011). 
We observed differences in baseline Lm in Mif-/- compared to Mif+/+ mice 
housed in a filtered air environment. This suggests MIF may influence 
lung homeostasis and/or development. MIF protein decreases in the 
lungs of aging mice (Mathew, Jacobson et al. 2013) indirectly implicating 
it in age-related changes. In neonatal mice exposed to hyperoxia, both 
excess and insufficient MIF alters neonatal alveolar development, 
suggesting that there is an ideal “dose” of MIF for optimal lung 
maturation (Sun, Choo-Wing et al. 2013). Despite the basal difference in 
airspace morphology, the effects of CS-exposure on MIF deficient animals 
were more than an additive. Since all studies used age-matched controls, 




arms. Moreover, we did not observe differences in basal DSB or apoptosis 
indicating that the effects of MIF on DNA damage and EndoC apoptosis 
in adult life are unlikely to account for the basal differences in alveolar 
morphology. Further studies will be necessary to determine if the 
observed basal differences in the adult lung are a result of premature 
aging and/or abnormal lung development. 
From a clinical and therapeutic perspective, our data suggest that 
relative MIF deficiency may predispose patients to COPD/emphysema 
and that normalization of MIF could have a therapeutic advantage. Our 
preclinical and in vitro data (Damico, Simms et al. 2011) implicate the 
capacity of MIF to antagonize p53 expression in its cytoprotective effects 
against CS. While p53-induced apoptosis predisposes to pathologic 
remodeling, p53 is also a tumor suppressor and prolonged and/or global 
p53 suppression would predictably increase risk of malignancies, 
especially in the face of chronic carcinogen exposures such as CS. 
Importantly, the effects of MIF deficiency were observed in the 
microvascular EndoC. This cell type rarely gives rise to tumors (i.e. 
angiosarcomas) in the lung and these tumors are not epidemiologically 
linked to CS exposure. Moreover, our data indicate that MIF does not 
directly impact on p53, but functions upstream of CS-induced DSB. 
Thus, we predict that restoring physiologic MIF would reduce CS-
induced DNA damage, promoting homeostasis and eliminating the 




Limitations of our analysis are imparted by the animal model used 
which must condense a prolonged exposure in humans into a restricted 
timeline. Consequently airspace remodeling is relatively mild. Second 
these studies were performed in a relatively resistant background strain, 
C57BL/6, to take advantage of a genetic model. While MIF expression 
was suppressed by chronic CS in this strain, it remained detectable 
within the lung after 6 months. Thus, the reduced DSB, delayed EndoC 
apoptosis (observed at 6 months not 0.5 months), and a diminished 
airspace enlargement observed in Mif+/+ mice, relative to Mif-/-, 
demonstrate the persistent cytoprotective role of MIF in response to CS 
exposure.  
From a methodologic standpoint, the most reliable and accurate 
stereologic methods to quantify emphysematous remodeling in small 
animal models are highly debated. We used an unbiased approach 
including systematic random sampling and the indirect/point counting 
method of unadulterated lung images to estimate Lm. This is in contrast 
to the mean linear intercept or direct method, which can substantially 
bias the Lm estimations, favoring larger values. Thus, in the face of 
heterogeneous tissue destruction, Lm derived from the point counting 
method represents the more accurate assessment of regional alveolar 
remodeling.  
Finally, our serum analysis has the following limitations; 1) it is a 




the relationship between MIF and other clinically relevant variables such 
as emphysematous remodeling quantified by high-resolution chest 
tomography, and 3) it does not define MIF levels directly in the lungs of 
patients. Prior clinical studies suggest that the lung is a major source of 
circulating MIF (Sakuragi, Lin et al. 2007); making it a reasonable 
clinical surrogate. Despite these limitations, this represents the first 
clinical link between MIF and COPD and provides the framework for 
understanding the role of this potential modifier in disease severity.  
Despite acknowledged environmental risks, it is well recognized 
that individual susceptibility and severity of COPD/emphysema is 
heterogeneous. While rare heritable risk factors have been identified as 
typified by alpha-one anti-trypsin deficiency, the contribution of other 
molecular antagonists of tissue destruction in emphysema is nascent. 
Our results provide strong support for a novel role for MIF as a 
determinant of disease severity in mouse and man, impacting on 
pulmonary EndoC apoptosis and alveolar remodeling. It establishes a 
role for MIF in controlling DNA damage and p53-derived apoptotic 
responses to smoke, by regulating DSB and caspase-3 activation in 
microvascular EndoC. The identification of this, and other such factors, 
may provide additional therapeutic targets directed at ameliorating tissue 







































Bandres, E., et al. (2009). "microRNA-451 regulates macrophage 
migration inhibitory factor production and proliferation of 
gastrointestinal cancer cells." Clin Cancer Res 15(7): 2281-2290. 
  
Baugh, J. A., et al. (2002). "A functional promoter polymorphism in the 
macrophage migration inhibitory factor (MIF) gene associated with 
disease severity in rheumatoid arthritis." Genes Immun 3(3): 170-176. 
  
Bernhagen, J., et al. (1993). "MIF is a pituitary-derived cytokine that 
potentiates lethal endotoxaemia." Nature 365(6448): 756-759. 
  
Betsuyaku, T., et al. (1999). "Neutrophil granule proteins in 
bronchoalveolar lavage fluid from subjects with subclinical emphysema." 
Am J Respir Crit Care Med 159(6): 1985-1991. 
  
Bloom, B. R. and E. Shevach (1975). "Requirement for T cells in the 
production of migration inhibitory factor." J Exp Med 142(5): 1306-1311. 
  
Boschetto, P., et al. (2006). "Association between markers of emphysema 
and more severe chronic obstructive pulmonary disease." Thorax 61(12): 
1037-1042. 
  
Calabrese, F., et al. (2005). "Marked alveolar apoptosis/proliferation 
imbalance in end-stage emphysema." Respir Res 6: 14. 
  
Calandra, T., et al. (1994). "The macrophage is an important and 
previously unrecognized source of macrophage migration inhibitory 
factor." J Exp Med 179(6): 1895-1902. 
  
Damico, R., et al. (2011). "p53 mediates cigarette smoke-induced 
apoptosis of pulmonary endothelial cells: inhibitory effects of macrophage 
migration inhibitor factor." Am J Respir Cell Mol Biol 44(3): 323-332. 
  
Damico, R. L., et al. (2008). "Macrophage migration inhibitory factor 
governs endothelial cell sensitivity to LPS-induced apoptosis." Am J 
Respir Cell Mol Biol 39(1): 77-85. 
  
Demedts, I. K., et al. (2006). "Role of apoptosis in the pathogenesis of 
COPD and pulmonary emphysema." Respir Res 7: 53. 
  
Foster, T. S., et al. (2006). "Assessment of the economic burden of COPD 






Giordano, R. J., et al. (2008). "Targeted induction of lung endothelial cell 
apoptosis causes emphysema-like changes in the mouse." J Biol Chem 
283(43): 29447-29460. 
  
Gordon, C., et al. "Circulating endothelial microparticles as a measure of 
early lung destruction in cigarette smokers." Am J Respir Crit Care Med 
184(2): 224-232. 
  
Henson, P. M., et al. (2006). "State of the art. Apoptosis and cell 
homeostasis in chronic obstructive pulmonary disease." Proc Am Thorac 
Soc 3(6): 512-516. 
  
Holloway, R. A. and L. E. Donnelly (2013). "Immunopathogenesis of 
chronic obstructive pulmonary disease." Curr Opin Pulm Med 19(2): 95-
102. 
  
Jung, H., et al. (2008). "Direct interaction between NM23-H1 and 
macrophage migration inhibitory factor (MIF) is critical for alleviation of 
MIF-mediated suppression of p53 activity." J Biol Chem 283(47): 32669-
32679. 
  
Kanazawa, H. and J. Yoshikawa (2005). "Elevated oxidative stress and 
reciprocal reduction of vascular endothelial growth factor levels with 
severity of COPD." Chest 128(5): 3191-3197. 
  
Kasahara, Y., et al. (2000). "Inhibition of VEGF receptors causes lung cell 
apoptosis and emphysema." J Clin Invest 106(11): 1311-1319. 
  
Kim, B. S., et al. (2013). "Xanthine oxidoreductase is a critical mediator 
of cigarette smoke-induced endothelial cell DNA damage and apoptosis." 
Free Radic Biol Med. 
  
King, J., et al. (2004). "Structural and functional characteristics of lung 
macro- and microvascular endothelial cell phenotypes." Microvasc Res 
67(2): 139-151. 
  
Kleemann, R., et al. (1998). "Disulfide analysis reveals a role for 
macrophage migration inhibitory factor (MIF) as thiol-protein 
oxidoreductase." J Mol Biol 280(1): 85-102. 
  
Kobayashi, M., et al. (2006). "Role of macrophage migration inhibitory 






Kong, Y. Z., et al. (2005). "Evidence for vascular macrophage migration 
inhibitory factor in destabilization of human atherosclerotic plaques." 
Cardiovasc Res 65(1): 272-282. 
  
Lugrin, J., et al. (2009). "Histone deacetylase inhibitors repress 
macrophage migration inhibitory factor (MIF) expression by targeting MIF 
gene transcription through a local chromatin deacetylation." Biochim 
Biophys Acta 1793(11): 1749-1758. 
  
Mannino, D. M. and S. Braman (2007). "The epidemiology and economics 
of chronic obstructive pulmonary disease." Proc Am Thorac Soc 4(7): 
502-506. 
  
Mathew, B., et al. (2013). "Role of migratory inhibition factor in age-
related susceptibility to radiation lung injury via NF-E2-related factor-2 
and antioxidant regulation." Am J Respir Cell Mol Biol 49(2): 269-278. 
  
Meyer-Siegler, K. (2000). "Macrophage migration inhibitory factor 
increases MMP-2 activity in DU-145 prostate cells." Cytokine 12(7): 914-
921. 
  
Mitchell, R. A., et al. (2002). "Macrophage migration inhibitory factor 
(MIF) sustains macrophage proinflammatory function by inhibiting p53: 
regulatory role in the innate immune response." Proc Natl Acad Sci U S A 
99(1): 345-350. 
  
Morand, E. F. (2005). "New therapeutic target in inflammatory disease: 
macrophage migration inhibitory factor." Intern Med J 35(7): 419-426. 
  
Morris, D. G., et al. (2003). "Loss of integrin alpha(v)beta6-mediated TGF-
beta activation causes Mmp12-dependent emphysema." Nature 
422(6928): 169-173. 
  
Niida, H. and M. Nakanishi (2006). "DNA damage checkpoints in 
mammals." Mutagenesis 21(1): 3-9. 
  
Oda, S., et al. (2008). "Macrophage migration inhibitory factor activates 
hypoxia-inducible factor in a p53-dependent manner." PLoS One 3(5): 
e2215. 
  
Onodera, S., et al. (2002). "Macrophage migration inhibitory factor up-
regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. 






Papaioannou, A. I., et al. (2013). "Can we delay the accelerated lung 
aging in COPD? Anti-aging molecules and interventions." Curr Drug 
Targets 14(2): 149-157. 
  
Pastukh, V. M., et al. (2011). "Oxidative DNA damage in lung tissue from 
patients with COPD is clustered in functionally significant sequences." 
Int J Chron Obstruct Pulmon Dis 6: 209-217. 
  
Prencipe, G., et al. (2011). "A polymorphism in the macrophage migration 
inhibitory factor promoter is associated with bronchopulmonary 
dysplasia." Pediatr Res 69(2): 142-147. 
  
Qi, D., et al. (2009). "Cardiac macrophage migration inhibitory factor 
inhibits JNK pathway activation and injury during 
ischemia/reperfusion." J Clin Invest 119(12): 3807-3816. 
  
Rosengren, E., et al. (1996). "The immunoregulatory mediator 
macrophage migration inhibitory factor (MIF) catalyzes a tautomerization 
reaction." Mol Med 2(1): 143-149. 
  
Ruwanpura, S. M., et al. (2011). "Interleukin-6 promotes pulmonary 
emphysema associated with apoptosis in mice." Am J Respir Cell Mol 
Biol 45(4): 720-730. 
  
Sakuragi, T., et al. (2007). "Lung-derived macrophage migration 
inhibitory factor in sepsis induces cardio-circulatory depression." Surg 
Infect (Larchmt) 8(1): 29-40. 
  
Seagrave, J., et al. (2004). "Effects of cigarette smoke exposure and 
cessation on inflammatory cells and matrix metalloproteinase activity in 
mice." Exp Lung Res 30(1): 1-15. 
  
Sun, H., et al. (2013). "A critical regulatory role for macrophage migration 
inhibitory factor in hyperoxia-induced injury in the developing murine 
lung." PLoS One 8(4): e60560. 
  
Takahashi, K., et al. (2013). "Cigarette smoking substantially alters 
plasma microRNA profiles in healthy subjects." Toxicol Appl Pharmacol 
272(1): 154-160. 
  
Tuder, R. M., et al. (2003). "Apoptosis and emphysema: the missing link." 
Am J Respir Cell Mol Biol 28(5): 551-554. 
  
Verbeken, E. K., et al. (1992). "The senile lung. Comparison with normal 






Waeber, G., et al. (1997). "Insulin secretion is regulated by the glucose-
dependent production of islet beta cell macrophage migration inhibitory 
factor." Proc Natl Acad Sci U S A 94(9): 4782-4787. 
  
Yang, S. R., et al. (2006). "Cigarette smoke induces proinflammatory 
cytokine release by activation of NF-kappaB and posttranslational 
modifications of histone deacetylase in macrophages." Am J Physiol Lung 
Cell Mol Physiol 291(1): L46-57. 
  
Zhang, B., et al. (2012). "Role of macrophage migration inhibitory factor 
in the proliferation of smooth muscle cell in pulmonary hypertension." 
Mediators Inflamm 2012: 840737. 
  
Zhang, Y., et al. (2012). "Macrophage migration inhibitory factor 



















Macrophage Migration Inhibitory Factor (MIF) 
is a Novel Inhibitor of ASK1-p38-XOR-














Chapter 4  
4.1 Abstract 
 
Cigarette smoke (CS) exposure is the leading cause of emphysema. CS 
mediates pathologic emphysematous remodeling of the lung via 
apoptosis of lung parenchymal cells resulting in enlargement of the 
airspaces, loss of the capillary bed, and diminished surface area for gas 
exchange. Macrophage migration inhibitory factor (MIF), a pleiotropic 
cytokine, is reduced both in a preclinical model of CS-induced 
emphysema and in patients with chronic obstructive pulmonary disease, 
particularly those with the most severe disease and emphysematous 
phenotype. MIF functions to antagonize CS-induced DNA damage, p53-
dependent apoptosis of pulmonary endothelial cell (EndoC) and resultant 
emphysematous tissue remodeling. Using primary alveolar EndoC and a 
mouse model of CS-induced lung damage, we investigated the capacity 
and molecular mechanism(s) by which MIF modifies oxidant injury. Here, 
we demonstrate that both the activity of xanthine oxidoreductase (XOR), 
a superoxide-generating enzyme obligatory for CS-induced DNA damage 
and EndoC apoptosis, and superoxide (O2-) concentrations are increased 
following CS exposure in the absence of MIF. Both XOR hyperactivation 
and apoptosis in the absence of MIF occurred via a p38 mitogen 
activated protein (MAP) kinase-dependent mechanism. Further, a MAP 




1 (ASK1) was necessary for CS-induced p38 activation and EndoC 
apoptosis. MIF was sufficient to directly suppress ASK1 enzymatic 
activity. Taken together, MIF suppresses CS-mediated cytotoxicity in the 



















Five million Americans suffer from emphysema (Centers for Disease and 
Prevention 2012), a morbid disease characterized histologically by the 
irreversible destruction of gas-exchanging surfaces in the lung. Cigarette 
smoke (CS) exposure is the main cause of emphysema (Forey, Thornton 
et al. 2011) and triggers apoptosis within the lung parenchyma (Rennard, 
Togo et al. 2006, Tsuji, Aoshiba et al. 2006, Yoshida and Tuder 2007) 
resulting in enlargement of the airspaces, loss of the capillary bed, and 
diminished surface area for gas exchange. Endothelial cell (EndoC) 
apoptosis represents an early (Gordon, Gudi et al.), necessary (Kasahara, 
Tuder et al. 2000), and sufficient (Giordano, Lahdenranta et al. 2008) 
event in emphysematous tissue destruction. Thus, we set forth to 
identify novel regulators of EndoC apoptosis and survival in the context 
of CS exposure postulating that these would represent potential 
determinants of disease severity and needed therapeutic targets. 
Emphysema is characterized by increased oxidative stress. CS 
amplifies the volume of inhaled oxidants (Pryor and Stone 1993) and also 
increases reactive oxygen species (ROS) produced by cells of the airway, 
alveoli, and immune system (Moodie, Marwick et al. 2004, Yang, Chida et 
al. 2006, Zhang, Venardos et al. 2006). The superoxide (O2-) and 
hydrogen peroxide generating enzyme xanthine oxidoreductase (XOR) is 




in patients with emphysema compared to controls (Pinamonti, Muzzoli et 
al. 1996, Heunks, Vina et al. 1999) and XOR activity is increased in the 
lungs of animals exposed to CS (Kim, Serebreni et al. 2013). Importantly, 
XOR is obligatory for CS-induced DNA damage, specifically double-
stranded DNA breaks (DSB), p53 expression, and EndoC apoptosis (Kim, 
Serebreni et al. 2013).  
Macrophage migration inhibitory factor (MIF) is significantly 
reduced in the serum of patients with severe emphysematous COPD 
(Fallica, Boyer et al. 2014) and in the lungs of mice exposed to chronic 
smoke (Fallica, Boyer et al. 2014, Sauler, Leng et al. 2014). MIF is an 
endogenous regulator of CS-induced EndoC apoptosis (Damico, Simms et 
al. 2011) with the capacity to antagonize CS-induced p53 expression and 
p53-dependent apoptosis. Acute exposure to CS is associated with a rise 
in total lung and lung microvascular EndoC associated MIF (Figure 4-1) 
(Damico, Simms et al. 2011, Sauler, Leng et al. 2014) suggesting a 
potential cytoprotective role that is lost over time. MIF deficiency (Mif-/-) 
exacerbates the toxicity of CS in vivo, accelerating emphysematous tissue 
remodeling, and preferentially sensitizes EndoC to CS-induced DNA 
damage and apoptosis (Fallica, Boyer et al. 2014). Thus, the 
cytoprotective effects of MIF act upon EndoC to modify emphysema 
severity. The mechanism(s) by which MIF antagonizes CS-induced DNA 
damage are unknown. Since MIF deficiency exacerbates DNA damage, 




al. 2014) and XOR activity is obligatory for these events, we hypothesize 
that MIF impacts on CS-mediated cytotoxicity in lung by regulating ROS 
production, in part, via XOR.  
In the present study, we demonstrate that MIF deficiency 
potentiates superoxide generation and XOR activation in response to CS. 
This occurs via a p38 MAPK-dependent mechanism. Further, we 
demonstrate that the apoptosis signal-regulating kinase 1 (ASK1), is 
upstream of p38 in response to CS and both kinases are required for 
EndoC apoptosis. Importantly, MIF suppresses CS-induced p38 
activation and directly antagonizes ASK1 kinase activity. Thus, MIF 
antagonizes ROS formation and subsequent EndoC apoptosis by 
repressing ASK1-p38 kinase signaling upstream of XOR activation and 















4.3.1 MIF is a determinant of CS-induced XOR activity and ROS 
production 
 
ROS are produced by multiple cellular sources in the lung, including the 
pulmonary vascular EndoC, the major target of CS-induced damage in 
the context of MIF deficiency (Fallica, Boyer et al. 2014). Important 
vascular sources of ROS are XOR, uncoupled nitric oxide synthase 
(NOS), and NAD(P)H oxidase (Cai, Griendling et al. 2003, Birukov 2009, 
Damico, Zulueta et al. 2012). More specifically, XOR is a source of 
superoxide and hydrogen peroxide within pulmonary EndoC. 
Importantly, XOR is elevated in human CS-induced lung disease 
(Pinamonti, Muzzoli et al. 1996, Pinamonti, Leis et al. 1998) and here we 
demonstrate that its increase is evident in EndoC and other lung cells 
from a patient with COPD (Figure 4-2). We have previously established 
that C57BL/6 mice exposed to CS have increased pulmonary XOR 
activity compared to filtered air-exposed controls (Kim, Serebreni et al. 
2013). Further, in Mif+/+ and Mif-/- mice exposed to chronic CS, increased 
XOR was detected in alveolar-capillary cells, comprising EndoC and non-
EndoC (Figure 4-3). In order to test the hypothesis that MIF modifies CS-
induced XOR activation, lung protein homogenates were collected from 




activity was measured as detailed in Materials and Methods. XOR activity 
was increased in response to CS in both genotypes relative to air 
controls; however activity was significantly greater in Mif-/- mice in 
comparison with their Mif+/+ counterparts (Figure 4-4A). XOR activity did 
not differ at baseline between genotypes. In addition, XOR protein levels, 
determined by Western blotting, did not differ at baseline or in response 
to acute CS (Figure 4-5A & B), suggesting that the increases in XOR 
activity observed in response to CS were unlikely due to the effects of 
MIF on XOR protein expression. Rather, these data provide evidence that 
MIF antagonizes CS-induced increases in XOR activity by modifying the 
activation status of XOR.   
In further support of this, intracellular O2- concentrations were 
also assessed qualitatively using the lipophilic cell-permeable dye, 
dihydroethidium (DHE). In the presence of MIF (Mif+/+ wild-type mouse 
lungs), 72 hours of CS exposure resulted in a mild increase in DHE 
fluorescence (Figure 4-4B). In contrast, CS exposure produced a robust 
increase in DHE staining in Mif-/- animals. Air-exposed Mif-/- mice had 
higher basal superoxide concentrations than wild-type controls despite 
similar basal XOR activity suggesting an XOR-independent mechanism 
to account for this difference. Ex vivo treatment with the thiol donor NAC 
antagonized DHE fluorescence demonstrating specificity (data not 




and potentiates CS-induced ROS production concurrently with increased 
XOR activity.  
 
4.3.2 The Role of p38 in CS-induced XOR activity 
  
An established mechanism for post-translation activation of XOR is via 
p38-dependent phosphorylation (Kayyali, Donaldson et al. 2001, Le, 
Damico et al. 2008). p38 MAPK activity has been linked to enhanced 
apoptosis (Cai, Chang et al. 2006), CS-induced endothelial permeability 
changes (Low, Liang et al. 2007), human COPD (Barnes 2013) and 
emphysema susceptibility in mice (Marumo, Hoshino et al. 2014).  In 
addition, p38 activation is increased with chronic CS in our pre-clinical 
model. Using IHC directed at phosho-p38, we detect increased activation 
of p38 in the microvasculature of the lungs in both genotypes, with more 
intensive staining observed in the Mif /- mice exposed to chronic CS 
(Figure 4-6). The contribution of the p38 signaling pathway in XOR 
activation in response to CS in vivo has not yet been established. We 
postulated that the increased XOR activation in Mif /- mice exposed to CS 
may be mediated by p38. To test the contribution of the p38 signaling 
pathway in XOR activation, we exposed Mif+/+ and Mif-/- mice to CS for 3 
days, after treatment with the p38 inhibitor (SB203580) or its vehicle 
given intraperitoneally before CS exposure. Dose and route were chosen 




homogenates were collected and XOR was measured as detailed in 
Materials and Methods. In response to CS, Mif-/- mice had significantly 
higher XOR activity compared to Mif+/+ mice, which was completely 
abrogated with SB203580 treatment (Figure 4-7), returning to levels 
comparable to Mif+/+ mice. Thus, the enhanced XOR activity observed in 
the absence of MIF is dependent on p38 MAPK activity.  
 
4.3.3 MIF antagonizes CS-induced and p38 dependent EndoC 
apoptosis 
 
Activation of p38 and other MAP kinases, such as the c-Jun N-
terminal protein kinase (JNK), are mediated through stress-inducing 
signals, including oxidative stress (Huot, Houle et al. 1997), which is a 
key component of CS-induced cellular injury. In addition, MIF deficiency 
potentiates p38 signaling responses in the context CS in vivo, as 
demonstrated by enhanced XOR activation and ROS production, 
suggesting a protective role for MIF as a modifier of ROS. To test the 
hypothesis that p38 is activated in response to CS and to evaluate the 
potential role of MIF in blocking CS-induced activation of p38, we used 
an in vitro approach. EndoC were pre-incubated with recombinant MIF 
protein or its carrier, treated with CS extract (CSE), and probed for p38 
phosphorylation by Western blot. In response to CSE, p38 activation, 




microvascular EndoC (Figure 4-8A) was rapid and transient. Similar 
findings were observed in primary rat pulmonary EndoC (Figure 4-9A). 
Total p38 protein did not differ across time points or with rMIF 
treatment. Pretreatment with exogenous MIF (rMIF) compared to carrier 
significantly abrogated the phosphorylation of p38 in EndoC, 
independent of species (Figure 4-8B and Figure 4-9B).  
To understand the functional outcome of p38 activation in vitro, 
EndoC were subjected to CSE exposure in the presence or absence of the 
p38 inhibitor SB203580 and analyzed for alterations in nuclear 
morphology consistent with apoptosis via Hoescht staining as previously 
described (Damico, Simms et al. 2011). The observed increase in p38 
activation in response to CSE was linked with increased apoptotic cell 
death (Figure 4-10) that was prevented by pharmacologic blockade of 
p38. 
Using a complementary approach to evaluate the antagonism of 
MIF on p38, EndoC were transfected with siRNA directed against MIF or 
non-targeting siRNA (Control, Ctrl siRNA) as previously described 
(Damico, Chesley et al. 2008), and exposed to CSE in the presence of 
SB203580 or its vehicle. MIF deficient EndoC were sensitized to CS-
induced apoptosis in vitro (Figure 4-8C). Pre-incubation with SB203580 
was sufficient to significantly diminish CSE-induced apoptosis to the 
level observed with Ctrl siRNA. SP600125, a JNK inhibitor did not have 




and a dependence on p38 kinase activity. Together these data provide 
strong evidence that 1) exogenous MIF blocks p38 activation and 2) 
increased CSE-induced apoptosis in the absence of MIF is p38-
dependent.     
 
4.3.4 p38 inhibition antagonizes DNA damage in MIF deficient 
mice 
 
Our in vitro analysis revealed that cellular apoptosis in response to CSE 
is regulated by p38. Further, we have previously shown that DNA 
damage and EndoC apoptosis are exacerbated in the absence of MIF in 
vivo (Fallica, Boyer et al. 2014). To address the role of p38 in vivo and in 
the context of MIF deficiency and CS exposure, Mif+/+ and Mif-/- mice were 
exposed to CS for 3 days with or without SB203580. Lung homogenates 
were collected and caspase 3/7 activity was measured as a marker of 
apoptosis. Baseline activity did not differ by genotype. In response to CS, 
both Mif+/+ and Mif-/- mice had significantly increased caspase 3/7 
activity; however, this activity was significantly higher in CS-exposed Mif-
/- mice compared to their Mif+/+ counterparts (Figure 4-12A). The increase 
in caspase 3/7 activity in Mif-/- mice was significantly reduced in animals 
treated with SB203580, suggesting that these observed cellular 





 To further test the contribution of this pathway specifically on 
EndoC, lung sections were probed for caspase-3 (green) in tandem with 
the microvascular endothelial marker, tomato lectin (red).  Apoptotic 
EndoC were increased in CS-exposed Mif-/- mice compared to their Mif+/+ 
counterparts as determined by increased overlay of the above markers 
(orange) (Figure 4-12B).     
 
4.3.5 CSE-induced p38 activation is ASK1 dependent 
 
 Having established that MIF antagonizes p38 phosphorylation we 
questioned whether the ability of MIF to block p38 activation occurred by 
a direct or indirect interaction. There is no evidence that MIF possesses 
kinase/phosphatase activity. However, it is well established that p38 
activation is mediated by the MAP kinase kinases (MKK), MKK3 and 
MKK6 (Zarubin and Han 2005), which are in turn regulated by MAP 
kinase kinase kinases (MAP3K). The MAP3K, ASK1, is activated and 
auto-phosphorylated in a redox-sensitive fashion (Adler, Yin et al. 1999). 
In quiescent cells, the redox sensitive thioredoxin (Trx) protein, which 
possesses a thiol-protein oxidoreductase (TPOR) motif similar to MIF is 
known to bind and inhibit ASK1 (Saitoh, Nishitoh et al. 1998, Nadeau, 
Charette et al. 2007). In the face of increased ROS, TPOR undergo 
oxidation, thereby releasing ASK1. Based on functional homology and 




of ASK1 activity. To test this hypothesis, we transfected EndoC with 
ASK1 or Ctrl siRNA and treated cells with CSE or its vehicle, PBS. 
Sufficient knockdown of ASK1 was achieved by 24 hours (Figure 4-13A) 
as demonstrated by Western blotting. In response to CSE, p38 
phosphorylation was not observed in ASK1 deficient EndoC (Figure 4-
13B), whereas cells derived from the control transfections showed rapid 
p38 phosphorylation.  
 To test the functional consequence of diminished ASK1, apoptotic 
responses to CS were quantified by nuclear morphology in EndoC 
transfected with Ctrl or ASK1 siRNA. Knockdown of ASK1 led to 
decreased CS-induced apoptosis compared to Ctrl siRNA transfectants 
(Figure 4-13C). The reduction in p38 activation in the absence of ASK1 
(Figure 4-13) mimics the effects of pre-treatment with exogenous rMIF 
(Figure 4-8) suggesting that MIF may be acting to antagonize CS-induced 
p38 activation by blocking its upstream activator, ASK1.  
 
4.3.6 MIF has the capacity to directly block ASK1 kinase activity 
 
It is well recognized that MIF can bind to or affect intracellular 
proteins 1) as an endogenous protein, 2) via pinocytosis into the cell, or 
3) through extracellular receptor ligand interactions (Kleemann, Hausser 
et al. 2000, Leng, Metz et al. 2003, Nguyen, Beck et al. 2003, Son, Kato 




hypothesis that MIF alters p38 through a direct interaction with ASK1, 
we utilized a cell free assay designed to measure the kinase activity of 
ASK1 in the presence or absence of rMIF. In this assay ASK1, ATP, and 
myelin basic protein (MBP, a non-specific MAPK substrate), 
concentrations were held constant while rMIF was added in a dilutions 
series. The addition of rMIF was sufficient to block ASK1 kinase activity, 
as determined by a reduction in ADP formation, in a dose dependent 
manner (Figure 4-14). Further, the half maximal inhibitory concentration 
(IC50) of MIF was approximately 1.6 nM, well within the known 
biologically active range for MIF (Bruchfeld, Carrero et al. 2009). These 
data indicate a mechanism by MIF, internalized or endogenous, directly 
inhibits ASK1 auto-activation, thereby diminishing downstream signaling 













Figure 4-1. Acute CS induces MIF in vitro and in vivo. Primary 
human lung microvascular EndoC were exposed to PBS or CSE for 4, 8, 
24, and 48 hrs and the supernatants were collected and analyzed via 
ELISA for MIF.  Alternatively, Mif+/+ and Mif-/- mice were exposed to acute 
CS, after which lung homogenates were collected and subsequently 
probed for Western blotting.  In vitro MIF secretion from EndoC was 
significantly increased in response to CSE by as early as 8hrs (A). In vivo, 
total MIF protein significantly increased in the tissue (B) and BAL (C).  








Figure 4-2. Increased XOR is detected in human COPD lung tissue.  
Human Lung tissue sections were obtained from a smoker and non-
smoker and analyzed via IHC. XOR positive EndoC were increased in the 
COPD patient compared to the control. Patient demographics highlight 





Figure 4-3. Chronic CS exposure results in increased XOR. Thin lung 
tissue sections from Mif+/+ and Mif-/- mice chronically exposed to air or 
CS were analyzed by IHC. Lung tissue sections were probed for XOR 
(green) in the presence of the EndoC marker, tomato lectin (red). Both 
genotypes displayed noticeable EndoC (orange) and non-EndoC (green) 
XOR expression, with CS-exposed Mif-/- mice exhibiting a visible 
increased intensity in co-staining signifying increased XOR in EndoC.  









Figure 4-4. MIF is a determinant of CS-induced XOR activity and 
ROS production. Mif+/+ and Mif-/- mice were exposed to 3 days of CS, 
after which lung homogenates or fresh frozen lung cross sections were 
respectively collected in buffer and immediately probed for XOR activity 
using a fluorometric readout or histologically probed for DHE as a 
measure of intracellular ROS. There was significant interaction between 
genotype and exposure, 2 way ANOVA P=0.02. Both genotypes displayed 
significant increases in XOR activity in response to CS; however Mif-/- 
mice responded with a significantly higher XOR activity (A). NS indicates 
no significant difference, P=0.1 vs Mif+/+ mice. While Mif+/+ mice showed a 
modest increase in CS-induced DHE staining, Mif-/- mice had higher 
baseline and more robust CS-induced DHE staining when compared to 













Figure 4-5. MIF and CS do not alter total XOR protein. Mif+/+ and Mif-
/- mice were exposed to 3 days of CS, after which lung homogenates were 
collected and subsequently probed by Western blotting (A). Normalized 
total XOR protein did not differ between genotypes or with CS-exposure 












Figure 4-6. Chronic CS exposure results in Increased p38 activation. 
Thin lung tissue sections from Mif+/+ and Mif-/- mice chronically exposed 
to air or CS were analyzed by IHC. Lung tissue sections were probed for 
phosphorylated p38 (green) and examined for perivascular (white arrows) 
differences.  p38 activation is present at baseline and increased in both 
genotypes, with increased intensity observed in Mif-/- mice.  Nuclei are 





Figure 4-7. The role of p38 in CS-induced XOR activity. Mif+/+ and 
Mif-/- mice were treated with SB203580 or its vehicle and exposed to 3 
days of CS, after which lung homogenates were collected and 
immediately probed for XOR activity. Data was normalized to the 
response of CS treated Mif+/+ mice. Mif-/- mice had a significant increase 
in XOR activity and SB203580 treatment reduced this XOR activity to 








Figure 4-8. MIF antagonized CSE-induced and p38-dependent 
apoptosis. Primary human lung microvascular EndoC were exposed to 
CSE for 5, 10, 15, and 30 minutes in the presence of rMIF or its carrier 
and subsequently harvested for Western blot analysis or analyzed with 
Hoechst stain for apoptosis in the presence or absence of SB203580 (SB). 
In response to CSE p38 activation (Phospho p38) was rapid and transient 
(A). The addition of rMIF was sufficient to block the phosphorylation of 
p38 (B). Total p38 was unchanged. Pharmacological blockade of p38 with 















Figure 4-9. MIF antagonized CS-induced p38 activation in rat 
EndoC. Primary rat lung microvascular EndoC were exposed to CSE for 
5, 10, 15, and 30 minutes in the presence of rMIF or its carrier and 
subsequently harvested for Western blot analysis. In response to CSE, 
p38 activation (phospho p38) was rapid and transient (A). The addition of 

















Figure 4-10. CS-induced apoptosis is p38-dependent. Primary human 
lung microvascular EndoC were subjected to CSE exposure in the 
presence or absence of the p38 inhibitor SB203580 (SB) and analyzed for 
alterations in nuclear morphology consistent with apoptosis via Hoescht 
staining. The observed Increase in CSE-induced apoptotic cell death was 
















Figure 4-11. CS-induced apoptosis in the absence of MIF is JNK-
independent. Primary human lung microvascular EndoC were exposed 
to CSE for 5, 10, 15, and 30 minutes and harvested for Western blot 
analysis. Alternatively, cells were transfected with MIF or Ctrl siRNA, 
treated with CSE or PBS in the presence or absence of the JNK inhibitor 
SP600125 (SP) and analyzed with Hoechst staining. In response to CSE, 
JNK activation (pJNK) was rapid and transient (A). Total JNK was 
unchanged. The pharmacological blockade of pJNK with SP had no effect 
of apoptosis (B). n=3-5 per condition. 
 
 
Figure 4-12. p38 inhibition antagonizes apoptosis in Mif-/- mice. 
Mif+/+ and Mif-/- mice were exposed to CS for 3 days after treatment with 
SB203580 (SB) or its vehicle. Lung homogenates and tissue sections 
were collected and subjected to a luminescent caspase 3/7 activity 
assay, or IHC, respectively. In response to CS, both Mif+/+ and Mif-/- mice 
had significantly increased caspase 3/7 activity (A). Activity was 
significantly higher in CS-exposed Mif-/- mice compared to their wild-type 
counterparts. Caspase 3/7 activity was significantly reduced with SB in 
Mif-/- mice. n=5 per condition.  Lung tissue sections were also probed for 
cleaved caspase 3 (green) in the presence of the EndoC marker, tomato 
lectin (red) (B). Both genotypes displayed noticeable EndoC (orange) and 
non-EndoC (green) apoptosis with Mif-/- mice exhibiting a visible increase 
in Endo death (white arrows), which was dramatically abrogated by SB 






Figure 4-13. CSE-induced p38 activation is ASK1 dependent. Primary 
rat microvascular EndoC were transfected with ASK1 or Ctrl siRNA, 
treated with CSE or PBS, and probed via Western blotting or analyzed 
with Hoechst staining. Sufficient knockdown of ASK1 was achieved by 24 
hours (A). In response to CSE, EndoC derived from the control 
transfections showed rapid and transient p38 phosphorylation which 
was not observed in ASK1 deficient cells (B). There was a significant 
reduction in apoptosis ASK1 deficient cells compared to Ctrl 









Figure 4-14. MIF antagonizes ASK1 kinase activity. A cell free assay 
was used to measure the kinase activity of ASK1 in the presence or 
absence of rMIF. ASK1, ATP, and myelin basic protein (MBP, a non-
specific MAPK substrate) concentrations were held constant while rMIF 
was added in a dilution series. rMIF was sufficient to block ASK1 kinase 
activity (ADP formation) in a dose dependent manner. MIF IC50 =1.6 nM.  
ASK1 activity in the presence of ATP and MBP was used as a buffer 
















Figure 4-15. The role of MIF in CS-induced activation of the ASK1-
p38-XOR pathway. Acute CS exposure resulted in increased MIF 
expression ((Damico, Simms et al. 2011, Sauler, Leng et al. 2014), Figure 
4-1). This functions, in part, to antagonize CS-induced ASK1-p38-XOR 
activation and resulting ROS, p53 expression, and EndoC apoptosis. 
Chronic CS is associated with loss MIF (17, 18). XOR expression and 
activation of p38 are also increased in human and murine CS-induced 
lung disease, as we show here and others previously (15, 26, 32).  When 
MIF is lost, we postulate that the ASK1-p38-XOR pathway is hyper-





Cigarette smoke (CS)-induced lung diseases, including emphysema, 
contribute to an estimated 2.5 million deaths worldwide and a healthcare 
cost approaching 38.8 billion dollars annually in the United States alone 
(Foster, Miller et al. 2006). Emphysema is a debilitating disease 
characterized by the irreversible destruction of the lung architecture with 
enlargement of the airspaces driven by enhanced EndoC apoptosis 
(Demedts, Demoor et al. 2006). The molecular regulators of EndoC fate in 
response to CS exposure are potential therapeutic targets and modifiers 
of disease phenotype. Despite this, no current therapies directly targets 
tissue destruction in emphysema. Further, our understanding of host 
factors predisposing to the emphysematous phenotype in humans is 
nascent (Ahmed, Jiang et al. 2014). Here we show that MIF acted to 
blunt the rise in intracellular ROS caused by CS exposure and 
antagonized CS-induced XOR activation and EndoC apoptosis in an 
ASK1-p38-dependent manner. 
MIF is a 12.5 kDa, evolutionarily conserved protein constitutively 
expressed by multiple cell types in the lung including pulmonary 
microvascular EndoC (Damico, Chesley et al. 2008). MIF is found in the 
serum under basal conditions and is elevated in acute and chronic 
inflammatory disease states (Morand 2005). MIF expression is altered in 
human COPD/emphysema. Specifically, serum MIF levels are 




smoking controls and vary according to the severity of COPD as 
estimated by the GOLD criteria. Thus, patients with severe COPD (GOLD 
Stage IV) have significantly lower circulating MIF than subjects with less 
severe COPD (GOLD II or III), implicating MIF in human disease severity 
and/or susceptibility(Fallica, Boyer et al. 2014). Similar findings are 
observed in a separate COPD cohort (Sauler, Leng et al. 2014), 
independently validating this association. Thus, human COPD 
represents a relative MIF deficient state and there appears to be an 
inverse relationship between disease severity and MIF levels. Preclinical 
data demonstrates that MIF deficient mice have accelerated CS-induced 
emphysema (Fallica, Boyer et al. 2014, Sauler, Leng et al. 2014). In the 
absence of MIF, alveolar EndoC are predisposed to increased CS-induced 
DNA damage and apoptosis (Fallica, Boyer et al. 2014). We have 
identified MIF as an intrinsic, negative regulator of lipopolysaccharide 
(LPS)- and CS-induced apoptosis in human pulmonary EndoC (Damico, 
Chesley et al. 2008, Damico, Simms et al. 2011) MIF functions to 
antagonize EndoC apoptosis by blocking death signals from both the 
death-receptor and mitochondrial apoptotic pathways (Damico, Chesley 
et al. 2008, Damico, Simms et al. 2011). Specifically, MIF is a novel 
positive regulator of the short isoform of the FLICE-like inhibitor protein 
(i.e. FLIPshort), which functions to antagonize signals via the death-
receptor pathway in response to LPS (Damico, Chesley et al. 2008). 




p53-dependent activation of the mitochondrial death pathway in CSE-
challenged EndoC (Damico, Simms et al. 2011). Thus, MIF has the 
unique capability of antagonizing death signals from multiple apoptotic 
pathways in EndoC, acting to stabilize intrinsic inhibitors of the 
apoptosis cascade and suppressing promoters of apoptosis. 
CS contains abundant oxidants and reactive oxygen species (ROS), 
including short-lived superoxide radicals, nitric oxide, and longer lived 
hydroquinones which contribute to the persistent oxidative stress 
observed following smoke exposure (Church and Pryor 1985). CS 
exposure modifies intracellular redox by altering both the expression 
and/or activity of pro- and anti-oxidant enzymes (Rangasamy, Cho et al. 
2004). Thus, we hypothesized that MIF could exert its cytoprotective 
effects by modifying redox responses in the lung in the context of CS 
exposure. An important endogenous source of CS-induced oxidative 
stress is XOR. XOR is elevated in human and murine CS-induced lung 
disease (Pinamonti, Muzzoli et al. 1996, Pinamonti, Leis et al. 1998, 
Kayyali, Budhiraja et al. 2003, Kim, Serebreni et al. 2013). Moreover, 
XOR is necessary for CS-induced EndoC DNA damage, p53 induction, 
and apoptosis, implicating it as a critical mediator of EndoC cytotoxicity 
in response to CS. Here we demonstrated that XOR activity increased 
significantly in Mif-/- mice exposed to CS compared to their wild-type 
(Mi+/+) counterparts without significant differences in XOR protein, 




With longer exposures this acute activation may provide a feed forward 
mechanism by which XOR expression increases with disease severity; 
increased XOR activity induces p53, and a p53-binding site is located in 
the promoter of XOR (predicted by SABioscience Text Mining Application, 
UCSC Genome Browser). This suggests that in the absence of MIF CS-
induced acute hyperactivation of XOR enhances caspase-3 dependent 
apoptosis, as we show here, and that significant increases in CS-induced 
p53 expression detected after 15d CS in MIF deficient animals, as we 
previously showed, may lead to long-term increases in XOR expression 
(Figures 4-2 & 4-3) and therefore activity (Fallica, Boyer et al. 2014). 
Given the persistent nature of ROS and RNS activation is emphysema, 
XOR expression is tied with its increased activity, as both are increased 
in human COPD (Pinamonti, Muzzoli et al. 1996, Pinamonti, Leis et al. 
1998, Ichinose, Sugiura et al. 2003) 
XOR hyperactivation occurred via a p38-dependent mechanism. 
The link between XOR activity and p38 signaling is established in other 
models including hypoxia (Kayyali, Donaldson et al. 2001) and ventilator-
induced lung injury (Le, Damico et al. 2008) where p38 signaling is 
linked to EndoC apoptosis and dysfunction (Cai, Chang et al. 2006, Le, 
Damico et al. 2008). Despite this established link between p38 signaling 
and XOR hyperactivation, potential upstream regulators of p38 in these 
models have not been established. Here we showed that the enhanced 




p38-dependent mechanism as demonstrated by its inhibition with the 
p38 inhibitor, SB inhibitor SB203580. In vitro studies demonstrated that 
CS exposure is sufficient to activate p38, as assessed by its 
phosphorylation status, in lung microvascular EndoC. Antagonism of 
p38 prevented CS-induced apoptosis of EndoC and was sufficient to 
prevent CS-mediated death of MIF-deficient EndoC in vitro. Thus, MIF 
deficient EndoC undergo apoptosis via a p38-dependent mechanism both 
in vivo and in vitro. In addition during the preparation of this manuscript, 
support for this potential p38 dependent mechanism was provided in 
epithelial cells (EpiC) (Lin, Yang et al. 2014). Although these EpiC were 
immortalized cells, this and our data in primary EndoC underlines the 
importance of this pathway on alveolar homeostasis.   
Additionally, we demonstrated that exogenous MIF was sufficient 
to suppress p38 phosphorylation in response to CS. Since MIF does not 
possess intrinsic kinase/phosphatase activity we speculated that MIF 
acts upstream of p38 to modify its activation state. ASK1 is a well-
recognized ROS-responsive kinase upstream of p38 MAPK and recently 
only speculated to be a therapeutic target for COPD due to its regulation 
of p38 (Millan, Bunnage et al. 2011, Barnes 2013). To assess the role of 
ASK1 in CS-induced p38 activation and apoptosis, we used a loss-of-
function approach. Using siRNA directed against ASK1, we demonstrated 
that ASK1 was necessary for phosphorylation of p38 and EndoC 




of p38 in response to CS and is obligatory for CS-mediated cytotoxicity. 
ASK1 activity in quiescent cells is regulated by protein-protein 
interactions which mask its capacity to auto-phosphorylate and activate 
the kinase. One recognized negative regulator of ASK1 is thioredoxin 
(Trx), which possesses a TPOR motif similar to MIF (Saitoh, Nishitoh et 
al. 1998, Nadeau, Charette et al. 2007). In the face of increased ROS, the 
TPOR residues undergo oxidation causing disassociation from ASK1, 
disinhibiting the kinase. Based on functional homology between MIF and 
Trx, we predicted that MIF may represent a novel direct inhibitor of ASK1 
and, thus, modify downstream signaling intermediates including p38 
MAPK. In support of this, we demonstrated that MIF was sufficient to 
directly inhibit the kinase activity of ASK1 at physiologically relevant 
concentrations. Collectively this work supports a model in which MIF 
protects EndoC in the lung to CS-toxicity by inhibiting signaling via a 
ASK1-p38-XOR pathway, thereby identifying additional potential 
therapeutic targets and disease modifiers. 
In potential contrast to our findings in EndoC and the intact lung 
exposed to CS, others examining the relationship between MIF and the 
p38 axis implicate exogenous MIF as a positive regulator of p38 via 
CD74-dependent mechanism (Santos, Lacey et al. 2004, Sanchez-Nino, 
Sanz et al. 2009). CD74, in conjunction with CD44, is capable of 
transducing the extracellular binding of MIF into activation of 




Leng et al. 2006, Starlets, Gore et al. 2006, Qi, Hu et al. 2009). We have 
not been able to detect CD74 expression on human lung EndoC (data not 
shown) and there is limited published data suggesting CD74 plays a role 
in EndoC signaling during inflammation(Morane Le Hiress 2014). 
Multiple factors may contribute to the differential role of MIF in the p38 
axis under these experimental conditions including differences in the 
cellular targets, role of ASK1 in the model, differences in both MIF 
receptors and/or p38 isoform expression in the target cell(s), dose of 
recombinant MIF, and kinetics of the analysis. Importantly, here we 
demonstrate that CS-induced p38 activation was ASK1-dependent and 
that MIF directly blocked ASK1 kinase activity, suggesting the effects of 
MIF on ASK1 can occur independently of CD74.  
While MIF has many potential intracellular binding partners, a 
direct interaction with ASK1 has yet to be demonstrated. The classic 
ASK1 inhibitor, Trx, is a redox-sensitive protein containing a TPOR motif 
(Saitoh, Nishitoh et al. 1998) similar in structure to MIF. The TPOR site 
consists of 2 reactive cysteine residues in a CXXC motif, which responds 
to cellular stress. In MIF, the intact CXXC motif is necessary for its 
biological function but does not appear to be required for binding to its 
intracellular receptor CSN5/Jab1 (Nguyen, Beck et al. 2003). 
Intriguingly, Trx has been demonstrated to bind to CSN5/Jab1 (Hwang, 
Ryu et al. 2004), and although both proteins contain reactive cysteine 




interaction. These observations may suggest potential molecular 
redundancy with MIF and Trx, as has been implied in studies of 
lymphocytes (Kondo, Ishii et al. 2004). Further studies examining the 
mechanism(s) by which these TPOR containing proteins inhibit and 
interact with ASK1 are needed but are currently beyond the scope of this 
manuscript.  
Another mitogen-activated protein kinase which lies down stream 
of ASK1, implicated both in ROS signaling and in CS-mediated EndoC 
dysfunction, is JNK (Schweitzer, Hatoum et al. 2011). We observed 
phosphorylation of JNK in response to CSE (Figure 4-11A) but inhibition 
of JNK was insufficient to abrogate CS-induced EndoC apoptosis (Figure 
4-11B). Thus, while JNK may contribute to EndoC signaling, the activity 
of this kinase is not required for EndoC apoptosis.  
Limitations of this study revolve around the kinetics of the 
molecular events as they relate to later markers of injury and 
remodeling. ASK1 auto-activation and p38 phosphorylation occur rapidly 
and transiently, making both justifiably difficult to assess in vivo. With 
such rapid activation of this pathway, the kinetics of activation in the 
presence of exogenous MIF could be altered or delayed rather than 
completely inhibited. The importance of this limitation is lessened by the 
use of complementary approaches, which demonstrated that ASK1 and 
p38 were obligatory to CS-induced cytotoxicity and that MIF directly 




deficiency in vitro and in vivo collectively arguing that these molecules 
interface on a common pathway. Other limitations may arise in that we 
utilize an acute CS-model with genetic knockouts to identify molecular 
mechanisms exacerbated by chronic CS exposure of wild type animals 
and in humans. Our preclinical and in vitro models of MIF deficiency 
represent a critical point in emphysema progression, where the 
cytoprotective effects of MIF are diminished, and cell damage/death by 
definition exceed repair. Understanding that MIF has pro-inflammatory 
activity and that acute versus chronic inflammation may differ, we have 
probed for several inflammatory endpoints and did not detect acute 
genotypic differences aside from increased lymphocytes in Mif /- mice 
(Fallica, Boyer et al. 2014). While with chronic CS exposure macrophages 
are increased in both genotypes, and increased lymphocytes are detected 
in Mif /- mice (18), the lack of other inflammatory differences 1) argue 
against a mechanism by which the proinflammatory effects of MIF play a 
role in COPD pathology and 2) fail to account for the EndoC specific 
alterations detected with chronic CS-exposure (Fallica, Boyer et al. 
2014).  
Redox signaling and more specifically an imbalance in oxidant and 
antioxidant production is a well-recognized contributing factor to disease 
progression. Our results provide strong support for a novel role for MIF 
as a determinant of ROS production in response to smoke exposure, 




ROS-generating enzyme XOR and antagonize ASK1-p38-dependent 
EndoC apoptosis (Figure 4-15). In our model, the acute production of 
MIF in response to CS acts to partially repress signaling via the ASK1-
p38-XOR pathway accounting for its cytoprotective effects. Following 
chronic exposure to CS, MIF expression is diminished (Fallica, Boyer et 
al. 2014, Sauler, Leng et al. 2014), potentiating injury signaling via this 
pathway and exacerbating emphysematous remodeling. In summary, this 
study establishes a role for MIF in controlling ROS responses to smoke 
by regulating p38-depedent XOR activity, and it specifically links MIF as 
a direct inhibitor of ASK1, upstream of p38 in CS-induced EndoC injury. 
The identification of this pathway provides additional therapeutic targets 
directed at ameliorating ROS production and EndoC apoptosis, driving 
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Chapter 5  
5.1 Abstract 
 
Macrophage migration inhibitory factor (MIF), a pleiotropic cytokine, is 
reduced both in a preclinical model of CS-induced emphysema and in 
patients with chronic obstructive pulmonary disease, particularly those 
with the most severe disease and emphysematous phenotype. In addition 
oxidative stress is continuously exacerbated in response to CS or with 
diease progression. MIF functions to antagonize CS-induced DNA 
damage, p53-dependent apoptosis of pulmonary endothelial cell (EndoC), 
xanthine oxidoreductase dependent oxidant production, and subsequent 
emphysematous tissue destruction. Using primary alveolar EndoC and a 
mouse model of CS-induced lung damage, we investigated the capacity 
and molecular mechanism(s) by which MIF may further modify oxidant 
injury. Here, we demonstrate that the downstream targets of nuclear 
factor erythroid 2-related factor 2 (NRF2), a major transcription factor 
and regulator of the antioxidant (AO) response element (ARE) and 
therefore AO production, are decreased following CS exposure in the 
absence of MIF. Both the production of ROS and the activity of the AO 
are regulated by a MIF dependent mechanism. MIF was sufficient 
enhance NRF2 gene expression and stabilize NRF2 protein. Further the 
deletion of the intracellular MIF receptor, c-Jun activation domain 
binding protein-1 (JAB1), was sufficient to increase ARE activity. Taken 
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together, MIF suppresses CS-mediated cytotoxicity in the lung by 


























Cigarette smoke (CS) exposure is the main cause of emphysema, a 
disease effecting five million people in the United States, initiates 
apoptosis within the lung parenchyma, and is linked to dramatic 
increases in oxidative stress (Rennard, Togo et al. 2006, Tsuji, Aoshiba et 
al. 2006, Yoshida and Tuder 2007, Forey, Thornton et al. 2011, Centers 
for Disease and Prevention 2012). CS-induced oxidative damage results 
in enlargement of the airspaces, loss of the capillary bed, and diminished 
surface area for gas exchange. CS is a mixture of thousands of extrinsic 
factors that dramatically augment the amount of oxidants in the lung in 
addition to increasing the production of endogenous reactive oxygen 
species (ROS) by cells of the airway, alveoli, and immune system (Pryor 
and Stone 1993, Moodie, Marwick et al. 2004, Yang, Chida et al. 2006, 
Zhang, Venardos et al. 2006). Exacerbation of oxidative stress is linked 
with Endothelial cell (EndoC) apoptosis, which represents an early, 
necessary, and sufficient event in emphysematous tissue destruction 
(Kasahara, Tuder et al. 2000, Giordano, Lahdenranta et al. 2008, 
Gordon, Gudi et al.). Thus, we set out to identify novel regulators of 
EndoC apoptosis and survival in the context of CS exposure postulating 
that these would represent potential determinants of disease severity and 
needed therapeutic targets. 
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The transcription factor nuclear factor erythroid 2-related factor 2 
(NRF2) is an important regulator of the antioxidant (AO) response 
element (ARE), AO production, and intracellular protection from 
increased ROS (Rangasamy, Cho et al. 2004, Boutten, Goven et al. 
2010). Importantly NRF2-regulated antioxidant activity is reduced in 
human CS-induced emphysema (Goven, Boutten et al. 2008, Suzuki, 
Betsuyaku et al. 2008).  In addition NRF2 deficient mice are susceptible 
to enhanced emphysematous tissue destruction (Rangasamy, Cho et al. 
2004, Sussan, Rangasamy et al. 2009). The loss of NRF2-dependent 
transcripts is also coincident with the loss of macrophage migration 
inhibitory factor (Mathew, Jacobson et al. 2013). 
 MIF, a pleotropic cytokine with thiol-protein oxidoreductase 
(TPOR) activity, is significantly reduced in the serum of patients with 
severe emphysematous COPD and diminished in the lungs of mice 
exposed to chronic CS (Fallica, Boyer et al. 2014, Sauler, Leng et al. 
2014). In addition, MIF is increased in response to acute CS, is an 
endogenous regulator of CS-induced EndoC apoptosis and DNA damage, 
and has the capacity to antagonize CS-induced p53 expression and p53-
dependent apoptosis, suggesting a potential cytoprotective role that is 
lost over time (Damico, Simms et al. 2011, Fallica, Boyer et al. 2014, 
Sauler, Leng et al. 2014). The antagonism of p53 by MIF is multifactorial 
but it can specifically be through direct interaction mediated by reactive 
cysteine residues on each protein (Mitchell, Liao et al. 2002, Lee, Oh et 
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al. 2006, Jung, Seong et al. 2008, Jung, Seong et al. 2008, Damico, 
Simms et al. 2011).  In addition, through this interaction with p53, MIF 
is recognized as a modulator of transcription factors such as hypoxia 
inducible factor 1 (HIF1)-alpha (Oda, Oda et al. 2008, Simons, Grieb et 
al. 2011). Our previous data linking MIF to altered XOR activity is also 
likely mediated through upstream MAP3K interactions involving the 
oxidoreductase activity of MIF (Chapter 4).  
The TPOR spanning region on MIF is necessary for binding c-Jun 
activation domain binding protein-1 (JAB1), a main intracellular receptor 
for MIF (Burger-Kentischer, Finkelmeier et al. 2005). Interestingly, JAB1 
is a key enzymatic component of the COP9 signalosome, which is 
implicated in the stabilitiy of the cullin/E3 ligase that targets NRF2 for 
degradation (Chamovitz and Segal 2001, Lyapina 2001, Cope 2002, 
Zheng 2002, Pintard 2003, Yamoah, Wu et al. 2005, Schmaler and 
Dubiel 2010). Since MIF deficiency exacerbates oxidative stress, EndoC 
apoptosis, potentiating airspace enlargement, and diminished NRF2 is 
coincident with these alterations, we hypothesize that MIF impacts on 
CS-mediated cytotoxicity in lung by regulating NRF2 activity in part 
through its interaction with JAB1 (Fallica, Boyer et al. 2014).   
In the present study, we demonstrate that in response to CS, MIF 
deficiency results in diminished antioxidant responses downstream of 
NRF2. In vitro exogenous MIF blocked ROS production similar to NAC, 
showing specificity for a role in antioxidant production. We also 
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demonstrate that MIF was sufficient to increase ARE activity. Further 
MIF increased or stabilized the gene and protein expression, respectively, 
of NRF2. Importantly, JAB1 was shown to be a negative regulator of 
NRF2 dependent ARE activity placing JAB1 downstream of MIF. In 
addition alterations in MIF expression did not have an effect on JAB1 
expression. Thus, MIF antagonizes ROS formation by stabilizing NRF2 



















5.3.1 MIF is a determinant of CS-mediated expression of 
antioxidant transcripts in vivo 
 
Cellular defense against oxidant stress occurs via the activation of 
antioxidant genes through a cis-acting sequence known as the anti-
oxidant response element (ARE) (Li and Jaiswal 1992). The transcription 
factor NRF2 binds and mediates expression of ARE containing gene 
products (Marini, Chan et al. 1997). We have previously established that 
MIF has the capacity to regulate the ROS generating enzyme XOR. 
Recognizing the capacity of MIF to bind JAB1, which may be involved in 
NRF2 ubiquitination, we rationalized that the observed changes in 
intracellular ROS could also result from a decrease in anti-oxidant and 
detoxifying gene products. We targeted our analysis on well-recognized 
transcriptional targets of the NRF2-ARE pathway. To test the effect of 
MIF on CS-induced redox responsive and regulator gene products in the 
intact lung, MIf+/+ and Mif-/- mice were exposed to filtered air or CS for 3 
consecutive days, and total lung RNA expression was characterized by 
quantitative PCR (qPCR). CS exposure resulted in an increase in mRNA 
for NADPH dehydrogenase, quinone 1 (NQO1), the prototypic NRF2-ARE 
target (Jaiswal 2000), and glutathione peroxidase 2 (GPX2), the major 
NRF2-dependent glutathione peroxidase in the lung (Singh, Rangasamy 
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et al. 2006). However, we were unable to detect changes in heme-
oxygenase 1 (HO-1) mRNA in response to CS (data not shown). Therefore 
an additional mechanism of higher intracellular ROS observed in these 
lungs (Figure 4-1), CS-induced NQO1 or GPX2 mRNA expression was 
significantly depressed in the absence of MIF (Figure 5-1) implicating MIF 
in efficient NRF2-ARE signaling responses to CS and optimal anti-
oxidant gene expression in vivo. 
 
5.3.2 Exogenous MIF antagonizes CS-induced ROS accumulation 
and potentiates NRF2-ARE in EndoC in vitro 
 
Based on the direct and/or indirect effects of MIF deficiency on CS-
induced ROS in vivo, we predicted that exogenous MIF would alter CS-
induced ROS production in vitro. Increases in intracellular oxidative 
stress were measured using 2',7'-dichlorodihydrofluorescein diacetate 
(H2DCFDA) which is cleaved by intracellular esterases to form the non-
fluorescent and redox-sensitive dye H2DCFDA. We have previously 
established that EndoC are major targets of CS-induced damage in the 
absence of MIF. Therefore exposure of primary human lung 
microvascular EndoC (HLMV EndoC) to CS extract (CSE) induces a rapid 
increase in intracellular ROS (Figure 5-2A) as assessed by an increase in 
H2DCFDA fluorescence. Pretreatment of EndoC with the anti-oxidant and 
reduced thiol donor, NAC, efficiently abrogates this increase 
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demonstrating specificity of the reaction. Importantly, pretreatment of 
these cells with rMIF (100ng/ml) significantly antagonizes CSE-induced 
increases in intracellular ROS. Thus, exogenous MIF is sufficient to alter 
the redox responses of human alveolar EndoC to CS.  
To determine if extracellular MIF is sufficient to influence 
transcriptional activity via effects on ARE containing promoters (present 
in both the promoters of NQO1 and GPX2), we transfected rat lung 
microvascular EndoC with an ARE-reporter plasmid. Cells were 
subsequently exposed to exogenous recombinant MIF protein (rMIF 
100ng/ml) or carrier and lysates were examined for luciferase activity per 
manufacturer’s recommendations (Materials and Methods). Treatment 
with exogenous MIF results in a 50 percent increase in ARE-driven 
transcriptional activity (Figure 5-2B). Thus, exogenous MIF can increase 
transcription of NRF2-mediated ARE-containing promoters.   
 
5.3.3 MIF stabilizes CS-induced NRF2 expression     
 
 The effect of MIF on NRF2-dependent ARE activity could arise 
through a direct effect of MIF on ARE promoters or through a mechanism 
whereby MIF modulates the stability and or the translocation of NRF2 to 
the nucleus.  MIF itself is not known to directly impact on gene 
transcription or mRNA stability, although it is implicated in the 
stabilization of other transcription factors like HIF1-alpha. To 
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understand how MIF acts to increase NRF2-dependent antioxidant 
responses we exposed rat lung microvascular EndoC to exogenous rMIF 
(100ng/ml) or carrier and lysates were examined for alteration in 
normalized NRF2 protein. Treatment with exogenous MIF resulted in a 2-
fold increase in NRF2 protein expression compared to carrier alone 
(Figure 5-3B). We also performed the complementary experiment, 
transfecting EndoC with siRNA targeting MIF or scrambled siRNA (CTRL) 
and analyzing NRF2 expression following a 24hr period. Near complete 
knockdown of MIF was achieved. In addition the siMIF-transfected 
EndoC had diminished NRF2 expression (Figure 5-4A). The addition of 
low dose rMIF (10ng/ml) did not have a substantial effect. Thus, 
exogenous MIF stabilizes NRF2 protein suggesting that the increased 
ARE activity is in part regulated by the capacity of MIF to enhance its 
promoter.   
 
5.3.4 Jab1 negatively regulates NRF2 activity 
 
The recognized intracellular receptor for MIF is JAB1. JAB1 through its 
association with a larger complex, the COP9 signalosome, can 
deneddylate cullin proteins, a process that may be necessary for the 
continuation of cullin-associated E3 ligase activity that targets cytosolic 
proteins for ubiquitination. NRF2 is held in the cytosol by its repressor 
Kelch-like EndoCH-associated protein 1 (KEAP1), which associates with 
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the cullin scaffolding. Further, MIF antagonizes JAB1 through a direct 
interaction, inhibiting JAB1 related protein interactions and downstream 
signaling. To test whether the effects of MIF of NRF2 are dependent on 
JAB1, we first transfected EndoC with siRNA targeting JAB1. After 24 
hours transfect EndoC were analyzed for JAB1 and NRF2 expression.  
Partial knockdown of JAB1 was observed, and this associated with a 
clear increase in NRF2 as compared to CTRL transfectants (Figure 5-4B). 
The addition of low dose rMIF (10ng/ml) appeared to have a small effect 
in increasing NRF2 protein similar to JAB1 knockdown.  
 Next we transfected EndoC with an ARE-reporter plasmid in 
tandem with siRNA targeted against JAB1. After 24 hours ARE activity 
was determined, showing a near 3 fold and significant increase in ARE 
activity in the absence of JAB1. Taken together JAB1 appears to be a 
negative regulator NRF2-dependent ARE activity, by reducing NRF2 













Figure 5-1. MIF is a determinant of CS-mediated expression of 
antioxidant transcripts in vivo. Mif+/+ and Mif-/- mice were exposed to 3 
days of CS and lungs were probed for NRF2-dependent gene expression 
by qPCR. In Mif+/+ mice, CS induced a significant increase in NQO1 (A) 
and GPX2 (B), whereas this response was absent in Mif-/- mice. n=3 to 5 






















Figure 5-2. Exogenous MIF antagonizes CS-induced ROS 
accumulation and potentiates NRF2-ARE in EndoC in vitro. Rat 
microvascular Endo were pretreated with rMIF and examined for ROS 
production or ARE-activity. rMIF significantly antagonized CSE-induced 
changes in DCF fluorescence as does NAC (A). n=6 per treatment. 
*P<0.05 vs. carrier. rMIF treatment was also sufficient to significantly 
increase ARE reporter activity over a 24hr period (B).  
! 245!





Figure 5-3. MIF stabilizes CS-induced NRF2 expression. Parallel rat 
microvascular Endo lysates were analyzed by Western blotting probing 
for NRF2 and normalized to GAPDH. Treatment with rMIF was sufficient 
to increase EC NRF2 protein expression. n=3 per arm. Values are 






















Figure 5-4. The regulation of NRF2 protein expression by MIF and 
JAB1 is opposite and reciprocal. Human microvascular EndoC were 
transfected with siRNA targeting MIF or JAB1 and anyalzed via Western 
blot, probing for NRF2, JAB1, and MIF. After 24 hours partial to 
complete knockdown of MIF or JAB1 was achieved. In the absence of 
MIF, NRF2 protein was diminished (A). In the absence of JAB1 NRF2 











Figure 5-5. Jab1 negatively regulates NRF2 activity. Human 
microvascular EndoC were transfected with siRNA targeting JAB1 and an 
ARE-containing promoter. After 24 hours ARE activity was analyzed with 
via luminescence. In the absence of JAB1, NRF2-ARE activity was 








Emphysema, a common form of COPD, contributes to an estimated 2.5 
million deaths and a health care cost approaching 38.8 billion dollars 
annually in the United States alone (Foster, Miller et al. 2006). It is a 
debilitating disease characterized by irreversible destruction of the lung 
architecture with enlargement of the airspaces driven by enhanced 
oxidative stress and alveolar cell apoptosis (Demedts, Demoor et al. 
2006). We have previously shown EndoC to be a major target of CS-
induced cell damage in the absence of MIF (Fallica, Boyer et al. 2014). In 
addition we have strong evidence that MIF impacts of ROS generation 
(Chapter 4). Recognizing the multifactorial potential of MIF as a redox 
sensor and determinant of EndoC fate, we thus set out to identify new 
molecular determinants of cell fate in response to CS, predicting that 
such factors could represent novel determinants of oxidative stress with 
disease severity (Damico, Simms et al. 2011, Kim, Serebreni et al. 2013).  
 Here, we provide evidence that MIF influences the redox response 
to CS in primary human and rat EndoC, and in the intact murine lung. 
The increase in intracellular ROS observed (Chapter 4) in the absence of 
MIF could arise from loss of its intrinsic oxidoreductase activity, failed 
detoxification and/or increased production. In addition there are 
multiple enzymatic sources of ROS in the lung such NADPH oxidase and 
XOR (Damico, Zulueta et al. 2012). XOR is induced in vitro and in vivo by 
CS exposure (Kim, Serebreni et al. 2013). Importantly, in the absence of 
! 249!
MIF there is a decreased antioxidant (NQO1 and GPX2) response that is 
coincident with increased XOR and ROS production (Chapter 4), 
suggesting that MIF is impacting both the generation and/or the 
clearance of ROS. MIF was sufficient to increase NRF2-ARE signaling in 
EndoC in vitro and was necessary for optimal expression of NRF2 targets 
in the response to CS in vivo. We have previously demonstrated that MIF, 
under the same conditions, antagonizes CS-induced DNA damage and 
p53-dependent apoptosis, linking these observations together (Fallica, 
Boyer et al. 2014). Thus in the absence of MIF both increased ROS, 
partly mediated through p38-dependent activation of XOR, and 
diminished detoxification appear to be driving acinar apoptosis in 
response to CS.  Further our previous data linking MIF to altered XOR 
activity suggests that the effects of MIF are mediated through upstream 
MAP3K interactions involving the oxidoreductase activity of MIF (Chapter 
4). Similarly, the reactive cysteine residues on MIF, that confer its 
oxidoreductase activity, are also sufficient for MIF protein-protein 
interactions with other intracellular proteins (Jung, Kim et al. 2001, 
Shen, Hu et al. 2003, Li, Lu et al. 2004, Burger-Kentischer, Finkelmeier 
et al. 2005, Jung, Seong et al. 2008, Jung, Seong et al. 2008). 
Intracellular MIF is not known to directly impact on gene 
transcription or mRNA stability. However through its effects on cytosolic 
p53, MIF can alter cell fate decisions by modulating the stability of 
nuclear p53 and other transcription factors, including HIF1 alpha (Lee, 
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Oh et al. 2006, Jung, Seong et al. 2008, Oda, Oda et al. 2008). Further, 
through JAB1 binding, MIF can alter several other transcription factors 
and their downstream gene-products (Bianchi, Denti et al. 2000, 
Chauchereau, Georgiakaki et al. 2000, Kleemann, Hausser et al. 2000, 
Chamovitz and Segal 2001, Hwang, Ryu et al. 2004, Lee, Oh et al. 2006, 
Oh, Lee et al. 2006, Villeneuve, Lau et al. 2010). Here we show MIF 
enhances the activity of the major transcriptional regulator of the ARE, 
NRF2, in a JAB1 dependent manner, leading to secondary effects on 
antioxidant gene expression and regulatory activity towards oxidative 
stress. The loss of MIF correlated with diminished NRF2 protein, while 
the loss of JAB1 potentiated NRF2 protein and activity. In addition the 
effects of JAB1 and MIF on NRF2 were independent of each one altering 
the expression of the other. Further, Nrf2 mRNA is constitutively 
expressed independent of inducers, implicating a post-transcriptional 
mechanism for the observed alterations in Nrf2 activity. Mechanistically, 
activation of Nrf2 is generally controlled at the protein level, whereby 
Nrf2 activity is limited under basal conditions through repressors like 
Kelch-like ECH-associated protein 1 (KEAP1) and activated by inducers 
or oxidative stress that disrupt repressor binding.  
JAB1 can interact with other transcription factors by stabilizing 
their association with coactivators, but the effects of MIF on JAB1 
regarding these transcription factors, while plausible, remains ill defined 
(Claret, Hibi et al. 1996, Kleemann, Hausser et al. 2000, Chamovitz and 
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Segal 2001). In addition, there is no indication that JAB1 stabilizes 
transcriptional repressors through similar nuclear interactions 
suggesting its role in NRF2 activity is also at the protein level. Further, 
the TPOR spanning region on MIF is necessary for binding JAB1 and the 
capacity of MIF to block JAB1 activity has been previously established 
(Burger-Kentischer, Finkelmeier et al. 2005). JAB1 acts as a coactivator 
for AP1 transcription, and MIF binding to JAB1 antagonizes this 
function, altering cell growth, proliferation, and or apoptosis-related 
protein expression depending on the cellular context (Bianchi, Denti et 
al. 2000, Kleemann, Hausser et al. 2000, Hwang, Ryu et al. 2004). 
Specifically JAB1, through its association with the COP9 signalosome 
has been implicated in the cycle of protein degradation and here, to 
extend we validate the plausibility of JAB1 explicitly regulating NRF2. 
However given the complex nature of this cycle more work is needed to 
further elucidate the exact mechanism. 
The COP9 signalosome, to which JAB1 associates, is involved in 
the deneddylation of proteins (Schmaler and Dubiel 2010). Neddylin 
(NEDD8) stabilizes cullins, allowing for activation of associated ubiquitin 
ligases (E3) (Lyapina 2001, Cope 2002, Zheng 2002, Yamoah, Wu et al. 
2005). KEAP1 tethers NRF2 to these cullin scaffolds, and when 
neddylated, the E3 ligase targets NRF2 for ubiquitination (Villeneuve, 
Lau et al. 2010). In order for this complex to efficiently degrade more 
cytosolic NRF2 it must cycle apart and back together (Chamovitz and 
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Segal 2001, Pintard 2003). JAB1, as part of the signalosome, is 
hypothesized to remove NEDD8, destabilizing the cullin complex in order 
for KEAP1 to bind another NRF2 (Cope 2002, Villeneuve, Lau et al. 
2010). In the presence of ubiquitin-conjugating enzyme E2M (UBC12) the 
complex will be re-neddylated, stabilizing the complex once again, 
allowing the cycle to continue (Chamovitz and Segal 2001, Schmaler and 
Dubiel 2010, Villeneuve, Lau et al. 2010). Therefore other potential 
sources by which MIF exerts an effect on JAB1 or NRF2 are KEAP1 and 
UBC12. Intriguingly, both of these proteins have redox sensitive cysteine 
residues, raising the likelihood that MIF may have a direct or indirect 
effect on their signaling and or function.  There is limited evidence this 
may be the case, as exogenous MIF may enhance the KEAP1 repressor, 
and NRF2 activator, DJ1 (Pei, Wu et al. 2014).  In addition the 
association of UBC12 with NEDD8 is redox sensitive; Under oxidizing 
conditions a modified cysteine residue on UBC12 prevents NEDD8 
association, and therefore the cullin is not activated and the target 
protein is not degraded (Downs, Kumar et al. 2013). However our data 
here argue against this having a significant effect, as the in vitro 
experiments were carried out under basal conditions in the absence of an 
oxidizing stimulus such as CSE. This JAB1 Nonetheless, under the 
premise that MIF antagonizes JAB1 activity, this scenario paints a 
picture whereby MIF would stabilize NRF2, by preventing its rapid 
targeting for proteosomal degradation (Mathew, Jacobson et al. 2013). 
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Additionally, through its effects on JAB1 function, MIF can also alter the 
expression of HIF1-alpha and p53, which are both targeted by specific E3 
ligases for proteasomal-degradation (Bae, Ahn et al. 2002, Nemajerova, 
Mena et al. 2007)  
It is not known whether MIF interacts with JAB1 as a single 
protein or as part of the multi-protein complex (COP9 signalosome) or 
how MIF may modulate these relative pools of JAB1. Intriguingly the 
MIF-JAB1 complex is detectable in the cytosol, but it is not known 
whether this complex, while together, has signaling or binding 
functionality as a cytosolic and or transcription factor similar to the 
individual capacities of MIF and JAB (Kleemann 2000, Bech-Otschir 
2001, Chamovitz and Segal 2001, Lee, Oh et al. 2006, Kudrin and Ray 
2007). In addition both MIF and JAB1 stabilize HIF1-alpha, albeit 
through different mechanisms, but this raises the question as to whether 
their relationship is purely antagonistic (Bae, Ahn et al. 2002, Oda, Oda 
et al. 2008, Simons, Grieb et al. 2011).  JAB1 inhibits the cyclin 
dependent kinase (CDK) inhibitor p27KIP1, which can induce G1 cell 
cycle arrest (Tomoda, Kubota et al. 1999). Exogenously MIF binds with 
cytosolic JAB1 and inhibits its control over p27KIP1, stabilizing cell cycle 
arrest (Tomoda, Kubota et al. 1999, Kleemann, Hausser et al. 2000). In 
contrast, JAB1 enhances JNK activity and downstream c-jun 
phosphorylation and MIF blocks this JAB1–dependent effect, possibly 
disrupting cell growth and or proliferation. However the exact mechanism 
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remains ill-defined, as MIF and JAB1 do not possess kinase activity and 
do not directly associate with JNK (Tomoda, Kubota et al. 1999, 
Kleemann, Hausser et al. 2000). This regulation of the MAPK pathways 
also contradicts MIF signaling mediated through extracellular receptors, 
which positively regulates cell survival and proliferation.  
One limitation of this study is we did not include a second 
stimulus in order to test the function outcome of JAB1 deficiency, such 
as increased or decreased cell death. However given the extensive 
interconnections of redox sensitive and cysteine containing proteins, the 
addition of CSE into our analysis may confound the interpretational 
value of absolute JAB1 effects on NRF2. In addition there is currently a 
lack of consensus as to the role of JAB1 on cell fate depending on context 
(Tomoda, Yoneda-Kato et al. 2004, Hallstrom and Nevins 2006, Liu, Pan 
et al. 2008, Damico, Simms et al. 2011).  
A second limitation arises in that we did not explicitly address the 
specific antagonism of MIF on JAB1. The combination of NRF2 protein 
loss observed in MIF deficient cells and NRF2 potentiation observed in 
JAB1 deficient cells, in addition to the previously observed antagonism of 
JAB1 by MIF, implies a direct mechanism by which MIF regulates JAB1 
and NRF2 protein stability. Despite a lack of evidence to suggest a direct 
effect of MIF on the ARE, future experiments should be directed at 
understanding whether MIF may have a direct effect on ARE responses 
in the absence of JAB1.  Alternatively, mutation of Cys60 on MIF reduces 
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the interaction of MIF and JAB1 and could also be employed to further 
examine the implicated direct interaction on NRF2 stability (Kleemann, 
Hausser et al. 2000, Nguyen, Beck et al. 2003).   
A third limitation is that we have not defined the expression of all 
of the suspected factors that may be involved in cycling of NEDD8 and 
NRF2 degradation, like UBC12 and KEAP1 respectively. While MIF has 
not been directly implicated in binding or altering these proteins, MIF 
may have the capacity for multiple and simultaneous interactions as 
both the TPOR motif and Cys81 are involved in binding (Chamovitz and 
Segal 2001, Burger-Kentischer, Finkelmeier et al. 2005, Lee, Oh et al. 
2006, Oh, Lee et al. 2006, Jung, Seong et al. 2008, Jung, Seong et al. 
2008, Luedike, Hendgen-Cotta et al. 2012). However further work is 
needed to uncover the complex networking of these cysteine-rich and 
redox-sensitive proteins when their cognate intracellular locations are in 
flux, especially in the context of specific stimuli like CS, which provokes 
the associated redox reactions. In addition there is binding redundancy, 
overlap in function, and the possibility for alternative compensation 
amongst these cysteine rich redox sensitive proteins, exemplified by the 
inter- and intra- relationship of MIF and thioredoxin  (TRX).  For example 
JAB1 also has the capacity to bind TRX (Hwang, Ryu et al. 2004).   
We also used a germ-line transgenic animal in our initial 
observations. Thus, we cannot rule out the possibility of secondary 
compensation. In addition limitations of our analysis are imparted by the 
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animal model itself. First, the model must condense pathologic events 
that take decades to develop in humans into a restricted timeline. 
Further, there are clear interspecies differences in inflammatory 
responses (Seok, Warren et al. 2013), susceptibility to oxidant injury 
(Frank, Bucher et al. 1978), and anatomy and respiratory physiology. 
This is not unique to our study but true of all pre-clinical studies using 
mice. These limitations are arguably balanced by the capacity to assess 
the causal relationships not easily addressed in human studies.  
Oxidative stress is a well-recognized contributing factor to 
emphysema disease progression. Our results support a novel role for MIF 
as a determinant of ROS clearance in response to smoke exposure, 
impacting on JAB1-dependent NRF2 protein degradation. In our model, 
the acute production of MIF in response to CS acts to partially enhance 
the NRF2 pathway by blocking JAB1, accounting for its cytoprotective 
effects in wild type animals. Following chronic exposure to CS, MIF 
expression is diminished coincidently, and likely causally, with NRF2 
expression, potentiating injury and exacerbating emphysematous 
remodeling (Mathew, Jacobson et al. 2013, Fallica, Boyer et al. 2014, 
Sauler, Leng et al. 2014). In summary, this study establishes a role for 
MIF in modulating ROS detoxification in response to smoke by regulating 
NRF2, and it specifically links MIF to enhanced antioxidant production in 
a JAB1 dependent manner. The identification of this pathway provides 
additional therapeutic targets directed at ameliorating ROS production 
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and EndoC apoptosis, driving forces behind tissue injury and remodeling 
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At the genesis of this project we sought to identify and characterize 
intrinsic molecular regulators of alveolar-capillary homeostasis and 
define their contribution to disease severity and CS-induced tissue 
destruction. Recent work by our lab, sheds light on the significance of 
intrinsic modifiers of EndoC homeostasis as well as cytoprotection from 
CS-induced damage, typified by MIF. We were the first to show that MIF 
expression is significantly reduced in human emphysematous COPD, 
and this observation has since been validated in a separate cohort 
(Fallica, Boyer et al. 2014, Sauler, Leng et al. 2014). Next we showed that 
MIF deficient mice were susceptible to enhanced emphysematous tissue 
destruction in response to chronic CS. These chronic outcomes 
correlated with amplified sub-acute CS-induced DNA damage, ATM 
kinase activation, and pulmonary EndoC apoptosis. Thus we established 
a novel role for MIF in controlling DNA damage and p53-derived 
apoptotic responses to CS, by regulating DSB and caspase-3 activation 
in microvascular EndoC.  
Recognizing that oxidative stress is a major characteristic of 
emphysema and an important inducer of apoptosis, our subsequent 
research sought to uncover a role for MIF in oxidant and antioxidant 
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imbalances that by definition contribute to oxidative stress. Our lab had 
previously shown that XOR, an important cellular source of oxidative 
stress, is obligatory for CS-induced DNA damage, p53 expression, and 
EndoC apoptosis (Kim, Serebreni et al. 2013). In addition XOR activity is 
elevated in patients with emphysema and CS exposed animals compared 
to controls, which is concurrent with declines in MIF expression, 
suggesting a potential interfacing of pathways or activity (Pinamonti, 
Muzzoli et al. 1996, Pinamonti, Leis et al. 1998). In our ensuing work we 
showed that the complete loss of MIF potentiates ROS production and 
XOR activation in response to CS. Both wild-type and MIF deficient mice 
have significant increases in XOR but this increase is substantially 
higher in the MIF null mice. This suggests that XOR has a basal 
response to CS and or may have other potential activators in the face of 
CS. However the substantial difference between CS-exposed genotypes is 
dependent on p38 activation. This p38-dependent activation is also 
sufficient to significantly increase apoptosis in the alveoli compared to 
CS-exposed wild-type mice. Because MIF does not possess kinase activity 
and given the potential impact of MIF in modulating redox reactions 
through its oxidoreductase activity, we suspected MIF was impacting on 
redox sensitive MAP3K upstream of p38. We demonstrated that ASK1 is 
one potential MAP3K upstream of p38 and also necessary for apoptosis. 
Importantly, MIF suppresses CS-induced p38 activation and directly 
antagonizes ASK1 kinase activity. Thus, MIF antagonizes ROS formation 
! 269!
and subsequent EndoC apoptosis by repressing ASK1-p38 kinase 
signaling upstream of XOR activation and increased ROS production. 
In further understanding the role of MIF in oxidative stress we also 
uncovered a novel potentiation of the major antioxidant transcription 
factor, NRF2, by MIF in a JAB1 dependent manner. Through its 
oxidoreductase activity, MIF binds and in some cases inhibits JAB1, 
which is suspected in the degradation or NRF2 through its association 
with the COP9 signalosome (Chamovitz and Segal 2001, Burger-
Kentischer, Finkelmeier et al. 2005, Lue, Thiele et al. 2007). In addition, 
coincident with deficits in MIF production and increased XOR, NRF2 is 
significantly diminished with human emphysema progression (Boutten, 
Goven et al. 2011). In this part of our investigation we demonstrated that 
in response to CS, MIF deficiency results in diminished antioxidant 
responses downstream of NRF2 suggesting that MIF is a positive 
regulator of NRF2 activity. MIF had the capacity to block ROS production 
similar to NAC, showing specificity for enhanced antioxidant production. 
Next we demonstrated that MIF was sufficient to increase NRF2-
dependent ARE activity in EndoC. In addition MIF sufficiently stabilized 
the gene and protein expression of NRF2. Importantly, we showed JAB1 
was a negative regulator of NRF2-dependent ARE activity, placing JAB1 
downstream of MIF. In addition alterations in MIF expression did not 
have an effect on JAB1 expression. Thus, MIF antagonizes ROS 
formation by stabilizing NRF2 dependent antioxidant responses in a 
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JAB1 dependent manner. These results, in addition to previous findings, 
indicate that with loss of MIF, JAB1 has a negative effect on NRF2 
antioxidant production, contributing to oxidative stress with 
emphysematous disease progression.  
 
6.1.2 MIF deficiency as a model for human emphysema 
 
CS-induced lung disease manifestations and onset of symptoms are 
multiple and invariably inconsistent which likely reflects the variance in 
genetic susceptibility. However in investigating the role of MIF in 
emphysema development there are several intriguing observations to 
suggest the dysregulation of MIF may be a major nodal point in the 
advancement of emphysematous processes. MIF has been shown to be 
directly involved in the regulation—or its absence is directly associated 
with the dysregulation—of several processes contributing to tissue 
destruction, including the enhanced oxidative stress, apoptosis, and 
alveolar airspace enlargement we present here, but also the transition 
from a predominantly innate immune response to an adaptive one, 
bacterial clearance and susceptibility to infections (Das, LaRose et al. 
2014).  
  The nodal point in disease progression may therefore be defined as 
a point whereby the cytoprotective and inflammatory effects of MIF are 
diminished, and cell damage and death by definition exceed repair, and 
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adaptive responses are enhanced, respectively. Regarding cytoprotection, 
MIF notably increases acutely in response to CS and its associated 
hypoxic conditions suggesting that the role of MIF may be protective in 
nature. In looking at the balance of antioxidants and oxidants, we show 
here that MIF regulates the hyperactivation of XOR, which is increased in 
human disease. In addition MIF is a positively regulator of NRF2, both of 
which are decreased with disease. This protective effect is also apparent 
in considering our in vitro and in vivo data, which provides strong 
support for MIF in blocking CS-induced p53 dependent apoptosis, 
specifically in EndoC; p53 is directly regulated by MIF and exacerbated 
with human disease (Morissette, Vachon-Beaudoin et al. 2008, Damico, 
Simms et al. 2011). However, acute increases in MIF, through paracrine 
or autocrine loops, also stabilizes HIF1A, which is necessary for VEGF 
production and EndoC homeostasis, both of which are diminished in 
human emphysema (Kanazawa and Yoshikawa 2005). Further MIF as 
well as VEGF, through extracellular receptor signaling can enhance 
survival through AKT signaling, which is also dysregulated in human 
COPD (Bozinovski, Vlahos et al. 2006, Lue, Thiele et al. 2007, Prakash 
Muyal, Kumar et al. 2014). This suggests MIF is important in enhancing 
cell survival on multiple levels and regulating oxidative stress, both of 
which are significantly dysregulated, skewing cell fate towards death in 
human disease progression. 
 While it is not addressed in this thesis, MIF has clearly been 
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implicated in controlling or enhancing innate immune responses, which 
are persistently more irregular with disease progression. MIF is sufficient 
to enhance macrophage phagocytotic activity and migration, which are 
both acutely increased in response to CS in mouse and man. This acute 
increase in MIF is further associated with proper clearance of bacteria, 
efferocytosis, and an increase in MMPs, and importantly all of these 
processes are dysregulated in emphysema (Betsuyaku, Nishimura et al. 
1999, Meyer-Siegler 2000, Onodera, Nishihira et al. 2002, Patel, 
Seemungal et al. 2002, Hoi, Morand et al. 2003, Seagrave, Barr et al. 
2004, Kong, Huang et al. 2005, Boschetto, Quintavalle et al. 2006, 
Roger, Delaloye et al. 2013, Das, LaRose et al. 2014). The relationship 
between MIF and MMPs may be counterintuitive because MIF can be a 
positive regulator; however MIF is not the only MMP regulator and the 
association of MMPs with lung disease is mainly described in current 
smokers or in COPD patients with mild disease, suggesting the positive 
association between MIF and MMPs is likely in the acute phase of 
responses to CS. And lastly there is limited evidence that MIF loss 
dramatically enhances T cell chemotaxis and infiltration in the lung, 
which is a defining characteristic in diseases with MIF deficiency and the 
later stages of COPD (Aoshiba, Koinuma et al. 2004, Rosen, Lee et al. 
2006, Hodge, Nairn et al. 2007, Kevill, Bhandari et al. 2008, Chang, 
Nadigel et al. 2011, Dancer and Sansom 2013, Eppert, Wortham et al. 
2013, Hou, Sun et al. 2013, Jonathan, Benjamin et al. 2013, Jonathan, 
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Benjamin et al. 2014). 
These latter gaps in knowledge regarding MIF may highlight a 
couple of limitations with the model. First, there are clearly differences in 
inflammation regarding the acute versus chronic nature of exposure. 
However as highlighted in Chapters 3 and 4, these differences are 
minimal between genotypes and our loss-of-function and clinical data 
argue against a model in which the pro-inflammatory functions of MIF 
promote COPD pathology. Secondly, in human disease there is likely 3 
phases of MIF expression—the acute increase, the chronic decline, and 
the transition phase between. Our model therefore represents a clear 
picture of processes in the later stages of COPD characterized by 
diminished MIF. However regarding therapeutic approaches, our model 
will be useful for addressing the nodal point, or transition phase, where 
the cytoprotective effects of MIF are lost and apoptosis outpaces repair. 
That is, the acute differences between genotypes would expose potential 
proteins and novel pathways altered during this phase, and therefore 
interesting candidates for pharmaceutical intervention. This proposal is 
further substantiated as subacute CS exposure in MIF expressing 
animals alters the post-translational modification of MIF (data not 
published), suggesting that the loss of MIF function may precede 
reductions in MIF expression, conceivably implicating this transition 
phase as a principal area of importance and future direction.  
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The other overarching limitation with our model encompasses the 
acute nature of our CS exposures for uncovering the molecular 
underpinnings of MIF regulatory activity. Repeating the chronic 
exposures needed to mimic human disease and produce detectable 
emphysema, are costly and inherently inefficient. We therefore utilize 
acute and sub-acute exposure periods to better understand the 
underlying molecular pathways altered by MIF in the face of CS. In many 
ways this limitation is also a strength. Notably, we can examine and 
correlate the potential significant acute CS-induced findings or 
differences with chronic alterations. This greatly enhances our ability to 
target points in the molecular pathway regulated by MIF for therapeutic 
intervention. For example XOR activity is acutely increased and its 
expression is enhanced chronically suggesting that the ROS derived from 
XOR persists and may in fact get worse. However we can disrupt or block 
XOR through pharmaceutical intervention as another plausible future 
direction.  
 
6.1.3 Conclusion  
 
The study of MIF in emphysema and COPD is only in its infancy. MIF 
has multiple functions, numerous binding partners, regulates cell fate, 
and has potential variability in the structure-function relationship with 
varying concentrations and cellular contexts. Therefore the full impact of 
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MIF on lung homeostasis is likely through multiple cellular and 
molecular paths that are collectively not well understood in the context of 
CS-induced lung disease. This thesis provides strong evidence that the 
cytoprotective effects of MIF are crucial for balancing increases in CS-
induced oxidative stress, cell damage, and apoptosis, the major 
underlying interconnected causes of persistent emphysematous tissue 
destruction. Thus uncovering this and other MIF pathways is promising 
for future therapeutic interventions that ameliorate or perhaps reverse 
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